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Introduction 
It is with great pleasure that I 
present the annual report of the 
Health Protection Surveillance 
Centre for 2009. It proved to 
be an extremely busy year and 
was dominated of course by the 
appearance of the first influenza 
pandemic of the twenty first 
century. Great credit is due to all 
those in public health departments around the country and 
at HPSC for making this report possible through their timely 
and comprehensive analysis and reporting on trends and 
developments, despite the huge workload caused by the 
pandemic.
At HPSC we have been working on influenza surveillance 
for over ten years now, and had no doubt that we were 
witnessing the emergence of a new pandemic virus in May last 
year. The pandemic was finally declared by the World Health 
Organization on June 11th 2009.  
For many, pandemic (H1N1) 2009 proved to be a mild illness, 
but for a substantial number of people the illness was severe 
and necessitated hospital admission.  Thankfully, many of the 
elderly population had previous immunity to the new virus and 
were protected from the usual mortality seen with seasonal 
influenza in their age group. 
It was the first time since influenza surveillance began in 
Ireland that we saw influenza circulating in the summer.  
School age children were involved in the spread of the virus 
with a number of outbreaks in Irish and other language 
colleges in the summer, followed by school outbreaks on 
return to class in September.  Although this age group had 
the highest incidence of attending general practice with flu-
like illness it was younger children who were most likely to be 
hospitalised with pandemic influenza. 
The Irish surveillance system showed that people attended GP 
practices in record numbers with influenza-like illness.  This 
was almost double the previous peak of seasonal influenza 
seen in 2001. People with severe obesity, chronic neurological 
disability and pregnancy were particularly vulnerable, along 
with those with the usual risk factors of chronic lung, heart, 
liver and kidney disease and diabetes.
Twenty seven deaths were reported with confirmed pandemic 
influenza.   
Over 1000 people were hospitalised, a little under half of 
whom had underlying medical conditions. One hundred 
people were admitted into intensive care units (ICU), many 
of whom required prolonged periods of intensive care. 
Nearly 20% of those admitted to ICU were previously healthy 
individuals with no underlying conditions and eight pregnant 
women were also admitted. 
The health service responded very effectively given the 
significant pressures it faced, caring for those who were ill 
and vaccinating almost a quarter of the population when the 
vaccine became available from late October onwards. The 
National Virus Reference Laboratory did great work providing 
a pandemic (H1N1) 2009 diagnostic service, in collaboration 
with hospital laboratories in Galway, Cork and Dublin.
2009 also saw the re-emergence of measles, particularly 
in disadvantaged groups such as the Traveller and Roma 
communities and in those who choose not to have their 
children vaccinated against vaccine preventable diseases. A 
large resurgence of mumps which had begun in late 2008 
was controlled by a catch-up vaccination campaign in 4th, 5th 
and 6th year secondary school pupils during the summer term 
of 2009. Reported complications in the mumps outbreak 
included 75 hospitalisations, 88 cases of orchitis, 19 cases of 
pancreatitis, 10 cases of meningitis, seven cases of deafness 
and six cases of encephalitis. 
The Health Protection Surveillance Centre provides 
epidemiological information to the National Immunisation 
Advisory Committee (NIAC) of the Royal College of Physicians 
of Ireland to aid the decision making process in relation to 
the Irish vaccination schedule.   The introduction of the 7 
valent pneumococcal vaccine into the childhood immunisation 
schedule in September 2008 began to show some early results 
in 2009 with an 84% reduction in invasive pneumococcal 
disease (IPD) in the under two year old target group and 
an impressive 19% reduction in the burden of IPD in all age 
groups and all serotypes.  On the advice of NIAC the Health 
Service Executive will shortly begin using a new 13 valent 
pneumococcal conjugate vaccine in the childhood schedule, 
which will hopefully lead to an even greater reduction in IPD.
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There were difficulties during 2009 in receiving complete data 
from all HSE areas on immunisation coverage.  Immunisation 
is one of the most cost effective interventions for any health 
service and it is crucial that priority is given to making sure 
that our immunisation service works effectively.  In terms of 
immunisation uptake, those working and living in Roscommon 
paved the way, reaching all targets with over 95% of children 
vaccinated appropriately at the ages of 12 and 24 months. 
In 2008 and 2009 we saw a slight reduction in the number 
of cases of tuberculosis reported, with 468 cases and 472 
cases respectively.  This compares to 480 cases in 2007. The 
rate of tuberculosis continues to fall slowly in the indigenous 
Irish population.  However, we must ensure that the falling 
incidence does not lead to a situation where patients and 
doctors may be less likely to consider tuberculosis as a cause 
of a prolonged cough.  Health professionals must be reminded 
to consider the diagnosis of tuberculosis and to ensure timely 
diagnostic testing for those ill in such circumstances.
The incidence of verotoxigenic E. coli (VTEC) infections 
continues to increase and to cause concern. The latest 
European data shows that Ireland now has the highest rate 
of VTEC in Europe. Out of the 241 cases notified in 2009, 24 
associated haemolytic uraemic syndrome (HUS) cases were 
reported. Twenty of these HUS cases were reported in children 
and one adult male died due to VTEC infection in 2009. The 
diagnostic laboratory in Cherry Orchard is undertaking more 
definitive molecular typing in 2010. This service will help 
detect linked cases which will allow public health services 
to identify any common sources.   As usual, many of cases 
of VTEC were thought to be linked to private wells and 
group water schemes.  These water sources are particularly 
vulnerable to animal faecal contamination after periods of 
heavy rainfall. 
The number of new HIV diagnoses remained stable at 395 
cases in 2009. This is almost certainly an underestimate and 
cases associated with men having sex with men continue 
to increase. This rise is associated with increases in other 
sexually transmitted diseases such as syphilis and gonorrhoea. 
New cases of chlamydia are now also at an all time high. We 
must continue to remind young people of the importance of 
taking precautions against the spread of sexually transmitted 
infections and the importance of having a regular sexual 
health check to ensure early diagnosis and prompt treatment 
of these infections.  
Antimicrobial consumption showed a decrease in both in-
patients and out-patients in 2009. This was accompanied by a 
19% decrease in the number of MRSA notifications compared 
with 2008. Despite these successes, there were worrying 
increases in the proportions of other resistant organisms 
causing serious infections in hospitals.  New mechanisms of 
resistance continue to emerge both in Ireland and abroad 
highlighting the need for ongoing commitment and resources 
to reduce the burden of antimicrobial resistance and 
healthcare associated infection in Ireland.
I’d like to thank the Scientific Advisory Committee, along 
with the HPSC sub committees for all their hard work 
throughout 2009.   Special thanks also to all at HPSC whose 
professionalism and commitment in an exceptionally busy year 
made this report possible.
Finally thanks are due to all those who assisted in the response 
to the 2009 influenza pandemic.  We were fortunate that the 
outcomes were not more severe. There was a tremendous 
effort across many parts of the Irish health service to mitigate 
the effects of the new virus. Personally, I would like to thank 
all the staff here at HPSC who put in long hours and went to 
huge effort to make sure that the best possible guidance and 
advice was always available. 
Dr Darina O’Flanagan
Director
Health Protection Surveillance Centre
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In 2009, 43 cases of invasive Haemophilus influenzae 
disease were notified in Ireland (1.0/100,000 total 
population). This is a marked increase compared to the 
previous years when 22 and 31 cases were notified in 
2008 and 2007, respectively (Figure 1). 
The main changes in 2009, when compared to 2008, are 
the doubling in the overall number of cases due to non-
typeable/non-capsular cases from 12 to 25, the increase 
in type e strains (four in 2009 compared to none in 
2008), but also the continuing decline in the number 
of type b cases from five to one (Figure 1). No other 
noteworthy change in the number of cases due to other 
serotypes has been observed in recent years.
Non-typeable/non-capsular cases accounted for the 
majority of the invasive H. influenzae cases notified 
in 2009 (58%, n=25/43). The remaining cases were 
due to H. influenza type b (2.3%, n=1), type e (9.3%; 
n=4), type f (7.0%; n=3) and isolates that were not 
typed (20.9%; n=9). The cases ranged in age from one 
week to 88 years. The incidence rates were highest in 
infants <1 year (6.6/100,000) and those aged 65+ years 
(3.4/100,000) (Table 1).
Cases occurring in children <10 years of age (n=13) and 
elderly adults >=65 years (n=16) accounted for 67% of 
all invasive H. influenzae notifications in 2009 (Table 1).
The clinical manifestations of invasive H. influenzae 
disease in the 13 children <10 years of age in 2009 
were two cases of meningitis, two cases of pneumonia 
and one case each of meningitis/septicaemia and 
septicaemia. Clinical diagnosis was not reported for 
seven cases. A breakdown by clinical diagnosis for 
all age groups by year between 2004 and 2009 is 
presented in Table 2.
Two invasive H. influenzae related deaths were reported 
in 2009, both of which occurred in unvaccinated adults 
over 60 years of age. One had a non-typeable infection 
and was not the primary cause of death. The second 
death was associated with an untyped H. influenzae 
strain. 
 
In 2009 one case of H. influenzae type b (Hib) occurred 
in an incompletely vaccinated four year-old child, who 
had received three doses of the 5 in 1 vaccine but not 
the Hib booster dose. In contrast, in 2008, five Hib cases 
were notified, three of which occurred in children <=3 
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2009: 43
Number of cases, 2008: 22
Number of cases, 2007: 31
Crude incidence rate, 2009: 1.0/100,000
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Figure 1. Annual number of invasive Haemophilus influenzae cases notified in 
Ireland, 2004-2009
years of age, with two cases occurring in infants <1 
year and one in the 1-4 years age group. Of these three 
cases, two were vaccinated and one had received one 
dose of the Hib vaccine. 
In 2009, no true Hib vaccine failures were reported, 
thus highlighting the positive impact the Hib booster 
catch up campaign has had in Ireland. This was also the 
case in 2008. In contrast, in 2007, two true Hib vaccine 
failures occurred in children aged 14 years or less, one 
of whom died from septicaemia. Both children received 
three doses of Hib vaccine when they were less than 
one year of age. Of note was the fact that one of the 
two true vaccine failures in 2007 occurred in a slightly 
older child, aged 10-14 years, who would not have been 
targeted by the catch-up programme. 
Since September 2008, the Hib booster dose has been 
administered at 13 months of age as part of the routine 
childhood immunisation schedule in addition to the 
three doses at 2, 4 and 6 months of age. Vaccination is 
routinely recommended for those at increased risk of 
Hib disease.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 7th July 2010. These 
figures may differ from those published previously due 
to ongoing updating of notification data on CIDR.
Table 1. Number and incidence rates of invasive Haemophilus influenzae cases by serotype plus number of Hib vaccine failures 
by age group, 2009
Age Group Type b Type e Type f Non-typeable/non-capsular
Not 
Typed Total
ASIR of 
Hib
ASIR of all H. 
influenzae TVFs
<1 0 0 0 2 2 4 0.00 6.6 0
1-4 1 0 1 2 0 4 0.41 1.7 0
5-9 0 1 1 3 0 5 0.00 1.7 0
10-19 0 1 0 1 0 2 0.00 0.4 0
20-34 0 0 0 1 1 3 0.00 0.3 0
35-54 0 0 1 2 0 3 0.00 0.3 0
55-64 0 1 0 5 0 6 0.00 1.8 0
65+ 0 1 0 9 6 16 0.00 3.4 0
All Ages 1 4 3 25 9 43 0.02 1.0 0
CIR 0.02 0.09 0.07 0.59 0.21 1.01 - - -
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000
TVFs, true Hib vaccine failures
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Table 2. Number of invasive Haemophilus influenzae cases by 
clinical diagnosis, 2004- 2009
Clinical 
Diagnosis 2004 2005 2006 2007 2008 2009
2004-
2009
% of 
Total
Septicaemia 8 14 13 6 3 9 53 25.7%
Pneumonia 5 0 3 6 3 8 25 12.1%
Meningitis 3 9 3 2 2 2 21 10.2%
Epiglottitis 1 3 3 1 1 0 9 4.4%
Cellulitis 1 1 2 1 1 0 6 2.9%
Meningitis & 
septicaemia 1 0 1 0 1 1 4 1.9%
Osteomyelitis 1 0 0 0 0 0 1 0.5%
Septic 
arthritis 0 1 0 0 1 0 2 1.0%
Unknown 18 6 13 15 10 23 85 41.3%
Total 38 34 38 31 22 43 206 100%
Table 3. Incidence rates of invasive Haemophilus influenzae by 
HSE area, 2004-2009
HSE Area 2004 2005 2006 2007 2008 2009
E 1.1 1.0 0.9 0.8 0.5 0.8
M 0.5 0.5 0.2 0.5 0.3 0.5
MW 0.8 0.3 0.8 0.6 0.8 2.2
NE 0.2 1.1 0.2 0.0 0.0 0.2
NW 0.4 0.0 2.0 0.4 0.0 0.4
SE 1.3 0.5 1.0 1.3 0.8 1.3
S 3.0 0.8 3.4 0.8 1.7 3.4
W 0.5 1.4 0.7 1.4 0.5 1.2
Ireland 0.9 0.8 0.9 0.7 0.5 1.0
In 2009, there were 162 measles cases (3.8/100,000) 
notified in Ireland.  This is nearly a three-fold increase 
compared to 2008 when 55 cases were notified.  This 
increase is a result of a measles outbreak that was first 
identified in August 2009.  
In Week 31 2009 (week ending 8th August 2009), a 
confirmed measles case, in an adult who worked in a 
general practice, was notified in the HSE-S.  In Week 33 
2009, a measles case in a Roma child was notified in the 
same Area, this case’s general practitioner worked in the 
same building as the previous case. In Week 37, 2009, 
two measles cases, one in a child from the Irish Traveller 
community and one in a hospital contact of this case, 
were notified in the HSE-S. During Weeks 38 and 39, six 
cases in Irish Travellers were notified in the HSE-S.  From 
then on measles continued to circulate and spread to 
other HSE Areas.  The measles outbreak continued into 
the early part of 2010.  
Measles cases by week of notification are shown in 
figure 1.  During Weeks 1-30 2009 42 measles cases 
were notified.  In contrast, 120 measles cases were 
notified between Weeks 31 and 52.  
At the start of the outbreak, a national outbreak control 
team was convened, which included health professionals 
from the departments of public health in the HSE 
Areas, HSE-Health Protection Surveillance Centre, HSE-
National Immunisation Office, HSE Population Health, 
HSE Social Inclusion, the Institute of Obstetricians and 
Gynaecologists, the National Virus Reference Laboratory 
and the field of Paediatric Infectious Disease. This 
group agreed public health strategies (vaccination and 
management of cases and close contacts, awareness-
raising among clinicians and in the community) to 
control the outbreak at national and local level.
Of the 162 measles cases notifed in 2009, one had 
no case classification specified, 58 cases (36%) were 
classified as possible while 103 (64%) were classified 
as confirmed, giving a crude confirmed incidence 
rate of 2.4 per 100,000 population.  Eighty-two of the 
confirmed cases were laboratory confirmed while 21 
were epidemiologically linked to a laboratory confirmed 
case.  
1.2 Measles 
Summary
Number of cases, 2009: 162
Number of confirmed cases, 2009: 103                                  
Crude incidence rate, 2009: 3.8/100,000
Crude confirmed incidence rate, 2009: 2.4/100,000                   
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Figure 1. Number of measles cases notified by week and month in 2009
The largest number of cases notified in 2009 was in the 
HSE-S (table 1).
In 2009, measles cases ranged in age from four months 
to 34 years.  The largest number of cases (n=41) was 
in the age group one to two years (figure 2) while the 
highest age specific incidence rate (37.7/100,000) was in 
those aged <1 year (figure 3).  Of the 162 measles cases 
87 (54%) were male, 74 (46%) were female while sex was 
not specified for one case.
Laboratory results were provided for 115 (71%) cases 
in 2009.  Eighty-two cases were laboratory positive 
for measles.  The laboratory results for five cases were 
inconclusive.  Twenty-eight cases were laboratory 
negative for measles, however, for 10 of these the 
specimens were not taken at the optimal time following 
disease onset or the date of specimen collection in 
relation to disease onset was unknown (the optimal 
time following disease onset for collecting oral fluid 
specimens for measles IgM testing is greater than seven 
days to two months and the optimal time for collecting 
serum specimens for measles IgM testing is greater 
than four days to two-three months).  All 18 cases that 
were laboratory negative for measles and were known 
to have a specimen collected at the optimal time were 
classified as possible cases.
Measles vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.
Vaccination data were reported for 136 (84%) measles 
cases in 2009.  Ninety-six cases (n=96/162, 59%) were 
unvaccinated; only 20 (n=20/96, 21%) of these were less 
than 12 months of age.
Thirty-two cases (n=32/162, 20%) had one dose of MMR 
vaccine; 25 (78%) of these were less than six years of 
age.  Only six (19%) of these 32 cases were classified as 
confirmed.  Four of the 32 cases (13%) were known to 
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Figure 3. The age specific incidence rate (per 100,000) of 
notified measles cases in 2009 by case classification
Figure 2. Number of notified measles cases in 2009 by age 
group and case classification
Table 1. Number of measles cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2009
HSE Area Number CIR
HSE-E 30 2.0
HSE-M 3 1.2
HSE-MW 3 0.8
HSE-NE 3 0.8
HSE-NW 0 0.0
HSE-SE 37 8.0
HSE-S 52 8.4
HSE-W 34 8.2
Total 162 3.8
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be vaccinated less than nine days before onset of illness 
and were probably incubating measles at the time of 
vaccination while four cases (13%) had no vaccination 
date reported.
Eight cases were reported as having received two 
doses of MMR.  Only two of these cases were classified 
as confirmed and neither of these cases had any 
vaccination dates or other vaccination details reported. 
Although ethnicity is not routinely collected as part 
of notification data and may be difficult to establish 
and report on, it was evident in the early stages of the 
outbreak that a substantial number of cases were linked 
to the Irish Traveller community. Based on available 
data, over a third (n=41/120, 34%) of the cases notified 
from Week 31 to Week 52 2009 were recorded as Irish 
Travellers while two cases (n=2/120, 1.7%) belonged 
to the Roma community.  In contrast, only 0.5% of 
the population of Ireland are Irish Travellers and 
approximately 0.1% belongs to the Roma community.  
By December 2009, verbal reports from the HSE-S 
highlighted transmission was also among children whose 
parents objected to vaccination, either for perceived 
safety reasons or for philosophical reasons. During the 
course of the outbreak a small number of cases were 
also reported in other citizens from Eastern Europe.
Sixty-eight cases were reported as hospitalised 
representing 42 percent (n=68/162) of all cases.  The 
hospitalised cases ranged in age from four months to 
34 years with 63 (93%) classified as confirmed cases 
and five (7%) classified as possible cases.  Length of 
hospitalisation was reported for 39 cases (n=39/68, 
57%) with a median duration of stay of two days (range 
one to eight days); fourteen cases were reported as 
hospitalised for one day. Of the 68 hospitalised cases, 
12 (18%) had no MMR details reported while 51 (75%) 
were unvaccinated.  Three cases (4%) were reported 
to have one dose of MMR; however, two of these were 
vaccinated less than three days prior to onset.  The 
remaining two hospitalised cases (3%) were reported 
to have had two doses of MMR although neither case 
had any vaccination dates or other vaccination details 
reported. 
There was probable nosocomial transmission of measles 
in two GP practices; two adults working in separate GP 
practices developed measles.  Measles cases in children 
were associated with both practices.  There was also 
probable nosocomial transmission of measles to a child 
in hospital.
Information on measles associated complications was 
reported for 93 (n=93/162, 57%) cases.  Pneumonia was 
reported for seven cases, ear infection/otitis media was 
reported for four cases, pneumothorax was reported for 
one and dehydration was reported for one case. Two 
of the cases with pneumonia were reported to have 
required ventilation.  The remaining 80 cases had no 
complications.
Three cases were reported as being infected outside 
Ireland.  The countries of infection were reported as 
France (n=1), Poland (n=1) and the United Kingdom 
(n=1).
Eight localised measles outbreaks were notified during 
2009, with 105 associated cases of illness.  The outbreak 
locations included four private houses (with 11 ill), three 
community outbreaks (with 48 ill) and one outbreak 
occurring among an extended family (with 46 ill).
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 27th September 
2010.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR. 
EU data are available at www.euvac.net and WHO 
European data are available at http://data.euro.who.int/
CISID/.
In 2009, 147 cases (3.5/100,000) cases of invasive 
meningococcal disease (IMD) were notified in Ireland. 
This continues the downward trend from the previous 
two years when 168 cases (4.0/100,000) and 179 
cases (4.2/100,000), were reported in 2008 and 2007, 
respectively (figure 1). When compared with rates 
reported in 1999 and 2000, incidence rates have 
substantially declined in recent years (figure 1).
Based on the meningococcal disease case definition, 
130 of the 147 cases (88.4%) notified in 2009 were 
case classified as definite, four (2.7%) as presumed and 
13 (8.8%) as possible. The vast majority of the cases 
(90.4%; n=133/147) were laboratory confirmed by 
means of blood or CSF culture or PCR testing, blood 
serology, detection of gram negative diplococci in 
skin lesions and skin culture or in CSF specimens, and 
by screening of nasal, throat and eye swabs. Most 
cases were confirmed by PCR alone (52.6%, 70/133). 
Confirmation of the remaining 63 cases was by blood or 
CSF culture only (n=11; 17.5%), by blood or CSF PCR 
and/or culture (n=60; 95.5%). Two were confirmed by 
detection of Gram negative diplococci in skin lesion 
microscopy exclusively. None were confirmed by 
serology exclusively. 
In 2009, male cases (n=82) exceeded female cases 
(n=64), resulting in a male to female ratio of 1.31:1.0. 
Cases ranged in age from one month to 89 years 
(median age of three years). The incidence of IMD was 
highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among infants <1 year 
of age (67.1/100,000), followed by children in the 1-4 
year age group (16.6/100,000), and the 15-19 year age 
group (7.2/100,000) (table 1). 
In 2009 the overall incidence of IMD in Ireland was 
highest in the HSE-MW area (4.4/100,000) with the 
lowest in the HSE-W area (2.7/100,000) (table 2).
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2009 and 
accounted for 119 (81%) of the 147 notifications (figure 
1). Since 2003 serogroup B has accounted for 80% or 
more of annual IMD notifications (figure 1). 
IMD due to serogroup C has remained at very low 
levels over the last seven years with no more than five 
cases occurring annually. In 2009, five (0.11/100,000) 
serogroup C cases arose (figure 1). All five cases 
occurred in individuals aged 20 years or less (age range 
1.3 Meningococcal Disease 
Summary
Number of cases, 2009: 147
Number of cases, 2008: 168
Number of cases, 2007: 179
Crude incidence rate, 2009: 3.5/100,000
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Table 1. Number of cases, deaths, age-group specific incidence 
rates per 1000,000 population and case fatality ratios of IMD in 
Ireland, 2009
Age Group No. Cases ASIR No. Deaths CFR (%)
<1 41 67.1 0 0.0%
1-4 40 16.6 2 5.0%
5-9 11 3.8 1 9.1%
10-14 6 2.2 0 0.0%
15-19 21 7.2 2 9.5%
20-24 9 2.6 0 0.0%
25+ 19 0.7 1 5.3%
All ages 147 3.5 6 4.1%
ASIR, age specific incidence rate per 100,000 population
CFR, case fatality ratio
8 months-20 years), three of whom were completely 
vaccinated and all recovered. One MenC vaccine failure 
also occurred in 2008, 2007, 2006 and again in 2005, 
while no failures arising in either 2004 or 2003.
The recent increase in the number of MenC vaccine 
failures is a reminder of the need for vigilance and 
monitoring of IMD due to serogroup C following the 
introduction of the MenC conjugate vaccine back in 
October 2000 (figure 1). Prior to the introduction of 
this vaccine, the serogroup C incidence rate in 1999 
was 3.7 per 100,000 total population. The National 
Immunisation Advisory Committee (NIAC) has recently 
recommended a booster dose of the MenC vaccine 
for close contacts of cases who have completed 
a course more than one year before, details of 
which are available at http://www.ndsc.ie/hpsc/A-Z/
VaccinePreventable/Vaccination/Guidance/
There were six IMD related notified deaths in 2009 
(case fatality ratio of 4.1%) compared to an average of 
5.5 deaths between 2005 and 2008. In 2009, the case 
fatality ratio (CFR) was highest amongst cases 15-19 
years of age (9.5%) as a result of two deaths among 
21 cases (table 1). The next highest CFR occurred in 
children aged 5-9 years (9.1%) and adults aged 25 years 
or more (5.3%) (table 1).
All six of the IMD deaths in 2009 were due to serogroup 
B disease (age range two years to 71 years). This is in 
marked contrast to the 25 deaths reported in 2000 due 
to serogroup B. In the same year, 11 deaths were due 
to serogroup C disease (out of a total of 139 cases). 
In 2001, three deaths from serogroup C disease were 
reported, one in a child <15 years of age and two in 
adults aged between 20 and 64 years. One death from 
serogroup C disease occurred in 2003, 2004 and again 
in 2008, all in adults over 45 year of age. Since 2001 
however, the decline in the annual number of serogroup 
C deaths has been quite significant, especially in those 
aged under 25 years of age, with no deaths in this age 
group being reported during this period of time (table 
3). 
Despite a reduction in the overall incidence in recent 
years, IMD continues to be treated as a serious public 
health concern due to its associated severity, high 
mortality rate and serious adverse sequelae. 
Effective vaccination is necessary for the complete 
prevention and control of IMD. Although effective 
vaccines are available against serogroups A, C, W135 
and Y forms of the disease, a suitable vaccine against 
serogroup B disease, the most common form of IMD 
in Ireland, is not yet available. Until such time that an 
effective meningococcal serogroup B vaccine, suitable 
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Figure 1. Number of invasive meningococcal disease (IMD) 
notifications in Ireland by serogroup, 1999-2008
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Figure 1. Number of invasive meningococcal disease (IMD) notifications in Ireland by serogroup, 1999-2009
Table 2. Number of cases and age specific incidence rates per 100,000 population of IMD by HSE area, 2009
HSE area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 74.8 16.9 5.3 1.1 4.0 3.6 0.4 3.3
M 105.7 6.3 0.0 5.6 5.7 5.5 0.0 3.2
MW 117.6 19.9 4.0 0.0 3.9 0.0 1.7 4.4
NE 62.9 31.6 6.7 3.7 0.0 3.6 0.4 4.3
NW 29.7 21.9 5.8 0.0 5.8 0.0 1.3 3.4
SE 59.3 18.5 0.0 0.0 12.4 0.0 0.7 3.3
S 69.9 8.9 4.8 5.0 11.9 2.1 1.0 3.7
W 0.0 8.8 0.0 3.7 17.0 3.1 0.7 2.7
Ireland 67.1 16.6 3.8 2.2 7.2 2.6 0.7 3.5
for use in infants, is on the market, IMD will remain a 
significant cause of morbidity and mortality in children 
and young adults in Ireland.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 7th July 2010. These 
figures may differ from those published previously due 
to ongoing updating of notification data on CIDR.
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Table 3. Number of cases, deaths and case fatality ratios by year of meningococcal serogroups B and C disease in Ireland, 
1999-2009
Meningococcal B Meningococcal C
Year No. Cases No. Deaths CFR% No. Cases No. Deaths CFR%
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0.0%
2003 206 11 5.3% 5 1 20.0%
2004 163 7 4.3% 5 1 20.0%
2005 169 5 3.0% 5 0 0.0%
2006 168 5 3.0% 4 0 0.0%
2007 157 6 3.8% 2 0 0.0%
2008 149 6 4.0% 4 1 25.0%
2009 119 6 5.0% 5 0 0.0%
Mumps notifications had declined in 2007 following 
a national mumps outbreak that began at the end 
of 2004, however, mumps notifications increased 
in the later part of 2008 and increased dramatically 
in the first half of 2009.  In total, there were 142 
cases (3.3/100,000) notified in 2007, 1,380 cases 
(32.5/100,000) notified in 2008 and 3,629 cases 
(85.6/100,000) notified in 2009 (figure 1).  Sixty percent 
(n=826/1,380) of cases in 2008 were notified between 
late September and the end of December and 83% 
(n=3,016/3,629) of cases in 2009 were notified between 
January and May 2009.
A national outbreak control team was convened in 
2009 to address the issue of ongoing transmission of 
mumps virus. Control measures implemented included 
an MMR vaccination campaign for students in fourth, 
fifth and sixth year in all second level schools during the 
final term of the 2008/2009 academic year concluding 
in September 2009. The decision was based on the 
fact that efforts to control mumps outbreaks among 
students in third level colleges had failed and that 
students in senior cycle of second level schools were the 
cohort most susceptible to mumps. The uptake of MMR, 
based on school/clinic session reports, among this 
cohort was 70.8% (source HSE-National Immunisation 
Office). 
Near the end of March 2009, the mumps outbreak 
control team recognised that due to the large number 
of cases (180 cases were notified on average each 
week in March) it may not be possible to collect 
enhanced data and laboratory specimens on all cases.  
Enhanced data was collected on approximately 30% 
of cases during January to March and approximately 
12% of cases during April to December.  However, the 
percentage of cases classified as confirmed was 38% 
both during January to March (n=593/1,546) and during 
April to December (n=782/2,083).  
In 2009, of the 3,629 mumps cases notified 38% 
(n=1,375) were classified as confirmed, 11% (n=417) 
were classified as probable, 50% (n=1,803) were 
classified as possible and one percent (n=34) had no 
case classification specified.
1.4 Mumps 
Summary
Number of cases, 2009: 3,629
Number of cases, 2008: 1,380
Number of cases, 2007: 142
Crude incidence rate, 2009: 85.6/100,000
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Figure 1. Number of mumps notifications by year and year of introduction of the measles-mumps-rubella (MMR) vaccine in 
Ireland
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2009 data collated by HPSC
The largest number of cases was notified in the HSE-E 
followed by the HSE-W, while the highest crude 
incidence rate was in the HSE-W (table 1).
In 2009, cases ranged in age from seven months to 96 
years; with a mean age of 22 years and a median age of 
21 years (age was unknown for 34 cases).  The largest 
number of cases and the highest age specific incidence 
rates (figures 2 and 3) were in those aged 15-19 years 
and 20-24 years.  Of the 3,629 mumps cases, 54% 
(n=1,964) were male and 45% (n=1,649) were female 
(gender was unreported for 16 cases).
Of the 3,629 mumps cases, seven percent (n=257) 
were unvaccinated, 10% (n=381) had one dose of the 
measles-mumps-rubella vaccine (MMR), 15% (n=562) 
were reported to have received two doses of MMR 
while for 67% (n=2,429) of cases the number of doses 
of MMR were not reported.  The vaccination date was 
reported for 37% (n=141/381) of cases reported to have 
received one dose of MMR.  Both vaccination dates 
were reported for 25% (n=140/562) of cases vaccinated 
with two doses of MMR.  Twenty-one percent 
(n=116/562) of the cases reported to have received two 
doses of MMR were classified as confirmed.  
Seventy-five cases were reported to have been 
hospitalised, representing two percent (n=75/3,629) 
of all cases and 10% (n=75/771) of cases where 
hospitalisation data were provided.  The number of days 
hospitalised was reported for 40% (n=30/75) of these 
hospitalised cases.  The number of days the cases were 
hospitalised ranged from one to 12 with a median and a 
mean of three days.  
Reported complications of mumps included orchitis 
(21%, n=88/412), pancreatitis (2.9%, n=19/656), 
meningitis (1.5%, n=10/671), deafness (1.1%, n=7/652), 
encephalitis (0.9%, n=6/663) and mastitis (0.6%, 
n=4/655).
The setting where the case most likely acquired 
mumps was reported for 20% (n=711/3,629) of cases. 
University/college was reported as the setting where the 
case most likely acquired mumps for 59% (n=418/711) 
of cases where this information was provided and social 
setting was reported for 20% (n=139/711) of these 
cases.
Thirty-two localised outbreaks of mumps were notified 
during 2009 with 280 associated cases of illness.  The 
majority of these cases were associated with outbreaks 
in educational settings.  The outbreak locations included 
13 private houses (with 37 ill), nine universities/colleges 
(with 181 ill), six schools (with 46 ill), one crèche (with 
two ill), an outbreak associated with a public house 
(with four ill), an outbreak associated with a residential 
institution (with four ill) and an outbreak associated 
with a sports team (with six ill).  As there was a 
national mumps outbreak in 2009 with widespread 
mumps activity many outbreaks, including community 
outbreaks, were not specifically notified.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 09th September 
2010.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.  
EU data are available at www.euvac.net.  
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Figure 2. Number of notified mumps cases in 2009 by age 
group and case classification
Figure 3. The age specific incidence rates (per 100,000) of 
notified mumps cases in 2009 (age is unknown for 34 cases)
Table 1. Number of mumps cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2009
HSE Area Number CIR
HSE-E 974 64.9
HSE-M 142 56.4
HSE-MW 341 94.5
HSE-NE 333 84.5
HSE-NW 156 65.8
HSE-SE 300 65.1
HSE-S 559 90.0
HSE-W 824 198.9
Total 3,629 85.6
Apart from Neisseria meningitidis, which is considered 
the most common cause of bacterial meningitis in 
Ireland, other forms of the disease do occur, including 
those caused by non-notifiable organisms, details of 
which are presented below. For information on invasive 
meningococcal disease (Neisseria meningitidis), see 
a separate chapter within this report. The figures 
presented in this chapter are based on data extracted 
from the Computerised Infectious Disease Reporting 
(CIDR) system on 7th July 2010. These figures may 
differ from those published previously due to ongoing 
updating of notification data on CIDR.
Haemophilus influenzae
In 2009, three cases of meningitis due to H. influenzae 
were notified, two of whom were under one year of age, 
with the remaining case aged between 5-9 years. One 
of the cases was attributable to a type e infection, the 
second was not typeable and the third was not typed. 
No deaths were reported. See a separate chapter on 
invasive H. influenzae disease for further details.
Leptospira species
One case of leptospirosis meningitis was notified in 
2009 in a young adult female, a canoeist aged 25-
29 years. The causative organism was identified as a 
Leptospira interrogans serovar icterohaemorrhagiae. 
See a separate chapter on non-IID zoonotic diseases for 
further details.
Listeria species
One case of listeriosis meningitis was notified in a 45-49 
year old in 2009. See a separate chapter on listeriosis 
disease for further details.
Streptococcus pneumoniae
In 2009, 28 cases of pneumococcal meningitis were 
notified, compared to 32 in 2008 and 35 in 2007. Cases 
in 2009 ranged in age from one month to 81 years. 
There were three pneumococcal meningitis related 
deaths reported aged between five and 18 years. See a 
separate chapter on invasive pneumococcal disease for 
further details.
Streptococcus pyogenes (Streptococcus group A 
infection (invasive) (iGAS))
There were no reported cases of iGAS causing 
meningitis in 2009. See a separate chapter on iGAS 
infection for further details.
Bacterial meningitis by other specified notifiable 
diseases
One fatal case of Salmonella enterica enteritidis related 
meningitis in a 45-49 year old was reported in 2009.
1.5 Other forms of Bacterial Meningitis
Summary
Bacterial meningitis, Not Otherwise Specified
Number of cases, 2009: 39
Number of cases, 2008: 40
Number of cases, 2007: 33
Crude incidence rate, 2009:  0.9/100,000
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Mycobacterium species
In 2009, eight tuberculosis meningitis cases were 
notified (provisional). Cases ranged in age from four 
months to 76 years. No tuberculosis meningitis deaths 
were reported. See a separate chapter on tuberculosis 
for further details.
Bacterial meningitis (not otherwise specified)
In total, 39 cases of meningitis under this disease 
category were notified in 2009, among whom one 
patient died. The causative pathogens were identified 
in 15 of these. No causative pathogen was identified 
in the remaining 24 (61.5%) cases in 2009, an increase 
compared to 2008 when 17 cases had no organism 
identified (42.5%; n=17/40). 
Among the bacterial meningitis (not otherwise 
specified) cases notified in 2009 were three cases of 
Escherichia coli meningitis, one of whom was a four 
month old infant and another (an adult aged 35-39 
years) that died. Seven cases of Group B streptococci 
meningitis were also notified in 2009, with all but one 
being under four months of age, and with no deaths 
reported. In addition, two cases of meningitis caused by 
Staphylococcus aureus were reported in 2009, neither of 
whom died. Other meningitis notifications include one 
each caused by the following pathogens: Streptococcus 
bovis in a one month old infant, Streptococcus Group 
D infection in a two month old infant and Enterococcus 
Faecalis in a 25-29 year old adult, all of whom 
recovered.
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Table 1. Annual notifications of bacterial meningitis other than meningococcal disease, 2007-2009
Notified under Causative organism 2007 2008 2009 2007-2009
Haemophilus influenzae disease (invasive) Haemophilus influenzae 2 3 3 8
Leptospirosis Leptospira species 1 1 1 3
Listerosis Listeria species 1 2 1 4
Salmonellosis Salmonella enteritidis 0 0 1 1
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae 35 32 28 95
Streptococcus Group A infection (invasive) Streptococcus Group A (S. pyogenes) 0 2 0 3
Tuberculosis* Mycobacterium species 6 6* 8* 20
 Beta Haemolytic Streptococcus Group B 9 6 7 22
 Escherichia coli 0 11 3 14
 Staphylococcus aureus 0 3 2 5
 Enterococcus faecalis 0 1 1 2
Bacterial meningitis, NOS Citrobacter koseri 0 1 0 1
(not otherwise specified) Gemella species 1 0 0 1
 Proteus mirabilis 1 0 0 1
 Serratia liquefaciens 0 1 0 1
 Streptococcus bovis 0 0 1 1
 Streptococcus Group D 0 0 1 1
 Unknown 22 17 24 63
 Total Bacterial Meningitis, NOS 33 40 39 112
Total  78 86 81 245
 
Notes
* Tuberculosis meningitis figures for 2008 and 2009 are provisional
Seventy eight cases (1.8/100,000) of pertussis were 
notified in 2009 compared to 104 cases in 2008.  Of the 
78 cases in 2009 61 (78%) were classified as confirmed, 
15 (19%) as possible while two (3%) had no case 
classification specified.
In 2009, the majority of cases (n=55, 71%) and the 
highest age-specific incidence rate (90.0/100,000) were 
in children aged less than one year with two thirds 
(n=52) of all cases aged less than six months (figures 1 
and 2).  Thirty-nine cases (50%) were female, 37 (47%) 
were male, while gender was not reported for two cases 
(3%).
In Ireland it is recommended that children be vaccinated 
with an acellular pertussis-containing vaccine at two, 
four and six months of age and a booster dose at four 
to five years of age.  Since 2008 a booster with low dose 
acellular pertussis vaccine is recommended for those 
aged 11-14 years.  The vaccine provides protection 
in over 80% of children who are fully vaccinated.  
However, protection declines over time, with little or no 
protection 10-12 years after primary immunisation, if no 
booster doses are administered.  
In 2009, the vaccination status was reported for 42 
(54%) pertussis cases.  Twenty-one (n=21/78, 27%) 
cases were unvaccinated; these cases ranged in age 
from one month to 12 years, with 20 cases aged less 
than six months.  Eleven unvaccinated cases (n=11/21, 
52%) were less than two months of age and were 
therefore not eligible for pertussis vaccine in the Irish 
schedule.  Twelve (n=12/78, 15%) cases were reported 
as incompletely vaccinated, but this included seven 
cases (n=7/12, 58%) who were less than six months of 
age and were therefore not eligible for three doses of 
pertussis vaccine in the Irish schedule.  Nine (n=9/78, 
12%) cases were reported as completely vaccinated for 
their age; four of these were reported to have had three 
doses of pertussis vaccine, one was reported to have 
four doses while the number of doses was not specified 
for four.  Three of the nine cases reported as completely 
vaccinated for their age were classified as confirmed.
 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 8th September 
2010.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
EU data are available at www.euvac.net. 
1.6 Pertussis
Summary
Number of cases, 2009: 78
Number of cases, 2008: 104
Crude incidence rate, 2009: 1.8/100,000
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Figure 2. The age specific incidence rate (per 100,000 
population) of notified pertussis cases in 2009 by case 
classification.
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Figure 1. Number of notified pertussis cases in 2009 by age 
group and case classification. “Mo” in graph indicates months 
i.e. 0-5 months and 6-11 months, the remaining age groups 
are in years.
In 2009, 19 cases (0.4/100,000) of rubella were notified 
in Ireland compared to 40 cases in 2008.
One of the cases in 2009 was classified as confirmed 
giving a crude confirmed incidence rate of 0.02 per 
100,000 total population.  The confirmed case was in 
the age group 25-34 years (figure 1).  Eighteen cases in 
2009 were classified as possible; the majority (=14, 78%) 
of these were less than three years of age (figure 1).  
The age specific incidence rates by case classification 
are shown in figure 2.
Of the 19 rubella cases 11 (58%) were male and eight 
(42%) were female.  The confirmed case was male.
Rubella vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.   
Vaccination status was reported for 16 (84%) of the 
rubella cases in 2009.  Seven cases (n=7/19, 37%) were 
unvaccinated and one case (n=1/19, 5%) was reported 
as incompletely vaccinated.  Eight cases (n=8/19, 42%) 
were reported as completely vaccinated for their age, 
only one (n=1/19, 5%) of these were reported to have 
two doses of MMR.  All 16 cases where vaccination 
status was reported were classified as possible cases.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 31st August 2010.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
WHO European data are available at http://data.euro.
who.int/CISID/. 
1.7 Rubella
Summary
Number of cases, 2009: 19
Number of confirmed cases, 2009: 1
Crude incidence rate, 2009: 0.4/100,000
Crude confirmed incidence rate:  2009 0.02/100,000
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Figure 1. Number of notified rubella cases in 2009 by age 
group and case classification
Figure 2. The age specific incidence rate (per 100,000 
population) of notified rubella cases in 2009 by case 
classification
Streptococcus pneumoniae (invasive)
Notifications
Notification by clinicians and laboratories of invasive 
Streptococcus pneumoniae infection is mandatory since 
January 2004.  Data on these notifications are collated 
in the Computerised Infectious Disease Reporting 
(CIDR) system.  For the purposes of this report the term 
invasive pneumococcal disease (IPD) will be used to 
describe these infections. 
In 2009, 433 cases of IPD (10.2/100,000) were notified
in Ireland. Eighty two percent (n=356) of notifications  
were classified as confirmed, 16% (n=69) as probable 
and 2% as possible (n=8). Compared with 2008 there 
was a 12% decrease in confirmed cases in 2009 (405 and 
356 cases, respectively).
 Of the 433 cases notified in 2009, clinical diagnosis was 
reported for 158 cases (36%), which included invasive 
pneumonia (n=82), septicaemia (n=45), meningitis 
(n=23) and meningitis & septicaemia (n=5). Peritonitis, 
soft tissue infection and abscess accounted for one case 
each.
More cases occurred in males (55%; n=240) than in 
females (45%; n=193).  Cases ranged in age from 4 
weeks to 101 years, with a median age of 61 years. The 
elderly i.e. those aged 65 years and older accounted for 
the greatest proportion of cases (45%, n=196), followed 
by children <5 years of age (12%, n=52) (figure1).
As in previous years, the incidence of IPD in 2009 
was high in the very young and very old and was 
relatively low in the age groups in between (figure 
1).  In children, the incidence was highest in infants <1 
year of age (29.5/100,000), followed by the 1 year old 
children (23.5/100,000).  In the age groups thereafter 
the incidence declined and did not exceed 14 cases 
per 100,000 in those aged 2-64 years.  In the elderly 
(* 65 years) the incidence increased considerably and 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of cases in 2009: 433
Number of cases in 2008: 465
Number of deaths in 2009: 18
Number of deaths in 2008: 17
Crude incidence rate, 2009: 10.2/100,000
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Figure 1. Number and age specific incidence rates (ASIR) of invasive pneumococcal disease notifications by age group, 2009
was highest in elderly adults 85 years of age and older 
(70.8/100,000), (figure 1). 
Comparing the 2008 and 2009 age specific incidence 
rates, there was a notable decline in IPD in infants < 1 
year of age (42%), in 1 year olds (33%) and in elderly 
adults 85 years of age and greater (21%) (figure 2).  The 
introduction of the 7-valent pneumococcal vaccine 
(PCV7) to the childhood immunisation programme in 
September 2008 would explain the reduction in burden 
of IPD seen in young children in 2009. 
Outcome was reported on just 24% (n=106) of the IPD 
notifications in 2009.  Therefore, figures presented 
may underestimate IPD mortality in Ireland. Based on 
the data available, 18 deaths potentially due to IPD 
infection were reported in 2009. Four deaths occurred 
in children (< 5 years of age) and the remainder 
(n=14) were in adults, age range 18-89 years.  Clinical 
presentation was reported for 13 of the 18 deaths; 
10 had meningitis and/or septicaemia and three had 
pneumonia.  
IPD notification data was extracted from CIDR on 16th 
August 2010. These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR.
Typing data
Of the 356 confirmed IPD cases notified in 2009, 279 
(78%) had an isolate submitted for typing; 37 different 
serotypes were identified.  The predominant serotypes 
associated with IPD infection in the overall population 
were 14, 7F, 19A and 3 (figure 3).  In children < 2 years 
of age 7F, 14 and 6B were the most common serotypes 
(figure 3).
Since April 2007, the National Pneumococcal Typing 
Project has been offering a typing service to Irish 
laboratories for all invasive S. pneumoniae isolates 
submitted.  Data from this project are used here to 
access the impact of introducing PCV7.  Comparing the 
cumulative number of IPD cases between April 2007 – 
June 2008 and April 2009 – June 2010,  there has been 
an 84% reduction in the burden of IPD associated with 
PCV7 serotypes, in children <2 years of age (figure 
4, table 1) and a 44% reduction when all age groups 
are included (table 1).  Overall there has been a 19% 
reduction in the burden of IPD when all age groups and 
all serotypes are included (table 1). 
PCV7 vaccine failures
Based on data received through the IPD enhanced 
surveillance undertaken by the Departments of Public 
Health, two PCV7 vaccine failures were reported in 
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Table 1. Number of IPD cases pre-PCV7 (April 2007-June 2008) and post-PCV7 (April 2009–June 2010) introduction 
PCV7 serotypes Non-PCV7 serotypes All IPD serotypes
<2 yrs *2 yrs All ages <2 yrs *2 yrs All ages <2 yrs *2 yrs All ages
Apr 07 – Jun 08 45 163 208 14 216 230 59 379 438
Apr 09 – Jun 10 7 110 117 19 217 236 26 327 353
% change -84.4 -32.5 -43.8 +35.7 +0.5 +2.6 -55.9 -13.7 -19.4
Date source:  National IPD Typing Project
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Figure 2.  Age specific incidence rates of invasive pneumococcal disease by age group in 2008 and 2009
2009.  One was in an 18 month old child and the other 
in a 3 year old child, due to serotype 19F and 14, 
respectively.  Both children survived.
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2009, 20.2% of S. pneumoniae isolates were PNSP, 
compared to 23.1% in 2008 (Data source: EARS-Net). 
For details on the antimicrobial resistance patterns of S. 
pneumoniae, please see the chapter on Antimicrobial 
Resistance within this report.
Reinforcing IPD Surveillance
To build on and improve the current IPD surveillance 
systems/initiatives in Ireland it is important that:
UÊÊÊ>LÀ>ÌÀiÃÊ>`ÊVV>ÃÊÌvÞÊ>ÊV>ÃiÃÊvÊ*Ê
diagnosed to the relevant Department of Public 
Health
UÊÊÊ>LÀ>ÌÀiÃÊÃi`ÊÛ>ÃÛiÊS. pneumoniae isolates 
for typing to the National IPD Typing Project based at 
Beaumont Hospital
UÊÊÊ>LÀ>ÌÀiÃÊÀi«ÀÌÊ`iÌ>ÃÊvÊS. pneumoniae 
isolates from blood and CSF to EARS-Net
UÊÊÊi«>ÀÌiÌÃÊvÊ*ÕLVÊi>ÌÊÕ`iÀÌ>iÊi>Vi`Ê
surveillance of IPD cases
The ongoing collection of good quality surveillance data 
is vital to accurately monitor: the burden of illness due 
to IPD, the antimicrobial resistance profiles, the impact 
of introducing PCV7 and also to estimate the impact of 
introducing new vaccines.
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Figure 3.  Most common S. pneumoniae serotypes associated with IPD infection by age 
group, 2009
*Denotes serotypes covered by PCV7
Figure 4.  Cumulative number of IPD cases due to PCV7 serotypes in children <2 years of 
age, April 2007 - June 2008 and April 2009 – June 2010
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On 25th April 2009, a public health emergency of 
international concern was declared by the World 
Health Organization (WHO) due to an outbreak of 
2009 pandemic influenza A (H1N1) infection in Mexico 
and the USA. On 11th June 2009, WHO raised the 
pandemic alert level to phase six, announcing the first 
influenza pandemic of the 21st century. WHO classified 
the severity of the disease as “moderate” based on 
scientific evidence available to them as well as the 
impact of the pandemic on member states’ health 
systems and social and economic functioning.  On 
July 16th 2009, the Department of Health and Children 
announced that Ireland would change the national 
approach to managing the pandemic from one of 
containment (or limiting the entrance and initial spread 
of the pandemic virus into the country) to one of 
mitigation (or minimising the impact of the pandemic 
virus as its circulation increased).  
The vaccination campaign against 2009 pandemic 
influenza A (H1N1) started on 2nd November 2009. 
Individuals at highest risk of influenza disease and its 
complications were provided with the vaccine in the 
early stages, with those at less risk of severe disease 
vaccinated later on. The mass vaccine programme 
concluded on 31st March 2010 as the numbers 
contracting pandemic influenza declined significantly. 
However, pandemic vaccine continued to be provided 
over the summer to those individuals at highest risk of 
influenza complications.
On 10th August 2010, the WHO declared the end of the 
2009 influenza A (H1N1) pandemic.
Since 2000, HPSC has worked in collaboration with 
the National Virus Reference Laboratory (NVRL), the 
Irish College of General Practitioners (ICGP) and the 
Departments of Public Health on the influenza sentinel 
surveillance project. During the pandemic period, 60 
practices (located in all HSE-Areas) were recruited to 
report electronically, on a weekly basis, the number of 
patients who consulted with influenza-like illness (ILI). 
Sentinel GPs were requested to send a combined nasal 
and throat swab to the NVRL on at least five ILI patients 
per week. Other indicators of influenza activity included 
a network of sentinel hospitals reporting admission 
levels and sentinel schools reporting absenteeism. 
Once the public health emergency was declared, 
routine seasonal influenza surveillance was augmented 
as follows: 
UÊÊ/ÜÊ>``Ì>ÊÀi}>Ê>LÀ>ÌÀiÃ]Ê
ÀÊ1ÛiÀÃÌÞÊ
Hospital (CUH) and Galway University Hospitals (GUH), 
started testing for 2009 pandemic influenza A (H1N1), 
in addition to the NVRL. 
UÊÊ>Vi`ÊÃÕÀÛi>ViÊvÊÌiÊwÀÃÌÊÓääÊ>LÀ>ÌÀÞÊ
confirmed 2009 pandemic influenza A (H1N1) cases 
was implemented, thereafter enhanced surveillance 
data were collated on hospitalised cases only.
UÊÊ
ÀÌV>ÊV>ÀiÉ
1ÊÃÕÀÛi>ViÊvÊ«ÀL>LiÊ>`Ê
confirmed adult and paediatric pandemic influenza A 
(H1N1) cases commenced in October 2009. 
UÊÊ>Ì>ÊÊ>ÊV>ÃÊÌÊ*ÊÕÌvÕÀÃÊViÌÀiÃÊÜiÀiÊ
monitored for self reported influenza by HSE-NE. 
UÊÊ``Ì>ÊÃÕÀÛi>ViÊ«ÀiVÌÃÊVÕ`i`ÊÌÀ}Ê
mortality data from the General Register Office and an 
influenza vaccine effectiveness study (IMOVE project).
Data in this report covers the entire pandemic period 
from April 2009 (week 17 2009) to August 2010 (week 
32 2010). During the 2009 pandemic, ILI activity 
peaked during week 43 2009, at 201.3 per 100,000 
population (figure 1). This is the highest rate recorded 
since sentinel influenza surveillance commenced in 
2000. The previous highest peaks occurred in week 2 
2009 (120.6 per 100,000 population) and week 8 2001 
(122.9 per 100,000 population). In mid-July 2009 (week 
30), the ILI rate was above the baseline threshold of 
17.8 per 100,000. This level of influenza activity during 
the inter-seasonal period had never been experienced 
2.1 Influenza
Summary
The 2009 influenza A (H1N1) pandemic summary:
Peak influenza-like illness rate: 201.3 /100,000 population 
(week 43 2009)
Total confirmed pandemic cases hospitalised: 1059
Total confirmed pandemic cases admitted to ICU: 100
Total deaths associated with pandemic: 27
European data available at:    
http://ecdc.europa.eu/en/Activities/Surveillance/EISN/
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in Ireland. The peak age specific ILI rates during the 
pandemic were in 5-14 year olds, followed by 0-4 year 
olds. ILI rates in the 0-4, 5-14 and 15-64 year olds were 
the highest age specific rates recorded since sentinel 
influenza surveillance began. ILI rates in those aged 65 
years or older were lower than the 2008/2009 season 
and were comparable to other seasons.
The percentage of influenza-related calls to GP out-of-
hours services in Ireland, peaked during week 45 2009 
at 10.6%. During the peak of the pandemic, the highest 
number of calls relating to influenza received by each 
service was on average three per hour. 
The NVRL, CUH and GUH tested a total of 23,142 
specimens for influenza virus during the pandemic 
period. Twenty one percent (n=4797; 20.7%) were 
positive for influenza virus. Over 99% (n=4759; 99.2%) 
of positive influenza specimens were confirmed 
(n=4464) or probable (n=295) 2009 pandemic influenza 
A (H1N1). Thirty-eight (0.8%) specimens were positive 
for seasonal influenza: 1 influenza A (unsubtyped), 
5 A (H1), 27 A (H3) and 5 B. The NVRL performed 
neuraminidase sequencing on 36 non-sentinel 2009 
pandemic influenza A (H1N1) isolates, all of which were 
susceptible to oseltamivir and zanamivir. The NVRL 
also sequenced and phylogenetically characterised the 
haemagglutinin gene from 18 2009 pandemic influenza 
A (H1N1) isolates, all of which form a monophyletic 
group with A/California/07/2009, demonstrating a very 
good match between the circulating and vaccine strains. 
A total of 1,059 confirmed cases of 2009 pandemic 
influenza A (H1N1) were admitted to hospital. Of these, 
100 (9.4%) were admitted to ICU (76 adults and 24 
paediatric cases). For hospitalised and ICU patients, 
the highest age-specific rates were in the 0-4 year age 
group. Of the 1,059 confirmed cases hospitalised, 507 
(47.9%) had pre-existing clinical conditions.1  The most 
frequently reported underlying medical conditions 
included: asthma (n=127, 12.0%), chronic respiratory 
disease2 (n=114, 10.8%), immunosuppression (n=79, 
7.5%) and chronic heart disease (n=62, 5.9%). Seventy-
three (6.9%) of all hospitalised confirmed cases were in 
pregnant women, eight of whom were admitted to ICU. 
Twenty-seven patients with confirmed 2009 pandemic 
influenza A (H1N1) died (pandemic (H1N1) 2009 was a 
contributing cause on the death certificate); 12 males 
and 15 females. Twenty (74.1%) deaths occurred in 
adults 35 years of age and older. The age range was 
8-83 years, with a median age of 52 years. Underlying 
medical conditions1 (including pregnancy) were reported 
for 25 of the 27 deaths (92.6%), with two deaths having 
no reported underlying medical conditions. Underlying 
conditions included chronic respiratory disease 2 (n=11), 
chronic neurological disease (n=9), immunosuppression 
(n=7), chronic heart disease (n=3), chronic liver disease 
(n=2), asthma (n=2), chronic renal disease (n=1) and 
severe obesity i.e. BMI *40 (n=1). One death (3.7%) 
occurred in a pregnant woman. Twenty five of the 
deaths (92.6%) occurred in hospitalised cases and 
15 (55.6%) deaths were in cases admitted to ICU. A 
summary of pandemic severity indicators is shown in 
table 1. 
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Figure 1: GP ILI consultation rate per 100,000 population,  baseline ILI threshold rate, and number of positive influenza 
specimens, by influenza week and season, week 40 2008-week 32 2010. Source: ICGP clinical ILI data and NVRL, CUH and GUH 
laboratory data. Virological data for the NVRL includes sentinel and non-sentinel data for all weeks. Virological data from GUH and CUH 
includes non-sentinel data from weeks 29 and 31 2009, respectively.
1. Some cases had more than one underlying medical condition. 
2. It cannot be established if chronic respiratory disease was in addition to, or included asthma.
One hundred and nine general outbreaks of ILI and 
2009 pandemic influenza were reported in Ireland 
during the pandemic period. These outbreaks involved 
2,578 people in total, of which 204 (7.9%) were reported 
as laboratory confirmed cases of 2009 pandemic 
influenza. Regional variation in ILI/pandemic activity was 
observed during the pandemic period. The majority of 
outbreaks were reported from HSE-E (n=29; 26.6%) and 
HSE-S (n=27; 24.8%). With the exception of HSE-M, 
all HSE-Areas reported general outbreaks of 2009 
pandemic influenza and ILI during the pandemic period. 
A total of 955,118 individuals were recorded as 
vaccinated with the pandemic vaccine, representing 
23% of the population of Ireland eligible for vaccination. 
It should be noted that pandemic vaccination data are 
provisional.
In the post-pandemic period, based on knowledge 
about past pandemics the 2009 pandemic influenza 
virus is expected to continue to circulate as seasonal 
virus for some years to come. Therefore, cases and local 
outbreaks due to 2009 pandemic influenza will continue 
to occur and such outbreaks could have a substantial 
impact on communities. WHO advises that national 
health authorities remain vigilant in the immediate 
post-pandemic period as the behaviour of the virus as a 
seasonal virus cannot be reliably predicted.
In addition, it is most likely that, compared with 
seasonal influenza, younger age groups will continue 
to be affected disproportionately by the virus. Groups 
identified during the pandemic as being at higher risk 
of severe or fatal disease will remain at increased risk 
though the number of such cases should diminish.  
In August 2010, WHO issued guidance on 
recommended activities during the post-pandemic 
period including advice on epidemiological and 
virological surveillance, vaccination and the clinical 
management of cases. WHO recommends: (1) the 
monitoring of clusters of severe respiratory illness or 
death; (2) investigation of severe or unusual cases 
clusters or outbreaks to facilitate rapid identification of 
important changes in the epidemiology and severity of 
influenza; and (3) maintaining routine ILI surveillance and 
surveillance of severe cases of influenza and respiratory 
illness.
For the 2010/2011 influenza season, existing 
surveillance systems have been strengthened and 
maintained. Data from these surveillance systems 
will assist in guiding the prevention, control and 
management of ILI/influenza. 
Further information on influenza is available on the 
HPSC website www.hpsc.ie
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Table 1: Summary table of severity indicators for laboratory confirmed 2009 pandemic influenza A (H1N1) cases - hospitalised 
cases, ICU cases and deaths. 
	  
,ŽƐƉŝƚĂůŝƐĞĚĐŽŶĮƌŵĞĚ
ϮϬϬϵƉĂŶĚĞŵŝĐŝŶŇƵĞŶǌĂ
A	  (H1N1)	  cases
/hĐŽŶĮƌŵĞĚϮϬϬϵ
ƉĂŶĚĞŵŝĐŝŶŇƵĞŶǌĂ
(H1N1)	  cases
ĞĂƚŚƐŝŶĐŽŶĮƌŵĞĚϮϬϬϵ
ƉĂŶĚĞŵŝĐŝŶŇƵĞŶǌĂ
(H1N1)	  cases
Total cases 1059 100 27
Crude rate per 100,000 population 25.0 2.4 0.6
Age range (years) 0-­‐84 0-­‐79 8-­‐83
Median age (years) 17 34 52
Females
533 50 15
50.3% 50.0% 55.6%
Cases with risk factor1
507 81 25
47.9% 81.0% 92.6%
1. Some cases had more than one underlying medical condition. 
In 2009, seven cases of legionnaires’ disease were 
notified in Ireland, a rate of 1.7 per million population. 
This was a significant drop compared to the rate 
recorded in the previous two years but the numbers are 
small (Table 1). Two deaths were recorded in 2009, but 
neither death was directly attributed to legionnaires’ 
disease.
Three cases were notified from HSE East, two from HSE 
North West and one each from HSE Midlands and HSE 
Mid-West. 
The majority of cases (57.1%) were male. The median 
age of cases was 63 years with a range from 50 to 85 
years.
All seven cases were confirmed by urinary antigen 
testing. The organism involved was Legionella 
pneumophila serogroup 1. 
Of the seven cases, three were travel-associated, one 
was hospital-associated and three were community-
associated. Countries of travel included Turkey (1), 
United Arab Emirates (1) and Latvia (1). A case of 
legionnaires’ disease is defined as travel-associated if 
the patient spent one or more nights away from home in 
accommodation used for commercial purposes (hotels, 
holiday apartments) in the 10 days before onset of 
illness. Travel-associated cases may involve travel within 
Ireland or abroad.
Pontiac fever
In 2009, there were two cases of pontiac fever reported. 
One case was probable and was linked to a travel-
associated case of legionnaires’ disease. The other case 
was laboratory confirmed by urinary antigen testing.
Pontiac fever is a self-limiting flu-like illness. The 
incubation period is 24-48 hours and patients recover 
spontaneously.
2.2 Legionellosis
Summary
Number of cases in 2009: 7
Crude incidence rate: 1.7 per million
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Table 1. Number of legionnaires’ disease cases per million population notified in Ireland, 2002-2009 
Age group 
(years) 2002 2003 2004 2005 2006 2007 2008 2009
<30 0 1 0 0 0 1 0 0
30-39 2 0 0 2 0 4 0 0
40-49 3 0 1 4 8 4 2 0
50-59 0 1 1 1 2 2 3 2
60-69 1 2 1 1 1 3 4 3
70+ 0 3 1 1 2 2 2 2
Total 6 7 4 9 13 16 11 7
CIR 1.5 1.8 0.9 2.1 3.1 3.8 2.6 1.7
Notifications
Sixty cases of invasive Group A streptococcal (iGAS) 
disease were notified in 2009.  This corresponds to 1.42 
iGAS cases per 100,000 population [95% confidence 
interval (CI), 1.08 to 1.82 per 100,000] and represents a 
decrease since 2008 when the iGAS rate was 1.65 per 
100,000 population (95% CI, 1.29 to 2.09 per 100,000).  
All 60 cases were confirmed, defined as patients 
with group A Streptococcus (GAS), or Streptococcus 
pyogenes, isolated from a sterile site. 
Patient demographics
Of the 60 cases, 34 (60%) were males and 26 (40%) were 
females, with ages ranging from 11 months–95 years 
(mean, 47 years; median, 47 years). iGAS was more 
common in young children and older adults (Figure 1).
 
Geographic spread and seasonal variation
Table 1 outlines the numbers and crude incidence rates 
(CIRs) of iGAS disease by HSE area from 2004 to 2009. 
Of note, the highest number of cases and CIR in 2009 
occurred in the HSE-E (n=32; CIR, 2.13 per 100,000 
population). 
In 2009, almost half of all cases (n=29) occurred 
between April and July, with another peak in January 
(n=7).
Enhanced surveillance data 
Enhanced data fields were entered by 13 laboratories 
for 50 (83%) iGAS cases, which represents an increase 
in completion of enhanced surveillance data from 2008 
(69%, 48 of 70 cases). The source laboratory could not 
be ascertained for six of the cases. A wide variation in 
completed fields was observed. 
Isolate details
GAS was isolated from a sterile site in 48 of 50 cases, 
primarily from blood cultures (n=44 isolates, or 94%) but 
also abscesses (n=1), deep tissue (n=2) and pleural fluid 
(n=1).
Serological typing data, based on the detection of 
M and T-proteins, were available on five isolates only 
from two laboratories: emm/M1 (n=2), M5 (n=1), M12 
(n=1) and M28 (n=1). Enhanced data were available 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Number of cases, 2009: 60
Crude incidence rate, 2009: 1.42 per 100,000 population
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Figure 1.  Age and sex specific rates of iGAS disease in 2009
on three patients with iGAS (emm/M1, M12 and M28), 
all of whom presented with streptococcal toxic shock 
syndrome (STSS). 
Clinical details
As in 2008 and previous years, bacteraemia (n=45 cases, 
including cases where bacteraemia was not specifically 
stated but GAS was isolated from blood) and cellulitis 
(n=13) were the most common clinical presentations, 
followed by necrotising fasciitis (n=5), STSS (n=7; 3 of 
which were implied based on the clinical presentation 
given), myositis (n=2), pneumonia (n=2), septic arthritis 
(n=2), erysipelas (n=1) and puerperal sepsis (n=1). 
Note that cases could have more than one clinical 
presentation.  
Risk factors
Risk factors associated with iGAS disease included 
age over 65 years (n=18), skin and wound lesions 
(n=16), diabetes (n=3), steroid use (n=1), malignancy 
(n=6), intravenous drug use (IVDU) (n=3), and varicella 
infection (n=2). Note that cases could have one or more 
associated risk factors: 21 cases had one risk factor, 11 
had two risk factors and two had three risk factors. No 
risk factors were identified for 22 cases. Among the 
seven cases with STSS, age over 65 years was identified 
as a risk factor in four cases, skin lesions in four cases 
and IVDU in one case. All STSS cases had at least one 
risk factor.
Clinical management
Surgical intervention was required for eight patients 
ranging in age from 2 to 74 years, who presented with 
a variety of clinical presentations including necrotising 
fasciitis (n=2), cellulitis (n=3), and abscesses or deep 
tissue infection (n=3).
Admission to the intensive care unit was required for 
16 patients (compared to seven in 2008), ranging 
in age from 2 to 79 years, with the following clinical 
presentations:
UÊL>VÌiÀ>i>Ê³ÉÊViÕÌÃÊ­rn®
UÊÊL>VÌiÀ>i>]Ê-/--Ê>`ÊiVÀÌÃ}Êv>ÃVÌÃÊ³ÉÊÞÃÌÃÊ
(n=4) 
UÊÊL>VÌiÀ>i>]ÊViÕÌÃ]Ê«ÕiÀ«iÀ>ÊviÛiÀ]ÊiÀÞÃ«i>ÃÊ>`Ê
STSS (n=1)
UÊÊ-/--Ê­r£®
UÊÊL>VÌiÀ>i>Ê>`Ê«iÕ>Ê­r£®
UÊÊi>À}i`ÊiVÊ}>`ÃÊ­r£®
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HSE 
Area 2004 2005 2006 2007 2008 2009
 n CIR  n CIR n  CIR   n   CIR    n   CIR    n   CIR    
HSE-E 25 1.67 19 1.27 37 2.47 28 1.87 31 2.07 32 2.13
HSE-M 0 0.00 1 0.40 2 0.79 0 0.00 0 0.00 2 0.79
HSE-MW 1 0.28 3 0.83 2 0.55 2 0.55 3 0.83 5 1.38
HSE-NE 1 0.25 3 0.76 5 1.27 3 0.76 10 2.54 3 0.76
HSE-NW 0 0.00 3 1.27 1 0.42 3 1.27 3 1.27 1 0.42
HSE-SE 7 1.52 1 0.22 4 0.87 10 2.17 8 1.74 8 1.74
HSE-S 1 0.16 1 0.16 3 0.48 4 0.64 5 0.80 5 0.80
HSE-W 0 0.00 18 4.34 7 1.69 7 1.69 10 2.41 4 0.97
IRELAND 35 0.83 49 1.16 61 1.44 57 1.34 70 1.65 60 1.42
Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area, 2004-2009
Risk factors included age over 65 years (n=7), skin and 
wound lesions (n=6), malignancy (n=2), IVDU (n=2), 
diabetes (n=1) and varicella infection (n=1). Seven 
patients had one risk factor and six had two risk factors. 
No risk factors were identified for three patients. 
Length of ICU stay was provided for 12 cases ranging 
from one to 44 days (mean, 8.4 days; median/mode, 7 
days). Surgical intervention was required for two of four 
patients with necrotising fasciitis.
Other epidemiological information
Three cases (all bacteraemia, including one with 
cellulitis) were reported as hospital-acquired compared 
to one case in 2008. As in 2008, no outbreaks of iGAS 
were notified in 2009.
Outcome
Outcome at seven-days following GAS isolation was 
reported for 30 cases: 
UÊÊÓÇÊÜiÀiÊÃÌÊ>ÛiÊ
UÊÊÌÀiiÊ«>ÌiÌÃÊ`i`\Ê-ÊÜ>ÃÊÌiÊ>ÊÀÊVÌÀLÕÌÀÞÊ
cause of death in two (both of whom were IVD users 
and aged 20-25 years)
The seven-day case fatality rate (CFR) for iGAS disease 
was 10% in 2009, an increase from 4% (one death) in 
2008.
In addition to the above, the overall outcome was 
stated for a further eight cases:
UÊÊÌÀiiÊ­>Ê>}i`ÊÛiÀÊÇxÊÞi>ÀÃ®ÊÜiÀiÊÀi«ÀÌi`ÊÌÊ
have died but it was not stated if these deaths were 
directly attributable to iGAS
UÊÊvÕÀÊ«>ÌiÌÃÊÜiÀiÊÀiVÛiÀ}
UÊÊiÊ«>ÌiÌÊÀiVÛiÀi`
Of the seven STSS cases, one patient died resulting in a 
case fatality rate (CFR) of 17% (with outcome provided 
for six of the seven cases).
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 48 
iGAS isolates (46 from blood, one from tissue and one 
from a wound) by 12 laboratories in 2009. All isolates 
were susceptible to penicillin (n=47) and vancomycin 
(n=40).  Resistance to erythromycin was reported in 
three (6%) of 48 isolates, to clindamycin in one (4.5%) of 
22 isolates and to tetracycline in one (4%) of 25 isolates.
While enhanced data were available for over 80% 
of cases, improved completion of the enhanced 
questionnaire for all cases will further augment our 
understanding of iGAS disease in Ireland.  
HPSC thanks the microbiology laboratories for their 
contribution to date and encourages those that do 
not, to complete enhanced data forms and to submit 
antimicrobial susceptibility data on all iGAS cases along 
with their EARS-Net quarterly returns.
The enhanced surveillance form can be downloaded 
from the HPSC web site at:http://www.hpsc.ie/
hpsc/A-Z/Other/GroupAStreptococcalDiseaseGAS/
SurveillanceForms/
Further information on iGAS disease in Ireland, 
including national guidelines, is available 
at: http://www.ndsc.ie/hpsc/A-Z/Other/
GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 14th September 
2010. 
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Tuberculosis, 2008
In 2008, 468 cases of tuberculosis (TB) were notified 
in Ireland, corresponding to a crude notification rate 
of 11.0 per 100,000 population, which remains stable 
in comparison to 2007 (11.3/100,000) and 2006 
(11.0/100,000). A summary of the epidemiology of TB 
in Ireland during 2008 is shown in table 1 while the 
number of cases and crude incidence rates from 1991 
to 2009* with three-year moving averages are shown in 
figure 1. 
The highest crude incidence rates were reported by 
HSE-E (15.8/100,000) and HSE-S (14.2/100,000) while 
the lowest rates were reported by HSE-NE (4.6/100,000) 
and HSE-NW (5.9/100,000). Rates reported in HSE-SE 
(6.5/100,000), -MW (7.2/100,000) and-W (7.5/100,000) 
were also significantly lower than the national incidence 
rate. Differences in age-standardised TB incidence rates 
were also found between HSE areas with the highest 
rates reported by HSE-E (15.3/100,000) and HSE-S 
(14.0/100,000) and the lowest rate reported by HSE-
NE (4.7/100,000). The remaining HSE areas had rates 
ranging from 6.0 (HSE-NW) to 10.0 (HSE-M) per 100,000 
population. 
The highest age-specific rate in 2008 occurred among 
those aged 25-34 years (19.0/100,000) followed by 
those aged 65 years and over (17.7/100,000). The rate 
among males (13.2/100,000) was higher than the rate 
among females (8.7/100,000). Rates among males 
were higher than females for all age groups except in 
the 0-14 year age group where the rate in males was 
lower (1.1 compared to 2.4/100,000). The highest rate 
among males (24.6/100,000) was in the group aged 
65 years and older while the highest rate in females 
(18.8/100,000 population) was in the 25-34 year age 
group. The male to female ratio (1.5:1) reported in 2008 
was consistent with the rate reported in previous years. 
During 2008, 43.6% (204 cases) of TB cases were born 
outside Ireland. This is a slight increase compared to 
the proportion of foreign-born cases reported during 
2.4 Tuberculosis, 2008
Summary
Number of cases in 2008: 468
Number of culture confirmed cases: 294
Crude incidence rate in 2008: 11.0/100,000
Number of TB deaths in 2008: 9
Number of cases in 2009*: 472 
Crude incidence rate in 2009*: 11.1
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Parameter 2008
Total number of cases 479
Crude notification rate per 100,000 11.3
Cases in indigenous population† 272 (56.8%)
Cases in foreign-born persons1 205 (42.8%)
Culture positive cases 296 (61.8%)
Pulmonary 343 (71.6%)
Smear positive pulmonary cases 162 (33.8%)
Multi-drug resistant cases (MDR) 3 (0.6%)
Mono-resistant to isoniazid 9 (1.9%)
Deaths attributable to TB 9 (1.9%)
Outcomes reported in cases 335 (69.9%)
TB meningitis cases 6 (1.4 per million)
*Data for 2009 are provisional data which may change significantly 
following validation
†Country of birth not reported for 1 case
Table 1: Summary of the epidemiology of TB in Ireland, 2008
Parameter 2008
Total number of cases 468
Crude notification rate per 100,000 11.0
Cases in indigenous population† 263 (56.2%)
Cases in foreign-born persons1 204 (43.6%)
Culture positive cases 294 (62.8%)
Pulmonary cases 336 (71.9%)
Smear positive pulmonary cases 158 (33.8%)
Multi-drug resistant cases (MDR) 2 (0.4%)
Mono-resistant to isoniazid 12 (2.6%)
Deaths attributable to TB 9 (1.9%)
Outcomes reported in cases 414 (88.5%)
TB meningitis cases 6 (1.3 per million)
2007 (40.0%) and higher than those reported between 
2003 and 2006 (range: 21%-34.6%). The crude rate in 
the indigenous population was 7.4 per 100,000 similar 
to that reported in 2007 (8.0 per 100,000 population) 
while the crude rate in the foreign-born population 
was 33.3 per 100,000 which is slightly higher than 
that reported in 2007 (31.3 per 100,000). There was a 
notable difference in age between those born in Ireland 
and those born outside Ireland, with a median age of 
52 years and 29 years respectively. In 2008, among 
countries in the EU and Western Europe who reported 
data to the European Centre for Disease Prevention and 
Control (ECDC), 22.4% of notifications were in foreign-
born cases. In the United Kingdom, France and Belgium, 
where crude incidence rates are similar to those 
reported in Ireland, the percentage of cases of foreign 
origin in 2008 ranged from 46 to 65%.1
Pulmonary TB was reported in 336 (71.9%) cases, 131 
(28.0%) had exclusively extrapulmonary disease and 
diagnostic type was not reported in one case. Of the 
extrapulmonary cases reported in 2008, there were 
six cases of TB meningitis corresponding to a rate of 
0.13/100,000 population (1.3/million population). 
Of the 468 cases reported in 2008, 62.8% (294 cases) 
were culture confirmed. Species identification showed 
M. tuberculosis in 93.9% (276 cases) and M. bovis in 
3.7% (11 cases) of the culture confirmed cases (organism 
was not reported for seven culture confirmed cases). Of 
the 336 cases with a pulmonary component, 229 (68.2%) 
were culture confirmed, and 158 (47.0%) were smear 
positive.  
The proportion of drug resistant TB cases notified in 
2008 was 5.3% (25 cases). The proportion of MDR-TB 
cases was 0.4% (2 cases). Mono-resistance to isoniazid 
was recorded in 12 cases, to streptomycin in five, to 
pyrazinamide in two cases, to ethambutol in one and 
to rifampicin in one case. Two cases were also resistant 
to isoniazid and streptomycin. Fifteen of the 25 (60.0%) 
drug resistant cases, including one (50.0%) of the MDR-
TB cases, were born outside Ireland.
In 2008, information on treatment outcome was 
provided for 88.5% (414) of cases. Of the 414 cases, 
338 (81.6%) completed treatment, 36 (8.7%) died, 30 
(7.2%) were lost to follow up, nine (2.2%) had treatment 
interrupted and one was still on treatment (0.2%). 
Nine (25.0%) of the 36 deaths were attributable to 
TB. Information on treatment outcome data increased 
compared to 2007 when these data were provided for 
86% of cases. It is of critical importance to TB control in 
Ireland that surveillance of TB and reporting of outcome 
data be maintained at a high level especially with the 
global threat of resistant strains. 
Guidelines on the Prevention and Control of 
Tuberculosis in Ireland were published in April 2010.2 
These guidelines are an update on the Report of the 
Working Party on Tuberculosis, originally published by 
the Department of Health in 1996.3 All the sections from 
the original guidelines have been updated and a new 
section on infection prevention and control has been 
added. The recommendations in these guidelines are 
based on a review of international literature, expert 
opinion and an extensive consultation process. They 
provide advice on the diagnosis and treatment of 
active TB and latent TB Infection (LTBI), contact tracing 
procedures and screening for TB in special situations 
e.g. healthcare settings, new entrants to Ireland, prison 
and homeless settings. Chapters on infection prevention 
and control, TB and HIV infection and BCG vaccine 
are also included. The guidelines aim to improve the 
prevention and control of the disease and to help 
Ireland meet World Health Organization (WHO) targets 
for the elimination of TB. The WHO aims to reduce 
the global incidence of TB to less than one case per 
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Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2009* and 
3-year moving averages, 1992-2008
*Data for 2009 are provisional data which may change significantly following validation
million population by 2050, which will eliminate the 
disease as a global health problem.  The importance 
of good surveillance data cannot be underestimated 
in this context as they will help guide where resources 
should be directed in order to implement effective TB 
prevention and control strategies in Ireland and in order 
to reach the elimination target by 2050.
Provisional 2009 data
There were 472 cases of TB provisionally notified in 
2009, corresponding to a crude rate of 11.1 per 100,000 
population. It is important to note that these data are 
provisional and may change significantly following 
validation. 
Of the 472 cases provisionally notified in 2009, 
UÊÊ*Õ>ÀÞÊ/	ÊÜ>ÃÊ`>}Ãi`ÊÊÓÓÊV>ÃiÃÊ­È£°¯®]Ê
extrapulmonary TB in 159 cases (33.7%) and 
pulmonary and extrapulmonary TB in 19 cases (4.0%). 
Diagnostic type was not reported for two cases.
UÊÊ"vÊÌiÊÎ££ÊV>ÃiÃÊÜÌÊ>Ê«Õ>ÀÞÊ`Ãi>ÃiÊ
component, 171 (55.0%) were culture positive and 136 
(43.7%) were smear positive.
UÊÊ/iÀiÊÜiÀiÊÃiÛiÊV>ÃiÃÊvÊ/	Êi}ÌÃÊ«ÀÛÃ>ÞÊ
notified corresponding to a rate of 0.15 per 100,000 
population (1.5/million population).
UÊÊ/iÀiÊÜiÀiÊÓÈÇÊ­xÈ°È¯®ÊV>ÃiÃÊLÀÊÊÀi>`Ê>`Ê££Ê
(40.5%) were foreign-born. Country of birth was not 
reported for 14 (3.0%) cases.
UÊÊ/iÀiÊÜiÀiÊÓÎÊV>ÃiÃÊ­ÈÓ°£¯®ÊÌwi`ÊÊ>iÃ]Ê£ÇxÊ
cases (37.1%) in females and sex was not reported for 
four cases (0.8%)
UÊÊ/iÊi>Ê>}iÊvÊV>ÃiÃÊÜ>ÃÊ{{ÊÞi>ÀÃÊ­À>}i\ÊäÊÌÊ£Ê
years).
UÊÊ,iÃÃÌ>ViÊÜ>ÃÊÀi«ÀÌi`ÊÊ£{ÊV>ÃiÃ]ÊwÛiÊvÊÜVÊ
were mono-resistant to isoniazid. No cases of MDR-TB 
were reported during 2009. Eight of the 14 resistant 
cases were born outside Ireland.
More detailed surveillance reports can be found under 
Topics A-Z at www.hpsc.ie
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Infectious Intestinal Diseases
03Health Protection Surveillance Centre   Annual Report 2009
Campylobacteriosis became a notifiable disease 
in Ireland in 2004 under the Infectious Diseases 
regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were 
collected nationally as part of the EU Zoonoses 
Regulations. It is an acute zoonotic bacterial disease 
characterised by diarrhoea, abdominal pain, malaise, 
fever, nausea and vomiting. Symptoms generally last 
for only a few days.  In the European Union, poultry 
meat still appears to be the most important food-
borne source of Campylobacter as the occurrence of 
the bacteria remained at high levels throughout the 
food chain: from animals to meat at retail. This was in 
contrast to the high prevalence observed in live cattle 
and pigs which was typically followed by a strong 
decrease during slaughter and at retail.1 Findings of the 
first national case control study conducted in Ireland 
investigating risk factors for sporadic Campylobacter 
infections show that consuming chicken, lettuce and 
eating in takeaways were important risk factors for 
contracting the disease in Ireland. Contact with sheep, 
peptic ulcer, hiatus hernia lower bowel problems were 
also independently associated with infection. However 
mains water supply showed protective effect from 
contracting the illness2.
Campylobacteriosis is the commonest bacterial cause 
of gastroenteritis in Ireland and Europe. During 2009, 
1,808 cases were notified in Ireland, corresponding 
to a crude incidence rate (CIR) of 42.6 per 100,000 
population. This is a slight increase compared to the 
number of cases reported during 2008 (n=1,747, CIR: 
41.2). The European Centre for Communicable Disease 
Prevention and Control (ECDC) annual epidemiological 
report on communicable diseases in Europe reported 
a European crude incidence rate of 46.7 per 100,000 
population during 2007.3 
Geographical variation in CIR was observed within HSE 
areas. The highest CIR was observed in HSE-W at 57.0 
per 100,000 population, an increase from the 2008 CIR 
of 44.4 per 100,000 population. The lowest CIR was 
observed in HSE-NE at 34.3 per 100,000 population, 
which remains stable in comparison to the 2008 CIR of 
33.7 per 100,000 population. Figure 1 illustrates the 
campylobacteriosis CIR by HSE area during 2009 and 
2008, with 95% confidence intervals. 
Campylobacteriosis is seen in all age groups with the 
highest burden of illness experienced by the 0-4 year 
age group. During 2009, this age group accounted 
3.1 Campylobacter 
Summary
Number of cases: 1,808
Crude incidence rate: 42.6/100,000
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Figure 1: Campylobacteriosis crude incidence rates per 100,000 population (95% CI) by HSE area, 2008 & 
2009.
Figure 1: National CIR of Campylobacter by Region, 2007 and 2008.
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for 27.6% of cases and had the highest age specific 
incidence rate (ASIR) of 165.1 per 100,000 population. 
The second highest ASIR observed was in the 5-9 year 
age group (46.5/100,000 population). The lowest ASIR 
was observed in the 35-44 year age group (26.1/100,000 
population) and the 10-14 year age group (26.3/100,000 
population). This preponderance in younger children 
is a well known characteristic of the disease and is also 
observed at European level. The highest European 
notification rate during 2007 was reported in males 
in the 0-4 year age group (118/100,000 population) 
and in females of the same age group (99/100,000 
population).3 
During 2009, 52.7% of all cases were male, 46.8% of 
cases were female and sex was not reported for 0.5% 
of cases. Further analysis of the age-sex distribution 
of campylobacteriosis cases shows a predominance 
of male cases in every age category, except the 25-
34 year age group. Figure 2 illustrates the number of 
campylobacteriosis cases and age specific incidence 
rates by age group (years) and sex during 2009.
Campylobacteriosis has a well documented seasonal 
distribution with a peak in early summer. During 2009, 
notifications of campylobacteriosis peaked during 
May (n=206), June (n=208) and July (n=229) with 
a smaller secondary peak observed in September 
(n=176). Figure 3 illustrates the seasonal distribution of 
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Figure 2: Campylobacteriosis notifications and age specific incidence rate per 100,000 population by age group 
(years) and sex, 2009 (CIDR)
Figure 3: Number of campylobacteriosis notifications by month, 2004-2009
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campylobacteriosis notifications in Ireland from 2004 to 
2009. 
Information on country of infection was recorded in 
14.2% of all cases, which is slight decrease on the 
proportion of cases with this information provided in 
2008 (17%). Of the 256 cases where country of origin 
was specified, indigenous cases accounted for 85.2%. 
There were also 38 cases (14.8%) with a recent history 
of foreign travel. These travel associated cases had 
exposures in 17 different countries. The majority of 
campylobacteriosis cases (89%) in Europe reported to 
ECDC during 2007 were also indigenous.3
Of the cases notified in Ireland during 2009, 99.7% were 
laboratory confirmed. However, as there is currently 
no national reference facility for routine typing of 
Campylobacter isolates, information on Campylobacter 
species is markedly incomplete. In 2009, 32.0% (n=578) 
of isolates were speciated.  Of the 578 speciated 
isolates, 88.4% of isolates were C. jejuni while 11.6% 
were C. coli. The remaining 67.7% (n=1,224) of 
Campylobacter isolates identified were not further 
speciated. This compares with 46% of Campylobacter 
isolates in Europe reported to ECDC during 2007 
remaining unspeciated.3 
During 2009, there were nine family outbreaks of 
campylobacteriosis reported with 33 associated cases 
of illness. These were all small clusters of illness with 
no more than six people ill in any outbreak. Mode of 
transmission was described in seven of the outbreaks 
with person to person spread being the most common 
route (n=6). Four of the outbreaks reported as person 
to person transmission also reported a foodborne 
transmission element. Foodborne and animal contact 
was suggested for the remaining outbreak. No 
information was available on mode of transmission for 
two outbreaks.
References:
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Table 1. Number of campylobacteriosis outbreaks and number 
ill, 2009 (CIDR)
Mode of transmission Number 
outbreaks
Number ill
Person-to-person & foodborne 4 15
Person-to-person 2 8
Foodborne & animal 1 4
Unknown 2 6
Total 9 33
Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faecal-oral route, with both 
ruminants and humans serving as reservoirs. Human 
cryptosporidiosis became a notifiable disease in Ireland 
in 2004, and the case definition in use is published in 
the HPSC case definition booklet. 
In 2009, 445 cases of cryptosporidiosis were notified 
in Ireland, a crude incidence rate of 10.5 per 100,000 
population, with 28% of notified cases reported as 
hospitalised for their illness. This was a 7% increase on 
the number of cases notified in 2008 (Figure 1). In 2007 
(the most recent year for which data are available), the 
ECDC reported an incidence rate overall of 2.4 per 
100,000 population in the European Union, with Ireland 
reporting the highest rate among those countries 
reporting on this disease at the time.1 
Consistent with previous years, the highest reported 
incidence was in children under 5 years, with over 90 
cases per 100,000 population in this age group (Figure 
2). While there is likely to be a bias towards testing of 
diarrhoeal stool specimens from children (as opposed 
to adults) for Cryptosporidium, it is also likely that this 
distribution reflects to some extent a true difference in 
risk between adults and children.
The crude incidence (CIR) rates by HSE area for 2009 
are reported in Figure 3. As in previous years, there was 
a strong urban-rural divide, with the HSE-E having a 
much lower reported incidence rate (0.73 per 100,000) 
than other HSE areas. The HSE-M and HSE-W reported 
the highest crude incidence rates (23.84 and 26.07 per 
100,000 respectively) –over twice the national rate. 
Since 2004, a large increase in cases has been recorded 
each spring, and in 2009 a similar peak in the reported 
number of cases occurred (Figure 4). This year, there 
was also a smaller peak in case numbers in September. 
Notably although only 16 notifications across the full 
year were specifically reported as being associated with 
foreign travel, eight of these were reported during the 
month of September. 
Speciation of Cryptosporidium specimens can provide 
valuable information on the epidemiology of this 
disease. C. hominis is a species primarily linked with 
humans, whereas both humans and animals can be 
sources of C. parvum infections. In 2009, around 17% of 
positive human Cryptosporidium specimens in Ireland 
were referred for speciation to the UK Cryptosporidium 
3.2 Cryptosporidiosis
Summary
Number of cases, 2009: 445
Number of cases, 2008: 416
Crude incidence rate, 2009: 10.5/100,000
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Figure 1: Annual number notifications cryptosporidiosis, Ireland 2004-
2009.
Figure 2: Age-specific incidence rate cryptosporidiosis, Ireland 2009
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Reference Unit in Swansea by a small number of hospital 
laboratories. This is a decrease on the proportion of 
cases for which specimens were typed in 2008 (35%). 
As in 2008, C. parvum was the most common species 
reported (Table 1).
Six outbreaks of cryptosporidiosis were reported in 
2009: one general outbreak and five family outbreaks 
(Table 2). All were small outbreaks, and between them 
accounted for only 7 cases. Table 2 lists the transmission 
routes and locations for these outbreaks. Three were 
reported due to person-to-person transmission; 
no waterborne outbreaks were reported. The 
overwhelming majority of cases in 2009 were reported 
as sporadic cases.
Reference
1.  ECDC. 2009. Annual Epidemiological Report on Communicable 
Disease in Europe. ISBN 978-92-9193-196-5.
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Table 2. Cryptosporidiosis outbreaks Ireland 2009
Month HSE-
area
Transmission route Type Location No. ill
Mar NWHB Person-to-person Family Private house 2
Apr MHB Animal contact Family Private house 3
Apr NEHB Unknown Family Private house 3
May NWHB Person-to-person General Community outbreak 3
Jun SEHB Unknown Family Private house 2
Jun WHB Person-to-person Family Private house 4
Table 1. Species distribution of Cryptosporidium cases, Ireland 
2009
Species Number of cases % of cases
C. parvum 68 15.3%
C. hominis 7 1.6%
C. sp:nontypeable 1 0.2%
C. species 369 82.9%
Total 445 100%
Figure 3: Regional crude incidence rates cryptosporidiosis, Ireland 2009. Figure 4. Seasonal distribution of cryptosporidiosis cases 2006-2009 
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Reported verotoxigenic E. coli (VTEC) incidence rates in 
Ireland have been rising steadily over the last five years, 
such that in 2008, Ireland reported the highest VTEC 
incidence rate of any Member State in the European 
Union.1 The dominant transmission routes for VTEC 
in Ireland appear to be person-to-person spread and 
waterborne transmission associated with exposure 
to water from untreated or poorly treated private 
wells.2,3,4 Other important transmission routes identified 
internationally include food, and contact with infected 
animals or contaminated environments.5
Full details on how surveillance of VTEC is conducted in 
Ireland are available at http://ndsc.newsweaver.ie/a3xarr
pcw5bqkeph6tk9uv?email=true 
Incidence
In 2009, there were 241 confirmed and probable cases 
of VTEC notified, equating to a crude incidence rate 
(CIR) of 5.7 per 100,000 (table 1). If only confirmed 
VTEC cases are considered, the 238 confirmed cases 
(CIR=5.6 [4.9-6.3]) notified this year represent a 12% 
increase on the number of confirmed cases notified in 
2008. Non-O157 VTEC made up 31% of cases in 2009.
One additional (HUS) case was reported as a suspected 
VTEC case. 
Regional and seasonal distribution
The highest crude incidence rates for VTEC overall this 
year were reported in the HSE-MW and HSE-NW, where 
the rates were almost twice the national crude rate. As 
in previous years, the HSE-E reported the lowest overall 
crude incidence rate (Table 2), one third of the national 
rate this year. The crude incidence rate in the HSE-NE 
was also low this year.
Historically, the HSE-NW has reported relatively high 
numbers of VTEC O26, and this year almost three-
quarters of VTEC cases in the NW were associated 
with serogroup O26. While it is possible that there 
is a true geographical difference in risk for different 
serogroups, it is also possible that regional variation in 
the serogroup-specific incidence to some extent reflects 
regional differences in laboratory diagnostic practice for 
non-O157 infections.
Typically, VTEC cases are most commonly associated 
with late summer; overall this year, almost 40% of cases 
were reported in quarter 3, although this varied by HSE-
3.3 Verotoxigenic E. coli 
Summary
Number of cases, 2009: 241
Number of cases, 2008: 226
Crude incidence rate, 2009: 5.7/100,000
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Table 1. Number and crude incidence rates confirmed and 
probable VTEC, Ireland 2004-2009
Year Confirmed 
cases 
Probable 
cases 
Total VTEC CIR VTECa 
(95% CI) 
2004 61 0 61 1.4 (1.1-1.8)
2005 125 0 125 3.0 (2.4-3.5)
2006 153 5 158 3.7 (3.2-4.3)
2007 115 52 167 3.9 (3.3-4.5)
2008 213 13 226 5.3 (4.6-6.0)
2009 b 238 3 241 5.7 (5.0-6.4)
a Data from the 2006 census were used to calculate rates 
b Confirmed cases include 167 VTEC O157 cases, 45 VTEC O26 
cases and 26 VTEC strains of other serogroups. Three probable cases 
were reported on the basis of detection of verotoxin genes without 
isolation of the implicated strain (all Ungroupable strains).
area with the HSE-MW and HSE-NW reporting their 
highest incidence in quarter 4 and the HSE-W reporting 
their highest number of cases in quarter 2 (Table 2).
Age-sex distribution
The reported disease incidence was highest among 
young children (median age =6 years), which is 
consistent with previous years. While there were roughly 
equal numbers of male and female cases, there were 
more females reported this year among adult cases and 
more males in younger age groups. 
Severity of illness and clinical features
154 notified cases were reported as symptomatic, 71% 
of the cases for whom this information was available 
(n=218). Reported symptoms included bloody diarrhoea 
in 76 cases (39%), and HUS in 24 cases (11%). Ninety 
VTEC cases were admitted to hospital in 2009 (37%), 
and an adult male in his sixties died due to VTEC 
infection.
Of the 24 HUS cases, twenty were paediatric HUS cases 
and there were four adult HUS cases. Thirteen (54%) of 
the 24 HUS cases were infected with VTEC O157 strains, 
five (21%) were infected with VTEC O26, two (8%) with 
VTEC O145, two (8%) with Ungroupable VTEC strains, 
and one (4%) each with VTEC O5 and VTEC O78 strains. 
The additional HUS case reported as a suspected VTEC 
case was a young child from whom a verotoxin-negative 
strain of E. coli O111 was cultured. E. coli O111 is 
one of the serogroups listed by the World Health 
Organisation as being frequently associated with HUS.6  
It is possible that during the course of the patients’ 
illness that the strain had lost its’ verotoxin genes. The 
loss of verotoxin genes during infection among HUS 
patients has been previously documented by Schimmer 
et al (2008) and Bielaszewska et al (2007). 7,8
The year 2009 had the highest annual number of 
non-O157 VTEC-associated HUS cases notified since 
VTEC surveillance was extended to include all VTEC 
strains in 2003, and the highest overall annual number 
of confirmed or probable VTEC-associated HUS cases 
since that time. 
VTEC typing
In 2009, 238 human VTEC isolates were confirmed 
and typed at the HSE PHL Dublin Mid Leinster, Cherry 
Orchard Hospital (Table 3). In addition, laboratory 
findings are included in Table 5 from three probable 
VTEC cases identified on the basis of detection of 
verotoxin genes in the absence of obtaining an isolate.  
As in previous years, PT32 was the commonest phage 
type (PT) reported among VTEC O157 strains (96/167), 
accounting for 57% of the confirmed VTEC O157 
reported. Other common phage types in 2008 were 
PT21/28 (n=13), PT8 (n=11), PT31 (n=12) and RDNC 
(n=9) –Table 3. Two sorbitol-fermenting VTEC O157 
were reported, one each PT31 and RDNC. All phage 
typing was undertaken at the HPA Laboratory of Enteric 
Pathogens (LEP), Colindale, UK
The verotoxin (VT) profiles of VTEC O157 strains were 
similar to those reported historically for human isolates 
in Ireland (Table 3). Eighty-nine per cent of VTEC O157 
strains carried the genes for VT2 only while 11% carried 
the genes for both VT1 and VT2. In contrast, 38% of 
non-O157 VTEC isolates carried the genes for VT1 only, 
26% for VT2 only, and 36% VT1 and VT2. 
There are new developments in the National VTEC 
Service provided at the DML-PHL in Cherry Orchard in 
relation to VTEC typing from 2010. Phage typing data 
will no longer be provided and the DML-PHL in Cherry 
Orchard will instead undertake timely molecular typing 
(i.e. pulsed field gel electrophoresis (PFGE)) of all human 
VTEC isolates, as this provides greater discrimination 
between isolates than phage typing, allowing more 
timely public health decision-making and intervention in 
the event of outbreaks.
Country of infection
At least seven VTEC cases (2.9%) in 2009 were 
considered to be foreign travel-associated. The 
countries of infection reported were France (n=2), Spain 
(n=2), Nigeria (n=1), Turkey (n=1) and Egypt (n=1). The 
overwhelming majority of infections in 2009 were as 
usual acquired in Ireland. 
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Table 2. Number and crude incidence rate of confirmed and probable VTEC by quarter and HSE area, Ireland 2009
Quarter E M MW NE NW SE S W Total
Q1 0 4 5 0 2 1 1 2 15
Q2 8 5 8 1 8 5 15 12 62
Q3 12 11 12 5 6 19 25 5 95
Q4 8 0 15 2 10 9 15 10 69
VTEC O157 14 19 29 7 6 28 38 26 167
VTEC O26 7 1 5 1 19 3 6 3 45
Other VTEC 7 0 6 0 1 3 12 0 29
Total 28 20 40 8 26 34 56 29 241
CIR VTEC*
(95% CI)
1.9 (1.2-
2.6)
8.0 (4.5-
11.4)
11.1 (7.7-
14.5)
2.0 (0.6-
3.4)
11.0 (6.8-
15.2)
7.4 (4.9-
9.9)
9.0 (6.7-
11.4)
7.0 (4.5-
9.6) 5.7 (5.0-6.4)
*Rates calculated using CSO census 2006 
Outbreak and environmental investigations
Forty-two VTEC outbreaks were notified in 2009, which 
included 115 of the 238 confirmed cases notified. Six 
outbreaks were described as general outbreaks and 36 
as family outbreaks. Two general outbreaks occurred 
in childminding facilities and one general outbreak was 
suspected to be linked to a food outlet. The remaining 
three occurred in private houses, and in two instances 
included either the families’ childminder or another 
child who was minded in that home.
Twenty-seven outbreaks (64%) were caused by VTEC 
O157, eight (19%) caused by VTEC O26, three (7%) 
by other non-O157 and four (10%) were caused by 
a mixture of VTEC strains. The suspected modes of 
transmission reported are listed in table 4. 
Person-to-person spread is an important mode of 
VTEC transmission particularly between young children, 
and was suspected to have played a role in 16 VTEC 
outbreaks in 2009 in which 35 persons were reported 
ill. These included the two outbreaks associated with 
childminding facilities mentioned above. 
The second most common transmission route 
reported for outbreaks in 2009 was waterborne, 
with drinking water believed to have contributed to 
12 outbreaks. For three family outbreaks, there was 
definitive microbiological evidence implicating their 
drinking water supply in transmission. These included 
two outbreaks where household private wells were 
implicated and one outbreak where a group water 
scheme was contaminated. Examination of water in 
all three outbreaks confirmed the presence of the 
same VTEC strain in the water as was identified in 
some or all of the associated patients in each of the 
outbreaks. For one further outbreak, although the 
VTEC strain identified in water from the household 
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Table 3. Verotoxin (VT) and phage typing (PT) results for VTEC referred to the PHL HSE Dublin Mid Leinster, Cherry Orchard 
Hospital in 2009
Serogroup PTc VT1 only VT2 only VT1 & VT2 VT type not 
reported
Total
O157 1 1 1
2 3 3
8 1 10 11
14 6 1 7
31 12 12
32 95 1 96
49 1 1
51 2 2
54 1 1
63 1 1
21/28 13 13
RDNCb 7 2 9
Untypable 1 1
N/K 6 2 1 9
O26 - 19 3 23 45
O Ungroupablea - 2 7 4 13
O145 - 4 4
O103 - 3 3
O105ac - 3 3
O128 - 1 1
O21 - 1 1
O3 - 1 1
O5 - 1 1
O55 - 1 1
O78 - 1 1
Total 28 167 45 1 241
aIncludes information on laboratory findings from 3 probable cases identified on the basis of detection of vt genes in the absence of obtaining an isolate.
b RNDC –reacts but does not conform to a designated phage type. 
cAll phage typing was undertaken at the HPA Laboratory of Enteric Pathogens (LEP), Colindale, UK
Table 4. VTEC outbreaks in Ireland 2009 by suspected mode of transmission
Suspected mode of transmission Number of outbreaks Number ill Number confirmed cases
Animal contact 1 4 4
Foodborne 1 1 3
Foodborne/waterborne 2 6 6
Person-to-person 11 26 32
Person-to-person & foodborne 2 4 4
Person-to-person & waterborne 3 5 9
Waterborne 7 14 19
Unknown/Not specified 15 34 38
Total 42 94 115
private well was not identical to the strain detected in 
the associated cases, the detection of VTEC in their 
drinking water was strongly suggestive that their private 
well was responsible for their infections. For seven 
further outbreaks, evidence implicating water as the 
transmission route was circumstantial in that E. coli 
and/or coliforms were detected in the suspected water 
samples. These included outbreaks where household 
private wells (n=5) and group water schemes (n=2) were 
suspected. No water result was available for the private 
well suspected in the remaining outbreak. 
In addition for four sporadic VTEC cases, environmental 
investigations identified VTEC of the same type in 
private household well samples as was found in the 
associated cases. In total, these reported waterborne 
incidents (outbreaks and sporadic cases) gave rise to 
39 VTEC cases, four of whom developed HUS. Drinking 
water from untreated/inadequately treated private 
water supplies remains a very important risk factor for 
VTEC infection in Ireland. 
Food was reported as a suspected transmission route in 
five outbreaks with 11 persons ill (Table 4). No definitive 
evidence was reported implicating any specific food. 
And animal contact was reported as the suspected 
transmission route for one outbreak with four persons 
ill. For one third of VTEC outbreaks, no suspected 
transmission route was reported.
Seasonal distribution of VTEC cases and private well 
water supply exposure data
As in previous years, the highest number of VTEC 
cases was reported between July and September, with 
an additional smaller peak this year in incidence in 
November (Table 5)
Among the enhanced data collected on VTEC cases 
is information on water supply exposures. In 2009, 90 
VTEC cases (37% of cases) reported exposure to private 
well water prior to onset of their illness (Table 5). The 
number and proportion of cases reporting this exposure 
was highest in the months of July and November [18 
cases (66.7%) and 17 cases (63.0%), respectively]. 
Annual rainfall totals in Ireland in 2009 were well above 
normal, with the summer period being extremely wet 
and with November being the wettest November on 
record since records began at many weather stations 
in Ireland.9 Thus there may be a correlation between 
the incidence of VTEC disease that might be due 
to exposure to private well water and rainfall. This 
suggests that private wells can be vulnerable during 
times of high rainfall and that householders who have 
private wells should be vigilant for changes in their 
water quality during periods of high rainfall.
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Table 5. Number and percentage of VTEC cases exposed to private well water during incubation period by month of 
notification, Ireland 2009
Exposed to 
private well? Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
Yes 4 5 5 6 18 10 10 5 17 10 90
No 3 1 1 10 14 9 5 12 24 8 7 8 102
Unknown 2 4 6 4 3 4 2 10 3 3 8 49
Grand Total 5 1 9 21 23 18 27 24 44 16 27 26 241
% exposed 
to private 
well
0.0% 0.0% 44.4% 23.8% 21.7% 33.3% 66.7% 41.7% 22.7% 31.3% 63.0% 38.5% 37.3%
Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from 
person to person via the faecal-oral route and is 
associated with poor hygiene and sanitation. Common 
source outbreaks due to contaminated food or water 
may also occur.
The incidence of hepatitis A in Ireland has been low in 
recent years and remained low in 2009, with 52 cases 
notified. This corresponds to a crude notification rate of 
1.2/100,000 population and represents a 24% increase 
compared to 2008, when 42 cases were notified (figure 
1). Case classification was reported for all cases. Fifty 
one cases were laboratory confirmed and one was 
classified as a possible case.
Fifty two percent of cases were male (n=27) and forty 
eight percent were female (n=25). All age groups were 
affected (figure 2). 
Eight cases were linked to travel outside of Ireland, 
seventeen cases were contacts of cases infected outside 
of Ireland and one case had travelled outside of Ireland 
within the incubation period of the disease but could 
also have been infected in Ireland. 
Of the remaining cases, eight were infected in Ireland  
and information on country of infection was not 
available for eighteen. 
Two hepatitis A outbreaks were reported in 2009 
and both of them occurred in the HSE-E. The largest 
outbreak involved mainly transmission in a school and 
included thirteen children and four young adults.  The 
index case was a young child who was infected in India.  
The remaining cases were infected in Ireland through 
person to person contact within the school. Some 
later secondary transmissions occurred within families 
and the wider community.  The outbreak lasted from 
May to December with low level spread.  A high level 
of awareness of good hand hygiene practices during 
3.4 Hepatitis A
Summary
Number of cases, 2009: 52
Crude notification rate, 2009: 1.2/100,000 population
Number of cases, 2008: 42
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Figure 1. Number of hepatitis A notifications, 1998-2009
the height of the (H1N1) 2009 pandemic may have 
contributed to the limited level of spread.  The second 
outbreak involved two adults who shared a house. 
Country of infection was uncertain for the index case 
but may have occurred in Spain.
There were no fatalities recorded in any of the hepatitis 
A cases in 2009.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 23rd June 2010. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis A, 2009
Rotavirus is the commonest cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal, 
often severe gastroenteritis of infants and young 
children, characterised by vomiting, fever and watery 
diarrhoea. Transmission is usually person-to-person, 
mainly via the faecal-oral route. Children less than 
two years of age are most susceptible to infection, 
although cases are occasionally seen in elderly and 
immunocompromised adults, particularly in institutional 
settings. By the age of six years old, virtually all 
children will have had at least one episode of rotavirus 
infection. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. In developed countries, mortality due to 
rotavirus is low; however, the morbidity and economic 
costs associated with infection are significant. Given 
the universal distribution of rotavirus, the numbers of 
notifications will always represent an underestimate of 
the true incidence and are likely to be more reflective 
of habits of presentation to medical practitioners and of 
styles of investigation, notification and testing.
Since 2004, rotavirus, although not specifically listed, 
has been a notifiable disease in Ireland under the Acute 
Infectious Gastroenteritis (AIG) disease category. Prior 
to 2004, only gastroenteritis cases in children under 
two years of age were notifiable. In April 2008 the case 
definition of AIG was amended specifying definitions 
for both rotavirus and the newly notifiable Clostridium 
difficile associated disease. On 4th May 2008 these 
amended definitions formally replaced the previous AIG 
case classification. 
Rotavirus case definition:
A case of rotavirus infection is a patient with acute onset 
of vomiting followed by watery diarrhea with fever, 
which typically lasts between three and eight days, AND 
one of the following laboratory criteria for diagnosis:
UÊiÌiVÌÊvÊÀÌ>ÛÀÕÃÊLÞÊ>Ì}iÊ>ÃÃ>Þ
UÊ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3.5 Rotavirus
Summary
Number of cases: 2,354
Crude incidence rate: 55.5/100,000 population
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Figure 1: Rotavirus crude incidence rate by HSE area and year, 2004-2009 (CIDR).
During 2009, there were 4,359 cases of AIG notified in 
Ireland, corresponding to a national crude incidence 
rate (CIR) of 102.8 per 100,000 population and 
representing an increase of 4.3% compared to 2008. 
Rotavirus notification numbers remained similar to the 
previous year with 2,354 rotavirus cases notified in 2009 
corresponding to a national CIR of 55.5 per 100,000 
population and representing an increase of 1.5% 
compared to 2008.  
Significant geographical variation was observed in 
regional rotavirus CIR. The highest regional CIR was 
observed in HSE-W at 105.5 per 100,000 population 
and in HSE-SE at 93.3 per 100,000 population. The 
lowest regional CIR was observed in HSE-MW at 30.5 
per 100,000 population and HSE-E at 30.7 per 100,000 
population.
Rotavirus infection has a well documented seasonal 
pattern in Ireland with the number of cases peaking 
each year in early spring. During 2009, this pattern was 
evident with rotavirus notifications peaking during April 
(n=686). Figure 21 illustrates the seasonal variation in 
rotavirus cases by month of notification from 2004 to 
2009. 
Rotavirus is the most common cause of acute gastro-
enteritis in children worldwide with children generally 
affected in the first 2-3 years of life. In 2009, 74.3% 
(n=1,748) of cases were aged two or under. Data from 
2004 to 2009 show that the peak incidence of clinical 
disease occurred in the 6-18 month age group. Figure 3 
presents the number of cases of rotavirus in children less 
than two years of age by year, 2001 to 2009.
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Figure 2: Number of rotavirus notifications by month, 2004-2009 (CIDR).
Figure 3: Number of cases of rotavirus in children less than two years of age by year, 2001 to 2009
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During 2009, 1,103 cases (46.9%) were female, 1,239 
(52.6%) were male and sex was not reported for 12 
(0.5%) cases.  This represented a ratio of females: males 
of 0.9:1.1, similar to the ratio observed in previous 
years.
There were 12 outbreaks of rotavirus notified during 
2009 with 74 cases of associated illness. One outbreak 
was reported as a rotavirus and norovirus coinfection. 
Of the 12 outbreaks, four occurred in crèches, four 
were family outbreaks in private homes, three were in 
hospitals and one was in a community hospital/long-
stay unit. Mode of transmission was reported as person 
to person spread in 10 outbreaks and no information on 
mode of transmission was reported for the remaining 
two. During 2009, 50% of all rotavirus outbreaks 
occurred during April, coinciding with the peak in 
rotavirus notifications. The largest outbreaks with the 
highest numbers ill also occurred during April. Table 1 
details the number of rotavirus outbreaks by location, 
transmission mode and month during 2009
Reference
1.  There is a ‘false’ second peak seen in 2005 during week 33, 2005 
caused by bulk uploading of notifications for the HSE-W
Table 1: Number of rotavirus outbreaks by location, transmission mode and month, 2009 
Outbreak month Outbreak location
Outbreak transmission mode
Total
Person-to-person Unknown
January Private house 1 1
February
Creche 1 1
Private house 1 1
March Creche 1 1
April
Comm. Hosp/Long-stay unit 1 1
Creche 2 2
Hospital 2 2
Private house 1 1
October Hospital 1 1
November Private house 1 1
Total 10 2 12
Salmonellosis presents clinically as an acute 
enterocolitis, with sudden onset of headache, 
abdominal pain, diarrhoea, nausea and occasionally 
vomiting. Fever is almost always present. Dehydration, 
especially amongst vulnerable populations such as 
infants, the immunocompromised and the elderly, may 
be severe. S. Typhi and S. Paratyphi can cause enteric 
fever, a severe systemic life threatening condition, 
but this is not very common in Ireland and is almost 
invariably travel-associated.
There were 333 cases of salmonellosis in 2009. Of 
these 332 were laboratory confirmed and there was 
one case classified as probable that was not laboratory 
confirmed. In addition to the cases of salmonellosis, 
there were nine cases of S. Typhi and eight cases of     
S. Paratyphi notified on CIDR. There were two fewer 
cases of paratyphoid detected by the clinical notification 
system than were identified by the NSRL in 2009.  The 
National Salmonella Reference Laboratory (NSRL) 
based in Galway has been providing reference services 
nationally since 2000. In 2009 the NSRL analysed 366 
human isolates submitted for Salmonella typing.
The national crude incidence rate (CIR) for salmonellosis 
in 2009 was 7.9 per 100,000 population which was a 
decrease compared to 2008 (10.6/100,000) as shown 
in figure 1. Figure 2 illustrates the regional variation 
in CIR during 2009. The highest CIR occurred in HSE-
NW (10.1/100,000), representing an increase of 2.1 per 
100,000 population compared to 2008. This was the 
only region to experience an increase in the regional 
CIR during 2009.  The lowest CIR occurred in HSE-S 
(5.6/100,000), representing a decrease of 3.2 per 
100,000 population compared to 2008. The largest 
decrease in regional CIR during 2009 was observed in 
HSE-M, with a decrease of 8.7 per 100,000 population. 
The female:male ratio for the year was 0.9:1.1. In terms 
of age distribution, 21.6% of cases occurred in children 
3.6 Salmonella 
Summary
Number of confirmed cases 2009: 332
Number of probable cases 2009: 1
Crude incidence rate 2009: 7.9/100,000
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Figure 1: Salmonellosis notifications and crude incidence rate per 100,000 population by year of 
notification (CIDR)
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under five. This is likely to be a reflection of clinicians 
more readily seeking clinical samples in that age group. 
This is also reflected in the age specific incidence rate 
(ASIR) with the 0-4 age group having the highest ASIR 
nationally (22.3/100,000 in females and 25.2/100,000 in 
males) in both sexes (figure 3). 
The seasonality of salmonellosis notifications in Ireland 
during 2009 is shown in figure 4. The highest number 
of notifications occurred between May and October. 
Further examination of these data show that the highest 
number of travel associated salmonellosis notifications 
are reported during this period. These are expected 
seasonal increases that correlate with peak holiday 
Figure 2: Salmonellosis notifications and crude incidence rate per 100,000 population by 
HSE area, 2009 (CIDR)
Figure 3: Salmonellosis notifications and age specific incidence rate per 100,000 
population by age group (years) and sex, 2009 (CIDR)
Figure 4: Salmonellosis notifications by month of notification and travel history, 2009 (CIDR)
-57-HPSC Annual Report 2009 3. Infectious Intestinal Diseases
periods and resultant increase of people travelling 
abroad. 
Of the 333 cases notified on CIDR during 2009, travel 
history was provided for 166 cases (49.8%). Of the 166 
cases where travel history was reported, 86 (51.8%) of 
salmonellosis cases were indigenous to Ireland and 80 
cases (48.2%) reported a recent history of travel. Where 
travel history was documented, the three countries with 
highest occurrence of recent travel and subsequent 
development of salmonellosis were; Spain (n=20), 
Nigeria (n=9) and Thailand (n=5). When serotyping 
data are analysed by travel history, 44.2% of all travel 
associated cases are S. Enteritidis whereas 43.8% of 
cases indigenous to Ireland are S. Typhimurium (table 1). 
During 2009, 366 human Salmonella isolates were 
referred to the NSRL for further typing, identifying 
72 serotypes. Table 2 presents the most dominant 
serotypes detected during 2009.  S. Typhimurium 
(n=118) was the most common serotype, followed by  
S. Enteritidis (n=87). 
The NSRL conducted phage typing analysis on all S. 
Typhimurium and S. Enteritidis isolates. Phage types 
were assigned to all 118 S. Typhimurium human 
isolates. DT193 (22.9%), DT104 (20.3%) and DT104b 
(11.9%) were the commonest phage types observed. 
All 87 S. Enteritidis isolated were typed. PT14b (23.0%), 
PT8 (14.9%), PT21 (12.6%) and PT1 (10.3%) were the 
dominant types.1
Of the 366 human isolates analysed by the NSRL, 185 
(50.5%) were fully sensitive to all antibiotics tested. 
The remaining 181 isolates exhibited some degree of 
antibiotic resistance. The three commonest resistance 
patterns+ seen were type ACSSuT (n=38, 10.4%) 
followed by ASSuT (n=36, 9.8%) and Na (n=35, 9.6%). 
Over 97% of human isolates with a resistance profile of 
ACSSuT or ASSuT were S. Typhimurium while 57.1% of 
human isolates with a resistance profile of Na were S. 
Enteritidis. One S. Concord isolate was resistant to nine 
antibiotics tested, one S. Indiana isolate was resistant 
to eight antibiotics tested and five S. Kentucky human 
isolates were resistant to seven antibiotics tested. 
Please refer to the NSRL’s Annual Report 2009 for more 
detailed analysis of results1.
The number of S. Typhi and S. Paratyphi cases 
diagnosed in Ireland remains elevated when compared 
to previous years. In 2009 there were nine cases of  
Table 2: Number and percentage of human Salmonella 
isolates by serotype, NSRL 2009. 
Salmonella serotype Number of isolates % Isolates
Typhimurium* 118 32.2
Enteritidis 87 23.8
Unnamed 12 3.3
Typhi 11 3.0
Paratyphi A 9 2.5
Kentucky 7 1.9
Dublin 6 1.6
Agona 6 1.6
Java 6 1.6
Other 104 28.4
Total 366 100.0
+Where A= Ampicillin, C= Chloramphenicol, Na = Naladixic acid, S= Streptomycin, Su= Sulphonamide and T= Tetracycline
*This includes 87 S. Typhimurium isolates and 31 isolates with serotype 4,5,12:i
Table 1: Percentage of Salmonellosis notifications by serotype and travel history, 
2009 (CIDR)
Salmonella 
serotype
Travel associated 
(%)
Indigenous (%) Travel history 
unknown (%)
Total (%)
S. Enteritidis 44.2 18.8 18.6 31.2
S. Typhimurium 11.6 43.8 35.3 25.2
Other serotypes 41.9 26.3 35.3 34.8
Serotype not 
specified
2.3 11.3 10.8 8.7
All serotypes 86 80 167 100.0
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S. Typhi reported and eight cases of S. Paratyphi (two 
fewer cases of paratyphoid than were identified by the 
NSRL). Four of the S. Typhi had known recent travel 
history to India, two to Bangladesh and one each to 
Pakistan and the Phillipines. For the remaining typhoid 
case the travel history of the patient was unknown. 
In the S. Paratyphi cases three had known recent 
travel history to Pakistan, two to India and one each 
to Bangladesh and Chile. The remaining paratyphoid 
case’s travel history was not specified. 
There were 15 outbreaks of Salmonella during the 
year resulting in 93 persons ill, one death and an 
associated hospitalisation rate of 21.5% (n=20 cases). 
This is a decrease of 31.8% compared to the number 
of salmonellosis outbreaks reported in 2008. Twelve 
outbreaks were family outbreaks, nine of which were 
in private houses, two were travel associated and one 
occurred across an extended family. Of the two travel 
associated family outbreaks, one reported exposure in 
Spain. Three general outbreaks occurred in community 
locations. Table 3 outlines the number of salmonellosis 
outbreaks and number ill by outbreak location and 
outbreak transmission mode during 2009.
One general outbreak in HSE-NE was caused by a 
mixture of Salmonella Kentucky and S. Agona strains 
resulting in 35 cases of illness, seven of which were 
laboratory confirmed. Although no specific food item 
was implicated, the outbreak was suspected to be food-
borne as all cases attended one of two private parties 
served by a single food caterer.
A national outbreak of 12 laboratory confirmed cases 
of S. Typhimurium DT193 occurred in early summer 
2009. No source was identified although food-borne 
transmission was again suspected.
A national outbreak of S. Enteritidis 14b occurred 
between November 2009 and March 20102. There were 
19 confirmed cases, including one person who died.3 An 
outbreak of S. Enteritidis 14b occurred in the UK around 
the same time which was associated with imported 
eggs, however, no link was identified with eggs or any 
other food source for the Irish outbreak.
References
1.  National Salmonella Reference Laboratory of Ireland, Annual Report 
for 2009.
2.  http://ndsc.newsweaver.ie/epiinsight/17zjkjbtdx5-i8xmmjicne 
3.  http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19489  
Table 3: Number of salmonellosis outbreaks and number ill by outbreak location and outbreak transmission mode, 2009 (CIDR)
Location Animal contact Foodborne Person-Person & 
Foodborne
Person-to-person Unknown Total
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
No. 
outbreaks
No. 
ill
Community 
outbreak 0 0 3 66 0 0 0 0 0 0 3 66
Extended family 0 0 0 0 0 0 1 2 0 0 1 2
Private house 1 4 1 2 2 4 4 8 1 2 9 20
Travel related 0 0 1 2 0 0 0 0 1 3 2 5
Total 1 4 5 70 2 4 5 10 2 5 15 93
Listeriosis 
Ten cases of human listeriosis were notified in 2009 
compared to 13 in 2008 and 21 in 2007. 
There was one pregnancy-related case and no neonatal 
cases reported. 
There were also nine adult cases. Five were male and 
four female, and ages ranged from 24 to 94 years 
of age. Five cases were reported as elderly (>65 
years) including at least two who were reported as 
having an underlying illness that predisposed them to 
listeriosis, and three were cases younger than 65 years 
also reported as suffering from an underlying illness 
that predisposed them to listeriosis. No enhanced 
information was available on the ninth case. 
There were no reported deaths among cases. 
Since 2007, the National Salmonella Reference 
Laboratory has offered a national service for typing of 
Listeria strains. In 2009, isolates for eight of the notified 
cases were received for typing at NSRL (80%). The 
serotype distribution of these strains is outlined in the 
table below.
The number of adult cases remains similar to previous 
years: however, the number of pregnancy-related and 
neonatal cases in Ireland had decreased since 2007 
when there were nine listeriosis cases among neonates 
and pregnant women, many of whom were of non-Irish 
origin.1 Targeted leaflets by Safefood aimed at pregnant 
women, in particular those whose first language was not 
English, may have had an effect. 2 A similar risk among 
pregnant women from ethnic minorities has recently 
been reported in England and Wales. 3
Listeriosis remains a hazard for the elderly, persons with 
underlying illness, and other vulnerable groups such as 
pregnant women and neonates. 
References
1.  Garvey, P et al. 2008. Human listeriosis: surveillance, epidemiology, 
transmission and prevention.  Epi-Insight 2008 9(7):1,4
2.  Safefood leaflet for pregnant women at http://www.safefoodonline.
com/
3.  Mook P et al. 2010. Emergence of pregnancy-related listeriosis 
amongst ethnic minorities in England and Wales. Eurosurveillance, 
Volume 15, Issue 27, 08 July 2010
3.7  Less common gastroenteric 
 infections
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Listeriosis notifications by case type and serotype, Ireland 2009 -typing data provided courtesy of Prof Martin Cormican and 
staff at the NSRL
Serotype 1/2 Serotype 4b Not referred for 
serotyping
Total
Adult or juvenile 4 3 2 9
Pregnancy-related 0 1 0 1
Neonatal 0 0 0 0
Total 4 4 2 10
Giardiasis
In 2009, there were 61 cases of giardiasis notified, a 
slight decrease on the number notified in 2008 (n=71) 
but similar to the number reported in 2007 (n=62).
Cases ranged in age from 0-75 years (median age=33 
years) with only eight cases less than fifteen years of 
age. Similar numbers of males (n=29) and females 
(n=32) were affected.
Nineteen cases (31%) were reported as being 
associated with foreign travel: the countries of infection 
reported were India (n=6), Dominican Republic (n=3), 
Sudan (n=2), Vietnam (n=2) and there was one case 
each reported associated with travel to Cambodia, Sri 
Lanka, Congo, Iceland, Egypt and Chad. Four cases 
were reported as being acquired in Ireland, and for the 
remaining 38 cases, country of infection was unknown or 
not specified.
In 2009, there was one small outbreak reported with 
three persons ill which was related to foreign travel. 
Yersiniosis
In 2009, there were three cases of yersiniosis, compared 
to three in 2008 and six in 2007. 
One case was a child and there were two adult cases; 
one case each male and female with the sex not 
reported for the third case. 
Two cases were reported as Y. enterocolitica and one as 
Yersinia species.
Foodborne intoxications
Notifications of foodborne intoxications in Ireland are 
uncommon. In 2009, there was one case of Clostridium 
perfringens (type A) food-borne disease, one case of 
staphylococcal food poisoning and one case of Bacillus 
cereus food-borne infection/intoxication notified. 
There was also one family outbreak of Clostridium 
perfringens (type A) food-borne disease notified with 11 
persons ill; none were hospitalised.
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Summary
Number of cases, 2009: 71
Number of cases, 2008: 76
Crude incidence rate, 2009: 1.7/100,000
In the last decade, the number of cases of shigellosis 
in Ireland has been low in comparison to the number 
of cases notified in the early 1990s (Figure). Shigellosis, 
however, remains a common cause of gastrointestinal 
illness in developing countries, and many cases notified 
in Ireland are now identified as being travel-associated.  
While person-to-person spread is an important 
transmission route between children, risks also remain 
from food, with at least four general outbreaks having 
been reported in Scandinavia in 2009 associated with 
imported fresh produce.1-5  Transmission between men 
who had sex with men (MSM) has been reported in 
Canada.6
Seventy one cases of shigellosis were notified in Ireland 
in 2009, all of which were laboratory confirmed. This 
compares to 76 cases in 2008 and 43 in 2007 (Figure).
Cases ranged in age from 1 to 60 years (mean age=29 
years, median age=29 years), with more males (n=40) 
than females (n=31) notified. This differs to the last 
four years where there were more females than males 
reported each year.
Information on travel history is very valuable when 
reviewing surveillance data for possible indigenous 
clusters, and data on country of infection in the national 
dataset is improving being available this year for over 
two-thirds (49/71) of notifications. In 2009, 41 cases 
(58%) were reported associated with foreign travel 
(Table 1). The countries of infection reported were 
Egypt (n=9), Nigeria (n=6), Morocco (n=4), three each 
3.8 Shigellosis
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Table 1. Number of notifications shigellosis by species and country of infection, Ireland 2009
Ireland Africa Asia Other Not known/ not 
reported
Total
S. boydii 0 1 1 0 2 4
S. dysenteriae 0 3 0 0 1 4
S. flexneri 3 13 3 3 7 29
S. sonnei 5 11 2 4 11 33
Species not specified/not known 0 0 0 0 1 1
Total 8 28 6 7 22 71
Figure. Annual number of notifications shigellosis, Ireland 1991-2009
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in India, Pakistan and South Africa, two in Dominican 
Republic, and one each in Chad, Argentina, Portugal, 
Northern Europe, Tunisia, Algeria, Uganda, Nicaragua, 
Ghana, Czech Republic and Mozambique. Eight 
infections (11%) were reported as being acquired in 
Ireland, while no country of infection information was 
provided for 22 (31%) cases. 
In 2009, Shigella sonnei was the most common species 
reported (n=33, 46%), closely followed by S. flexneri 
(n=29, 38%). There were also four S. boydii (6%), 
four   S dysenteriae (6%) and one confirmed case (1%) 
for which the species was not reported. The species 
distribution of cases by country of infection is reported 
in Table 1. 
 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains which 
can be used by public health personnel to outrule/
provide evidence for links between cases during 
investigations of case clusters. The National Salmonella 
Reference Laboratory (NSRL) in University College 
Hospital, Galway can provide laboratory services 
for speciation, serotyping, antimicrobial resistance 
profiling, and where appropriate, Pulsed Field Gel 
Electrophoresis (PFGE) of Shigella isolates.
In 2009, 48 human Shigella isolates were referred to 
the NSRL, over two-thirds of all confirmed cases. The 
species/serotype distribution of these cases is reported 
in Table 2.
There were three shigellosis outbreaks notified in 2009, 
details of which are provided in Table 3. For the family 
outbreak in the HSE-M, the index case acquired their 
illness abroad. 
Although foreign travel is a major risk factor for 
shigellosis among Irish residents, indigenous risks are 
likely to be through person-to-person spread (in some 
instances from persons who have contracted shigellosis 
abroad), and from food as demonstrated by the 
Scandinavian outbreaks associated with imported foods 
in recent years. 
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Table 2. Species/serotypes of isolates referred to NSRL in 2009 
(Data courtesy of Prof. Martin Cormican and staff at NSRL)
Strain Number of isolates
Shigella boydii 1
Shigella dysenteriae 2
Shigella dysenteriae E112707-96 1
Shigella dysenteriae type 2 1
Shigella flexneri 1b 5
Shigella flexneri 1c 3
Shigella flexneri 2a 11
Shigella flexneri 2b 2
Shigella flexneri 3a 1
Shigella flexneri 6 2
Shigella sonnei 19
Total 48
Table 3. Shigellosis outbreaks, Ireland 2009
Month HSE-area Transmission Route Location Type Number ill
Mar E Person-to-person Private house Family 2
Jul M P-P/Foodborne Private house Family 6
Jul E P-P/Foodborne Community General 3
Vectorborne and Zoonotic Diseases
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Toxoplasmosis
During 2009, 37 cases of toxoplasmosis were notified 
compared to 49 each in 2008 and 2007.  
In contrast to the previous four years, no congenital 
cases were reported.
The 37 cases ranged in age from 14 years to 77 years 
(median, 28 years).  Of the 37 cases, 28 (76%) were 
female. The high number of cases reported among 
women of child-bearing age may reflect enhanced 
testing during pregnancy (Table). 
 
      
Brucellosis
During 2009, no cases of brucellosis were notified 
compared 3 in 2008 and 28 notifications in 2007. 
The age and sex distribution for human brucellosis cases 
in recent years in Ireland suggests that occupational 
exposure is likely to be the main transmission route for 
this disease. 
The case definition permits inclusion of acute and 
chronic cases. In previous years, many cases were 
reported as chronic cases with only small numbers of 
acute cases reported.  
 
4.1 Non-IID Zoonotic Diseases
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Table: Toxoplasmosis notifications by age and sex, Ireland 2009
Age group Male Female Total
<1 yr 0 0 0
1-4 yrs 0 0 0
5-14 yrs 0 1 1
15-24 yrs 3 4 7
25-44 yrs 3 21 24
45-64 yrs 1 2 3
65+ yrs 2 0 2
Total 9 28 37
Q Fever
Seventeen cases of Q fever were notified during 2009, 
seven of whom were reported to have been hospitalized 
(41%). This compares to 13 notifications in 2008 and 17 
notifications in 2007. 
Seven cases occurred in males and ten in females 
(table). The cases ranged in age from two to 67 years 
(mean age, 42 years; median age, 44 years). All cases 
were classified as confirmed.
The disease is commonly acquired through occupational 
exposure to infected sheep and other small ruminants, 
e.g. by farmers, veterinarians, and abattoir workers. 
Over a number of years, the south of the Netherlands 
has been experiencing large community outbreaks 
of Q fever during the summer months. Some clusters 
have been linked with Q fever outbreaks on goat farms. 
Further investigations and control measures are ongoing 
including the introduction of mandatory vaccination of 
small ruminants in the region.1
In response to the outbreak in the Netherlands, the 
ECDC conducted an assessment on the risk to the EU 
from Q fever.2
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Table: Q fever notifications by age and sex, Ireland 2009
Age group Male Female Total
<5 yr 1 0 1
5-14 yrs 0 1 1
15-24 yrs 0 1 1
25-44 yrs 3 4 7
45-64 yrs 1 4 5
65+ yrs 2 0 2
Total 7 10 17
Echinococcosis
In 2009, there was one notification of echinococcosis in 
an adult. This is the third case of echinococcosis notified 
in Ireland since the disease became notifiable in 2004; in 
2008, two adult cases were notified. 
Because of the long incubation period for this disease, 
it is possible that infection occurred many years ago. As 
no enhanced information is collected on cases of this 
disease in Ireland, it is not possible to conjecture if their 
infections were acquired in Ireland or abroad.
In 2009, 90 cases of malaria were notified in Ireland, 
similar to the numbers reported for the previous three 
years (Figure 1). Malaria, in particular that caused by 
Plasmodium falciparum, is a potentially fatal illness, and 
one individual in 2009 died as a result of their illness. 
Furthermore, 62% of cases required hospitalisation 
(42/68 cases for which data were provided). 
Table 1 describes the distribution of cases by country 
of birth and reason for travel. The primary reason for 
travel reported was ‘visiting family in country of origin’ 
(Table 1). The majority of cases reported were non-Irish 
born (75%), and even among those described as Irish-
born, half reported their reason for travel as ‘visiting 
family in country of origin’ (presumably the children of 
immigrants).
Where country of infection was reported, around two-
thirds of cases reported being exposed in Nigeria, with 
most of the remaining cases reporting travel to other 
Sub-Saharan African or Asian countries (Table 2). One P. 
falciparum case was reported not to have travelled to a 
malaria endemic country for many years. 
P. falciparum was responsible for the majority of cases 
which were acquired in Africa, while P. vivax was the 
most common species acquired in Asia (Table 2). As 
4.2 Malaria 
Summary
Number of cases, 2009: 90
Number of cases, 2008: 82
Crude incidence rate 2009: 2.1/100,000
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Table 1. Number of cases malaria by reason for travel and country of birth, Ireland 2009
Reason for travel
Country of birth
Nigeria Other Africa Asia Ireland Other Not specified Total
Visit family country origin 26 5 8 1 40
Holiday travel 2 1 2 2 7
Other 4 2 4 6 16
Not specified 3 24 27
Total 35 8 4 16 2 25 90
Other reasons for travel include: new entrants, Irish citizens living abroad, volunteer workers, etc
Figure 1. Annual number of notifications malaria, Ireland 1991-2009
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expected, the median interval between return/arrival 
from a malarious area and onset of illness was shorter 
for P. falciparum cases (7 days) than P. ovale (87 days) 
and P. vivax (237 days) cases. 
Half of all cases in Ireland in 2009 were notified during 
quarter 3 (Figure 2), coinciding with the summer holiday 
period, and most likely reflecting increased travel to 
endemic countries during this time. This seasonal peak 
was most prominent among cases who reported their 
reason for travel to an endemic country as ‘visiting 
family in country of origin’. Cases reported among 
holidaymakers were more common during winter 
months (Figure 2).
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Table 2. Number of cases malaria by infecting species and country of infection, Ireland 
2009
Species
Country of infection
Nigeria Other Africa Asia Ireland
Not 
specified Total
P. falciparum 35 11 1 1 23 71
P. ovale 3 1 1 5
P. vivax 1 3 2 6
P. malariae 1 1
Not Specified 3 1 3 7
Total 41 14 6 1 28 90
Figure 2. Number of malaria notifications by reason for travel and quarter 
of notification, Ireland 2009. [Other includes: new entrants, Irish citizens 
living abroad, volunteer workers, etc.]
Twenty-four cases of leptospirosis were notified in 
Ireland in 2009, a 20% reduction compared to the 30 
cases notified in 2008 (Figure 1). This equates to a crude 
incidence rate of 0.57 per 100,000 (95% CI 0.34-0.79). 
The last year for which data are available across the 
EU is 2007. Among the 25 countries that reported on 
leptospirosis incidence at that time, Ireland reported the 
second highest incidence rate. The incidence in the EU 
as a whole was 0.22 per 100,000. 
The leptospirosis notification dataset is typically 
dominated by adult males, and this year is no exception. 
Twenty-three cases (96%) were male and the age range 
was 17-81 (mean age =42 years, median age=40 years). 
This is consistent with the exposures most commonly 
associated with leptospirosis in temperate regions, 
e.g. occupational contact with farm animals, and 
watersports.
Among the 19 cases for which hospital admission status 
was reported, 17 (89%) required hospitalization. No 
deaths were reported. 
Seven cases (29%) were believed to have acquired 
their illness occupationally –at least three of these were 
farmers. Seven (29%) cases reported canoeing/kayaking 
activity. For two of these cases, these activities occurred 
outside of Ireland –one in Asia and one in the United 
Kingdom. For three cases (13%), their infections were 
reported to have been possibly due to engaging in 
more common outdoor activities such as gardening/DIY, 
or holidaying in a tropical destination. One case (4%) 
was reported as resulting from accidental exposure to 
river water after falling in. No risk factor information was 
available for the remaining six (25%) cases. 
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, annually around 
two thirds of cases are diagnosed by the National Virus 
Reference Laboratory. Positive specimens are generally 
referred to the UK Leptospirosis Reference Unit for 
confirmation and for typing where possible.Species 
information was available for only two cases in 2009 –
one each Leptospira interrogans hardjo and Leptospira 
interrogans icterohaemorrhagiae.  Species was not 
reported for the remaining 22 cases.
Activities that continue to be associated with 
leptospirosis risk in Ireland include farming and 
recreational activities such as water sports. In the last 
few years, travel to Asia has emerged as a risk factor for 
leptospirosis. In general the incidence of leptospirosis is 
higher in tropical climates than in temperate areas like 
Ireland.
4.3 Leptospirosis           
Summary
Number of cases, 2009: 24
Number of cases, 2008: 30
Crude incidence rate, 2009: 0.57/100,000
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Figure 1: Annual number of leptospirosis notifications, Ireland 1991-2009
(data source: CIDR)
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Blood-borne and 
Sexually Transmitted Infections
Health Protection Surveillance Centre   Annual Report 2009
Hepatitis B is a vaccine preventable disease which is 
transmitted through percutaneous or mucocutaneous 
contact with the blood or body fluids of an infected 
person. The main routes of transmission are through 
sexual contact, or vertical transmission from mother to 
baby, or through injecting drug use.
Over 90% of people infected as adults clear the virus 
within a year of infection, but there is a high probability 
of developing chronic infection if hepatitis B is 
acquired in infancy (90%) or early childhood (25-50%). 
A proportion of people with chronic infection develop 
progressive fibrosis which can lead to cirrhosis, liver 
failure and hepatocellular carcinoma (liver cancer).
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%) and most cases are in well 
defined risk groups such as people with multiple sexual 
partners, household or sexual partners of known cases, 
babies of positive mothers, injecting drug users and 
people who were born in hepatitis B endemic countries.
The number of hepatitis B cases reported in 
Ireland decreased by 14% in 2009, with 820 cases 
(19.5/100,000 population) notified compared to 
949 in 2008 (figure 1). Fifty eight percent (n=472) of 
notifications were from the HSE-E, corresponding to a 
notification rate of 31.5/100,000 population. 
All cases were laboratory confirmed. Ninety three 
percent contained information on acute/chronic status. 
Where status was known, 89% of cases were chronic 
(n=683) and 11% were acute (n=83).
Acute cases (recent infections)
Of the 83 acute cases notified in 2009, 86% (n=71) 
were male and 14% (n=12) were female.  The highest 
notification rates were in young to middle aged adults. 
Eighty six percent (n=71) of acute cases were aged 
between 20 and 54 years when notified (figure 2). 
Female cases were younger than males overall, with 
a median age of 30.5 years compared to 35 years for 
males.
5.1 Hepatitis B
Summary
Number of cases, 2009: 820
Crude notification rate, 2009: 19.5/100,000 population
Number of cases, 2008: 949
HPSC Annual Report 2008  
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Figure 1. Number of hepatitis B notifications by acute/chronic status, 1999-2009
Information on risk factor was available for 69% (n=57) 
of acute cases. Of these, 74% (n=42) were likely to have 
been sexually acquired. Twenty two were men who have 
sex with men, nineteen were heterosexual and sexual 
orientation was not known for one case. A further eight 
cases (14%) were born in a hepatitis B endemic country 
(hepatitis B surface antigen prevalence > 2%). No risk 
factors were identified for twenty six cases (31%).
Country of birth was known for 72% of acute cases 
(n=60).  Seventy two percent (n=43) were born in Ireland 
and 8% were born in Eastern or Central European 
countries. Where country of infection was known, 75% 
(n=33) of acute cases were infected in Ireland, 9% (n=4) 
were infected in Thailand and 7% (n=3) were infected in 
Poland. Information on reason for testing was available 
for 69 acute cases. Most were identified because they 
were symptomatic (64%, n=44) or through STI services 
(14%, n=10).
Chronic cases (long-term infections)
Of the 683 chronic cases notified in 2009, 54% (n=368) 
were male, 45% (n=308) were female and sex was not 
known for 1% (n=7). Eighty nine percent (n=610) of 
chronic cases were aged between 20 and 54 years when 
notified (figure 2). The median age for female cases was 
27.5 years and the median age for males was 33 years. 
Some enhanced data were available for 50% (n=339) 
of the chronic cases notified in 2009. Of these, 67% 
(n=227) were born in hepatitis B endemic countries 
or were identified as asylum seekers. A further 16% 
(n=45) were likely to have been sexually acquired and 
4% (n=13) were children born to hepatitis B infected 
mothers.  Data on country of birth was available for 39% 
(n=265) of chronic cases. The most common regions of 
birth were Eastern or Central Europe (32%, n=86), Sub-
Saharan Africa (28%, n=75) and Asia (26%, n=69). 
Reason for testing was known for 64% (n=436) of 
chronic cases. Thirty three percent (n=144) were 
identified through antenatal screening programmes, 
19% (n=84) were identified through asylum seeker 
screening programmes, 14% (n=63) were tested in STI 
settings and 10% (n=44) were identified through routine 
health or hospital screens.
Twenty six chronic cases were known to have been born 
in Ireland. Eight of these were residents of intellectual 
disability institutions. Their ages ranged from 42 to 
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Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis B by acute/chronic status, 2009
67 years. Most were diagnosed as a result of routine 
screening and may have been infected for some time.  
A further six Irish cases were acquired through sexual 
exposure.
Two outbreaks of hepatitis B were reported in 2009 
both involving MSM sexual exposure among young 
adult males.
Discussion
Notification rates for hepatitis B in Ireland had increased 
considerably since the late 1990s, mostly due to 
increasing immigration from countries with intermediate 
or high hepatitis B endemicity and increases in sexually 
transmitted hepatitis B in Ireland.  However, the number 
of new notifications for hepatitis B decreased in 2009.  
This may be partly explained by reduced immigration 
rates to Ireland. 
Although most chronic cases were young adults at the 
time of notification, this reflects their age when tested. 
Most of those who acquired their infection in endemic 
countries are likely to have been infected as infants 
or in early childhood and have now been infected for 
several decades. This has implications for the likely 
future burden of disease due to hepatitis B in Ireland.  
The number of acute cases acquired sexually, both 
heterosexually and through MSM contact, is of concern 
and indicates a target area for prevention activities.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 26th June 2010. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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The hepatitis C virus is primarily transmitted through 
sharing contaminated equipment when injecting 
drugs or through receipt of unscreened blood or 
blood products. Sexual, occupational and perinatal 
transmission can also occur but are less common. 
Infection is initially asymptomatic in approximately 70 to 
90% of cases, but between 55 and 85% of those infected 
fail to clear the virus and develop chronic infection. A 
proportion of people with chronic infection develop 
progressive fibrosis which can lead to cirrhosis, liver 
failure and hepatocellular carcinoma (liver cancer).
Hepatitis C became a notifiable disease in Ireland 
in 2004. There was an 18% decrease in the number 
of cases reported in 2009 (n=1258) compared with 
2008 (n=1537) (figure 1).  The crude notification rate 
decreased from 36 to 30/100,000 population.
The sex distribution of cases was very similar to previous 
years with a strong predominance of male cases (figure 
2).  In 2009, 66% (n=830) of cases were male, 33% 
(n=418) were female and sex was not known for 10 
cases. The highest notification rates were in young to 
middle aged adults. Seventy one percent (n=898) of 
cases were aged between 25 and 44 years (figure 2). The 
median age for females was younger (32 years) than that 
for males (35 years).
The geographic distribution of cases was skewed, with 
the HSE-E reporting 74% of all cases (n=929) notified 
in 2009. Their age-standardised notification rate, of 
62/100,000 population, was over 3 times that of the next 
highest area (figure 3).
Some information on most likely risk factor was available 
for 54% of cases (n=684) in 2009. The most likely risk 
factor for 77% (n=528) was injecting drug use.  A further 
3.5% (n=24) were either prison inmates or homeless. 
5.2 Hepatitis C
Summary
Number of cases, 2009: 1,258
Crude notification rate, 2009: 30/100,000 population
Number of cases in 2008: 1,537
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Figure 1. Number of hepatitis C notifications, 2004-2009
Although mode of transmission was not reported for 
these cases, injecting drug use is likely to have been the 
source of infection in many of these cases.
Thirty cases (4%) were reported as infected through 
receipt of blood or blood products. Of these, fifteen 
were infected in Ireland. No further information was 
available for three cases, but the remainder were all 
infected through anti-D or blood transfusions acquired 
many years in the past, but were notified for the first 
time in 2009. Fourteen cases (2%) were known to be 
asylum seekers, forty six cases (7%) were born in an 
endemic country and the most likely risk factor for 
twenty cases (3%) was sexual exposure.
Discussion
The number of cases of hepatitis C notified in 2009 
decreased to a level similar to that recorded in 2006.  
However, the high hepatitis C notifications seen in 
previous years (2005 to 2008) may not accurately reflect 
incidence trends in Ireland.  It is likely that many of the 
cases notified in these years were not newly acquired 
infections but were diagnosed by screening certain 
groups identified as been at risk.  These notifications 
may also include some cases diagnosed before 2004 
(when hepatitis C became notifiable) as a result of 
repeat testing.   There was an 18% decrease in hepatitis 
C notifications in 2009 compared to 2008.  The lower 
2009 figure may reflect a decrease in the number of 
previously diagnosed cases been notified due to repeat 
testing.
Risk factor information on hepatitis C has improved 
over the last few years.  For 2009, risk factor data 
were available for 54% of cases compared with only 
38% in 2008.  Where risk factor data were available, 
injecting drug use remained the predominant mode of 
transmission. Although information on risk factor was 
not available for 46% of cases, the age and sex profile 
of these cases did not differ significantly from those for 
whom information was available.
The prevalence of hepatitis C in the general population 
in Ireland is thought to be very low. Infection is mostly 
in defined risk groups such as injecting drug users 
and people who received unscreened blood or blood 
products in the past. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 25th June 2010. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis C, 2009
Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2007-2009
A total of 395 new HIV diagnoses were reported to 
the HPSC during 2009. This compares to 404 in 2008 
and represents a 2.2% decrease. The rate of newly 
diagnosed HIV infection in Ireland in 2009 was 93.2 per 
million population. The cumulative total number of HIV 
infections reported in Ireland since surveillance began to 
the end of December 2009 is 5,637. 
The total number of AIDS diagnoses reported to the 
end of 2009 is 1,038 with reports of 33 new AIDS 
diagnoses during 2009. The total number of deaths 
among AIDS cases reported to the end of 2009 is 414 
with reports of two deaths among AIDS cases in 2009. It 
is important to note that there is both under-reporting 
and late reporting of both AIDS cases and deaths 
among AIDS cases. Figure 1 shows the number of HIV 
and AIDS diagnoses annually in Ireland from 1990 to 
2009.
Figure 2 shows probable route of transmission for newly 
diagnosed cases among the three major risk groups; 
heterosexual contact, men who have sex with men 
(MSM) and injecting drug users (IDUs) between 1990 
and 2009. 
The 315 reported cases of HIV with information 
available on probable route of transmission indicate 
that:
UÊÊ{Ç°Î¯Ê­£xÈÊV>ÃiÃ®ÊÜiÀiÊÀi«ÀÌi`Ê>ÃÊ`ÕiÊÌÊ
heterosexual transmission 
5.3 HIV and AIDS
Summary
Number of HIV cases: 395
Crude HIV incidence rate: 9.3/100,000 population
Number AIDS cases: 33
Number deaths in AIDS cases: 2
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Figure 1. New HIV and AIDS diagnoses by year of diagnosis (1990-2009)
UÊÊ{£°n¯Ê­£ÎnÊV>ÃiÃ®ÊvÊiÜÊviVÌÃÊÜiÀiÊ>}Ê
MSM. 
UÊÊ°£¯Ê­ÎäÊV>ÃiÃ®ÊvÊiÜÊviVÌÃÊÜiÀiÊ>}Ê
IDUs.
During 2009, 136 babies were born to 131 HIV infected 
mothers (5 twin deliveries) in Ireland. Based on serial 
HIV PCR testing; 122 are not infected, 13 remain of 
indeterminate status (i.e. do not meet the criteria for 
HIV infection and are <18 months at time of test) and 
one is infected. The infected baby was born to a mother 
who was known to be infected during pregnancy and 
is originally from sub-Saharan Africa. In addition, HIV 
infection was newly diagnosed in four children. All four 
were born in sub-Saharan Africa with the probable route 
of transmission reported as mother to child transmission 
(MCT).
Of the 395 cases, 34.7% (137 cases) were female and 
65.3% (258 cases) were male. Of the 137 female cases 
newly diagnosed in 2009, 25 (18.2%) were reported to 
be pregnant at HIV diagnosis.  A breakdown of cases in 
2009 by probable route of transmission and sex can be 
seen in Table 2. 
Most of the newly diagnosed cases (68.1%) were 
aged between 25 and 44 years. The mean age at HIV 
diagnosis among the three major risk groups was:
UÊ Heterosexual: 35.6 years (range 16-73 years)
UÊ IDUs:  35.9 years (range 22-57 years)
UÊ MSM:  35.6 years (range 18-80 years)
The 307 reported cases of HIV with information 
available on geographic origin indicate that: 
UÊ{x°¯Ê­£{£ÊV>ÃiÃ®ÊÜiÀiÊLÀÊÊÀi>`Ê
UÊÎ£°Î¯Ê­ÈÊV>ÃiÃ®ÊÜiÀiÊLÀÊÊÃÕL->>À>ÊvÀV>
UÊÈ°n¯Ê­Ó£ÊV>ÃiÃ®ÊÜiÀiÊLÀÊÊ7iÃÌiÀÊÕÀ«iÊ
UÊ{°¯Ê­£xÊV>ÃiÃ®ÊÜiÀiÊLÀÊÊ>ÃÌiÀÊÕÀ«iÊ
UÊ{°È¯Ê­£{ÊV>ÃiÃ®ÊÜiÀiÊLÀÊÊ-ÕÌÊiÀV>Ê
UÊ{°Ó¯Ê­£ÎÊV>ÃiÃ®ÊÜiÀiÊLÀÊÊ
iÌÀ>ÊÕÀ«i°Ê
Of the 156 cases acquired through heterosexual 
contact, 56% (87 cases: 58 female and 29 male) were 
born in sub-Saharan Africa and 26% (40 cases: 18 female 
and 22 male) were born in Ireland.
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Figure 2: New HIV diagnoses in Ireland by probable route of transmission (1994 to 2009)
Table 2: HIV diagnoses in Ireland by probable route of transmission 
and sex (2009)
Probable route of 
transmission Sex Number  
MSM
Male 138
Sub total 138
Heterosexual contact
Female 96
Male 60
Unknown 0
Sub total 156
Injecting drug user
Female 6
Male 24
Sub total 30
Mother to child
Female 3
Male 2
Sub total 5
Other
Female 1
Male 0
Unknown 0
Sub total 1
Undetermined
Female 31
Male 34
Unknown 0
Sub total 65
Total  395
Information on stage of infection at time of HIV 
diagnosis was available for 304 of the 395 cases. Of 
the 304 cases where stage of infection was known, 235 
were asymptomatic at time of HIV diagnosis and 27 
were diagnosed with AIDS at the same as HIV diagnosis 
(i.e. diagnosed “late”).
Discussion
Since 2002, the annual HIV total has been in excess 
of 320 infections. The data suggest that the epidemic 
is concentrated among a number of risk groups. The 
numbers may fluctuate from year to year. Due to the 
voluntary nature of the reporting system, it is likely 
that the number of case reports is an underestimate. In 
addition, 10-20% of case reports are incomplete each 
year.  
More detailed information on the epidemiology of HIV 
and AIDS in Ireland in 2009 is available at www.hpsc.ie/
hpsc/A-Z/HepatitisHIVAIDSandSTIs/HIVandAIDS/
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Clinicians and laboratories notify their respective 
departments of public health of anonymised probable 
and confirmed cases of sexually transmitted infections 
(STIs). These notifications are then reported to HPSC 
in aggregated form o n a quarterly basis. Because of 
delays in STI reporting, annual data are not always 
available nationally in a timely manner. Consequently, 
this report focuses on STIs notified to HPSC in 2008. 
In 2008, 11,294 STIs were reported in Ireland, a 
decrease of 5.2% compared to 2007 when 11,915 STIs 
were reported (table 1). Despite the overall decline, 
there were increased notifications of Chlamydia 
trachomatis (up by 25.2%, n=6,290) and gonorrhoea (by 
6.5%, n=444). A decrease in notifications was observed 
for many STIs, in particular, non-specific urethritis 
(n=1,636), and ano-genital warts (n=2,134), notifications 
for these infections decreased by 12.5% and 35% 
respectively. The overall decrease should be interpreted 
with caution as one STI clinic in the HSE-MW Area was 
unable to provide returns. Three infectious diseases 
accounted for 89.1% of all STI notifications in 2008: ano-
genital warts, Chlamydia trachomatis and non-specific 
urethritis.
STIs in males accounted for 52.2% (n=5,898) of all 
notifications; 45.1% were in females (n=5,097). Gender 
data were not reported for 2.6% of notifications (n=299) 
(table 2). The number of notifications among males 
generally exceeded that of females for all STI diseases 
with the exception of C. trachomatis, herpes simplex 
(genital) and trichomoniasis (table 2). In 2008, the 
highest number of notifications was in the 20-29 year 
age group, accounting for 60.0% of all STIs notified 
(table 2). This age group also had the highest number of 
notifications for each of the STI diseases except syphilis 
and hepatitis B (acute or chronic) (table 2).
During 2008, 47.1% (n=5,322) of all STI notifications 
were from the HSE-E. Four areas (HSE-E, HSE-SE, 
5.4  Sexually Transmitted Infections  
 (STIs), 2008
Summary
Total number of STI notifications in 2008: 11,294
Three most common STIs reported in 2008:
1.  Chlamydia trachomatis infection (genital): 6,290 
cases (148.4/100,000)
2. Ano-genital warts: 2,134 cases (50.3/100,000)
3. Non-specific urethritis: 1,636 cases (38.6/100,000)
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Table 1 Notifiable sexually transmitted infections from 1999 to 2008
Sexually Transmitted Infection 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Ano-genital warts 3049 3735 3993 3932 3981 4174 3456 3494 3283 2134
Chancroid 1 16 1 1 0 1 0 1 1 0
Chlamydia trachomatis infection (genital) 869 1343 1649 1922 2258 2803 3353 3144 5023 6290
Gonorrhoea 175 290 349 214 186 270 342 431 417 444
Granuloma inguinale 1 0 0 0 0 1 0 0 0 0
Hepatitis B (acute or chronic) 2 15 39 57 112 85 80 20 25 14
Herpes simplex (genital) 275 269 331 358 375 411 441 455 988 394
Lymphogranuloma venereum 2 0 0 1 0 0 1 0 2 0
Non-specific urethritis 1265 1726 1634 2025 2332 2746 2106 2161 1870 1636
Syphilis 6 46 279 303 235 144 282 134 212 312
Trichomoniasis 47 78 64 73 59 60 83 52 94 70
Total 5692 7518 8339 8886 9538 10695 10144 9892 11915 11294
HSE-S and HSE-W) accounted for more than 85% 
(n=9,684/11,294) of the STI notifications in 2008 (table 
3). The breakdown of STI data by geographical area 
should, however, be interpreted with caution, as figures 
are largely a reflection of the area where cases availed 
of STI services rather than a reflection of the burden of 
STIs in the population in that area. 
Summary Statistics on Selected STIs, 2008
Ano-genital warts
In 2008, 2,134 cases of ano-genital warts were notified 
(50.3/100,000 population) which accounted for 18.9% of 
all STI notifications reported. This number represents a 
decrease of 35% since 2007. More cases were notified 
among males than females (1,173 versus 959) and in the 
20-29 year old age group which had 63.9% (n=1,364) of 
all such cases reported. 
Chlamydia trachomatis infection (genital)
The crude incidence rate in 2008 for C. trachomatis 
infection was 148.4/100,000 (6,290 notifications). 
Chlamydia notifications constituted 55.7% of all STI 
notifications reported in 2008 and represent an increase 
of 25.2% since 2007. More cases were notified among 
females than males (3,540 versus 2,481) and 60.7% 
(n=3,820) of cases were reported in the 20-29 year old 
age group.
Non-specific urethritis
In 2008, 1,636 cases of non-specific urethritis were 
notified (38.6/100,000), a decrease of 12.5% since 
2007. These notifications constituted 14.5% of all STI 
notifications reported. Almost 10-times more cases were 
notified among males than females (1,486 versus 150). 
Cases in the 20-29 year old age group represented 
62.2% (n=1,017) of reported cases. 
Herpes simplex (genital)
The crude incidence rate for genital herpes in 2008 
was 9.3/100,000 (394 notifications). The notifications 
constituted 3.5% of all STI notifications reported in 2008 
and represent a decrease of 60.1% since 2007. More 
cases were notified among females than males (238 
versus 149) and in the 20-29 year old age group (53.8% 
of all such cases notified; n=212).
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Table 2 Notifiable sexually transmitted infections by gender and age group, 2008
Sexually Transmitted Infection Male Female Gender Unknown 0-19 20-29 30-39 40+
Age 
Unknown Total
Ano-genital warts 1173 959 2 178 1364 355 130 107 2134
Chancroid 0 0 0 0 0 0 0 0 0
Chlamydia trachomatis infection 
(genital) 2481 3540 269 814 3820 819 170 667 6290
Gonorrhoea 360 73 11 31 247 92 48 26 444
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Hepatitis B (acute or chronic) 12 2 0 1 4 8 1 0 14
Herpes simplex (genital) 149 238 7 34 212 69 53 26 394
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 0
Non-specific urethritis 1486 150 0 100 1017 368 143 8 1636
Syphilis 229 76 7 1 90 116 86 19 312
Trichomoniasis 8 59 3 2 27 19 14 8 70
Total 5898 5097 299 1161 6781 1846 645 861 11294
(% of Total) 52.2% 45.1% 2.6% 10.3% 60.0% 16.3% 5.7% 7.6% -
Gonorrhoea
In 2008, 444 cases of gonorrhoea were notified 
(10.5/100,000), an increase of 6.5% since 2007. These 
notifications constituted 3.9% of all STI notifications 
reported in 2008. Considerably more cases were 
notified among males than females (360 versus 73) and 
most frequently in the 20-29 year old age group (55.6% 
of all such cases reported; n=247). 
Hepatitis B
The data presented here reflect only those cases 
notified through STI services. Further information on the 
epidemiology can be found in the hepatitis B chapter of 
this report.
Note: Crude incidence rates calculated for the year 
2008 based on census 2006 denominator data.
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Table 3 Notifiable sexually transmitted infections by HSE area, 2008
Sexually Transmitted Infection HSE-E
HSE-
M
HSE-
MW*
HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W Ireland
Ano-genital warts 206 8 0 0 284 402 568 666 2134
Chancroid 0 0 0 0 0 0 0 0 0
Chlamydia trachomatis infection (genital) 3541 152 558 166 79 940 325 529 6290
Gonorrhoea 304 5 26 8 7 33 30 31 444
Granuloma inguinale 0 0 0 0 0 0 0 0 0
Hepatitis B (acute or chronic) 0 0 0 2 0 0 9 3 14
Herpes simplex (genital) 210 1 0 0 8 47 58 70 394
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 0
Non-specific urethritis 842 0 0 2 225 161 301 105 1636
Syphilis 190 26 32 1 3 24 14 22 312
Trichomoniasis 29 6 6 5 0 12 6 6 70
Total 5322 198 622 184 606 1619 1311 1432 11294
(% of Total) 47.1% 1.8% 5.5% 1.6% 5.4% 14.3% 11.6% 12.7% -
* Data not available from STI Clinic in HSE-MW. Above data based on lab-confirmed reports provided by the laboratory to public health
Since 2000, case-based records are available nationally 
on syphilis cases. An enhanced surveillance system is 
in place whereby enhanced forms are completed by 
Departments of Public Health in conjunction with the 
clinician and are then forwarded to HPSC. The data 
presented in this chapter relate to the case-based 
reports received on syphilis (some with enhanced 
details) which are held on a national database at HPSC. 
The syphilis figures presented here are not comparable 
with the aggregate counts of syphilis notifications 
provided by HSE areas as part of the routine quarterly 
reporting of sexually transmitted infections (See STI 
chapter for more details). This difference arises because 
case-based reports are not received for all syphilis cases 
notified. 
The first section of this report focuses on 2008 data and 
the second part on the main syphilis trends between 
2000 and 2008.
Syphilis 2008
In 2008, case-based reports with enhanced surveillance 
data were received on 221 syphilis notifications, an 
increase of 75 cases compared with 2007 (n=146). 
One-hundred-and-twenty-five (2.9/100,000 population) 
cases were diagnosed with early, infectious syphilis (i.e. 
primary, secondary and early latent stages) and 96 cases 
were latent, late, tertiary, other or unknown.
The 125 cases of early syphilis were analysed in more 
detail since the disease is infectious at this stage and 
therefore has the greatest public health implications. 
Cases ranged in age from 19 to 63 years of age (median 
35 years). The majority of cases were diagnosed in the 
HSE-E (92%, n=115/125) and the majority of the cases 
were also resident in HSE-E (75%, n=94/125). Ireland 
was recorded as the country of birth for 70% of early 
cases (n=88/125), while 72% of early cases (n=90/125) 
were acquired in Ireland.
Eighty percent of early syphilis cases (n=100/125) were 
5.5 Syphilis, 2008
Summary
Number of case-based syphilis reports with enhanced 
surveillance data, 2008: 221
Number of early syphilis cases, 2008: 125
Crude incidence rate of early syphilis, 2008: 
2.9/100,000
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Figure 1 Quarterly number of early syphilis cases diagnosed in Ireland by sexual orientation, 2000-2008, based on completed 
enhanced forms (excluding fifteen cases without quarterly year details) 
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men who had sex with men (MSM). These cases ranged 
in age between 19 and 57 years (median 35 years), with 
the 25-29 years age group having the highest number 
of cases (n=24). Among MSM diagnosed with early 
syphilis, 31% percent (n=31) were primary syphilis, 
36% (n=36) were secondary and 32% (n=32) were early 
latent. One case was reported as early syphilis but the 
detailed stage of disease was not given. 
Sixty percent (n=60/100) of early syphilis MSM cases 
had between 1 and 9 sexual contacts in the 12 months 
prior to diagnosis; 15% (n=15/100) had 10-19 sexual 
contacts; 7% (n=7) had 20-39 sexual contacts; 5% 
(n=5/100) had more than 40 sexual contacts, while 
the number of contacts was not recorded for 13% 
(n=13/100) of cases. The most common mode of 
transmission was reported as oral sex in 62% (n=62) of 
early syphilis MSM cases.
 
Syphilis trends, 2000-2008
Between 2000 and 2008, a total of 1,996 case-based 
reports were received on syphilis. Most syphilis cases 
were among males (73%; n=1,465) while females 
accounted for 26% of cases (n=516); gender was not 
recorded for 15 cases (1%). Cases ranged in age from 0 
to 95 years, with a median age of 33 years. The majority 
of cases occurred in the 25-29 year old and 30-34 year 
old age groups: 397 and 405 cases respectively. Fifty 
percent (n=992) were classified as early, infectious 
syphilis. The other stages reported were: congenital 
(n=4), late (n=392) and unknown (n=608). 
Enhanced surveillance forms were completed for 66% 
(n=1,313/1,996) of individual case-based reports and 
894 (68%) of these 1,313 cases were reported as early 
syphilis. The majority of these 1,313 cases were male 
(81%; n=1,065). Most male cases occurred in the 30-
34 years age group (22%, n=229/1,065) while most 
of cases among females were in the 25-29 years age 
group (33%, n=80/241). 
Among the cases with enhanced data, self-referral 
was the most frequent reason for attending (31%, 
n=412/1,313), followed by GP referral (12%, 
n=159/1,313) and contact referral (11%, n=144/1,313). 
While self-referral was also the most frequent reason 
for attending among MSM cases (40%, n=318/805), 
the next most frequent reason was routine visit 
(12%, n=95/805), followed by contact referral (11%, 
n=88/805).  However, among non-MSM cases 25% of 
cases were antenatal referrals (n=118/473). The other 
most frequently reported reasons for attending among 
this group were self referral (17%, n=82/473) and GP 
referral (16%, n=78/473).
Early syphilis is far more common in the MSM 
population in Ireland compared to the non-MSM 
population (figure 1, table 1). Enhanced data were 
reported for 805 MSM cases between 2000 and 2008, 
85% (n=682) of which were early syphilis cases. 
In the 12 months before diagnosis, the most common 
range was 1-9 sexual contacts in 59% (n=400/682) of 
early syphilis MSM cases. Oral sex (36%, n=245/682) 
was the most common mode of transmission reported 
for early syphilis MSM cases. 
Eleven percent (n=73/682) of early syphilis MSM cases 
for which enhanced data was received were the result 
of re-infections. The re-infection rate among early 
syphilis non-MSM cases with enhanced data for the 
same period was 4% (n=7/197). 
A higher proportion of early syphilis cases among MSM 
were reported to be HIV positive (19%, n=128/682) 
compared to early syphilis non-MSM cases (8%, 
n=16/197). There was no difference between these 
groups in relation to concurrent STIs, which were 
relatively common among all early syphilis cases, with 
20% of cases (n=177/894) having an STI other than 
HIV.  A history of STIs was more frequent among early 
syphilis MSM cases (41%, n=281/682) than among early 
syphilis non-MSM cases (18%, n=35/197).
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Table 1 A breakdown of early syphilis cases by sexual orientation in Ireland, 2000-2008, based on completed enhanced forms
Diagnosis Heterosexual MSM** Unknown Total
 Male Female* Unknown  Male  
Primary 45 13 2 255 5 320
Secondary 34 29 1 253 3 320
Early Latent 34 37 0 164 5 240
Other 0 2 0 10 2 14
Total 113 81 3 682 15 894
* Includes one female bisexual
** Includes 55 male, bisexual cases
06
Other infections
Health Protection Surveillance Centre   Annual Report 2009
Not all viral infections are notifiable, but some can 
and do cause encephalitis. In this chapter, the focus is 
on those viral pathogens that cause encephalitis, but 
are not notifiable in their own right (apart from one 
exception, herpes simplex virus).
In 2009, five cases of viral encephalitis (caused by 
non-notifiable organisms) were notified in Ireland, 
which is a crude incidence rate of 0.12 per 100,000 
total population. The number of viral encephalitis 
notifications in 2009 is the same as that which was 
reported in 2008, and less than the eight reported in 
2007 and the 16 recorded in 2006. The decrease in viral 
encephalitis in 2007, compared to 2006 was particularly 
related to a decrease in varicella zoster virus associated 
encephalitis notifications. Between 2004 and 2009, 45 
cases of viral encephalitis were notified, 20 of which 
(44.4%) were attributable to herpes simplex virus.
Of the five cases notified in 2009, three cases occurred 
in males and two in females giving a ratio of 1.5:1.0.
Cases ranged in age from 41 to 86 years. The highest 
incidence rates were in adults aged >=65 years 
(0.4/100,000) (table 1).
The causative agent was identified in four of the five 
cases of viral encephalitis notified; herpes simplex virus 
(n=3), varicella zoster virus (n=1) and unknown (n=1). 
Three of the cases due to herpes simplex occurred in 
adults aged between 40 and 74 years. Another case was 
caused by varicella zoster virus in an adult aged 85+ 
years. No deaths from viral encephalitis were notified 
between 1997 and 2009.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 7th July 2010. These 
figures may differ from those published previously due 
to ongoing updating of notification data on CIDR.
6.1 Viral Encephalitis
Summary
Number of cases, 2009: 5
Number of cases, 2008: 5
Number of cases, 2007: 8
Crude incidence rate, 2009: 0.1/100,000
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Table 1. Number, age-specific incidence rates per 100,000 
population and proportion of viral encephalitis cases by age 
group, 2009
Age Group Number Proportion 
(%)
ASIR
<1 0 0% 0.0
1-4 0 0% 0.0
5-9 0 0% 0.0
10-44 2 40% 0.1
45-64 1 20% 0.1
65+ 2 40% 0.4
All ages 5 100% 0.1
ASIR, age specific incidence rates per 100,000 population Figure 1. Annual number of viral encephalitis notifications, 
1997-2009
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unknown enterovirus varicella zoster virus herpes simplex virus 
Not all viral infections are notifiable, but many can and 
do cause meningitis. In this chapter, the focus is on 
those viral pathogens that cause meningitis, but are not 
notifiable in their own right (apart from one exception, 
herpes simplex virus).
In 2009, 142 cases (3.3/100,000 total population) of 
viral meningitis were notified in Ireland. Most of the 
cases were classified as confirmed (74.6%, n=106) with 
another 36 (25.4%) where the case classification was 
not specified because the causative organism details 
were unavailable. The numbers of cases in both sexes 
were different with more cases in males (n=80) than in 
females (n-61), giving a ratio of 1.31:1.0. Gender was 
not reported for one case. 
Cases ranged in age from three weeks to 83 years 
with a median age of 19 years. Seventy-seven percent 
(n=109/142) of all cases were <35 years of age. Children 
<1 year of age had the highest incidence rate: 67.1 per 
100,000, followed by those in the 15-19 year group, 
4.1/100,000 (table 1). 
In 2009 the overall incidence of viral meningitis in 
Ireland was equally highest in both the HSE-NE and 
HSE-W areas (4.3/100,000) followed by the HSE-E area 
(3.7/100,000) (table 2).
Of the 142 cases notified in 2009 the causative agent 
was reported as enterovirus (n=91; 64.1%), herpes 
simplex virus (n=11; 7.8%), varicella zoster virus (n=4; 
2.8%) and unknown (n=36; 25.4%) (table 1).
In Ireland, viral meningitis activity tends to be highest 
in the second half of the year. In 2009 the numbers of 
cases peaked in July (n=35) and August (n=22) with an 
average of 14.7 cases per month (total n=88) between 
July and December. In contrast, viral meningitis was 
lower during the first six months of the year with a 
monthly average of nine cases (total n=54). 
6.2 Viral Meningitis
Summary
Number of cases, 2009: 142
Number of cases, 2008: 97
Number of cases, 2007: 45
Crude incidence rate, 2009: 3.3/100,000
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Table 1. Number and age specific incidence rates per 100,000 population of viral meningitis notifications by causative organism, 2009
Age Group entero-virus
herpes simplex 
virus
varicella zoster 
virus unknown Total ASIR
<1 29 5 0 7 41 67.1
1-4 2 1 0 2 5 2.1
5-9 7 0 0 3 10 3.5
10-14 3 0 0 1 4 1.5
15-19 8 0 0 4 12 4.1
20-24 6 1 0 6 13 3.8
25-34 16 2 2 4 24 3.3
35-44 17 1 0 5 23 3.7
45-54 2 0 1 2 5 1.0
55-64 0 1 0 2 3 0.7
65+ 1 0 1 0 2 0.4
Total 91 11 4 36 142 3.3
ASIR, age specific incidence rate
Although the number of viral meningitis cases fluctuates 
from year to year, the number of cases notified in 2009 
(n=142) exceeded the yearly average (n=70.4) between 
1997 and 2009 (range 23-161) (figure 1). 
High numbers of cases occurred in 2000 (n=98), 
2001 (n=161) and 2006 (n=148). These upsurges in 
notifications coincided with an increase in reports by 
the National Virus Reference Laboratory (NVRL) of 
laboratory confirmed non-polio enterovirus isolates. 
Towards the end of 2005 NVRL introduced PCR testing 
of CSF samples for enteroviral nucleic acid. This was in 
addition to the routine method of viral isolation from 
stool samples. 
2009 was a high incidence year for viral meningitis with 
numbers similar to 2001 and 2006 when 161 and 148 
cases were reported, respectively. The majority of cases 
in both 2006 and 2009 were attributable to enterovirus.
One viral meningitis associated death (a confirmed case) 
was reported in 2009 with herpes simplex type 6 being 
identified as the causative organism. Only one other 
death from viral meningitis (a probable case) has ever 
been notified since 1997; it occurred in 1997 and the 
causative organism of which was not reported.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 17th August 2010. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Table 2. Age specific incidence rates per 100,000 population of viral meningitis notifications by HSE area, 2009
HSE Area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 79.5 4.8 6.3 3.4 3.0 0.7 2.3 3.7
M 0.0 0.0 0.0 0.0 5.7 5.5 1.9 2.0
MW 19.6 0.0 4.0 0.0 0.0 3.5 1.3 1.7
NE 173.0 3.9 0.0 0.0 7.4 0.0 1.2 4.3
NW 0.0 0.0 0.0 0.0 0.0 6.2 2.6 2.1
SE 59.3 0.0 0.0 3.1 6.2 6.2 2.0 3.3
S 69.9 0.0 7.2 0.0 2.4 2.1 2.2 3.2
W 34.7 0.0 0.0 0.0 10.2 18.6 2.6 4.3
Ireland 67.1 2.1 3.5 1.5 4.1 3.8 2.1 3.3
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Figure 1. Annual number of viral meningitis notifications, 1997-2009
Five cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2009 compared to two cases in 2008.  All 
cases in 2009 were aged greater than 54 years and were 
sporadic CJD cases.  Four cases were male and one was 
female.
In total, 48 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December  
1996.  Figure 1 shows the 48 CJD notifications by 
age group.  The majority (n=41, 85%) of the cases 
were aged greater than 54 years.  Of the 48 cases, 27 
were male and 21 were female.  Forty-five cases were 
sporadic CJD, two were familial CJD and one was 
iatrogenic CJD.
Variant CJD (vCJD) is specified as a separate notifiable 
disease.  No cases of vCJD were notified in 2009.  
Four cases of vCJD were notified since vCJD became 
notifiable in December 1996.  A summary of these four 
cases was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on 
notifications from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.  The figures 
were extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on the 09th September 
2010 and may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.  Annual figures published here are based 
on the year the notification was entered on CIDR and 
consequently may differ from annual figures published 
by the Irish National Creutzfeldt-Jakob Disease 
Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2009: 5
Number of cases, 2008: 2
0
5
10
15
20
25
30
0-
4
5-
9
10
-1
4
15
-1
9
20
-2
4
25
-3
4 
35
-4
4 
45
-5
4 
55
-6
4 
65
+
 
U
nk
no
w
n
Age group (years)
N
um
be
r 
of
 c
as
es
 n
ot
ifi
ed
-87-HPSC Annual Report 2009 6. Other Infections
Figure 1.  Number of CJD notifications (n=48) from December 1996 to 2009 
by age group
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During 2009, 468 outbreaks of infectious diseases 
were reported with 7,769 associated cases of illness, 
including 590 (7.6%) cases hospitalised.  In June 2009 
the World Health Organization announced that the 
A(H1N1) influenza had become  a global pandemic.  
This was characterised by extensive influenza activity 
in Ireland that increased the number of outbreaks (and 
outbreak cases of illness due to influenza) beyond levels 
seen in previous years. 
Regional variation in all outbreaks was observed 
between HSE areas with the highest rate observed 
in HSE-NW at 28.7 per 100,000 population while the 
lowest rate was observed in HSE-MW at 6.1 per 100,000 
population. Table 1 details the regional distribution 
of all outbreaks of infectious disease, outbreaks of 
infectious intestinal disease (IID) and outbreaks of  
non-IID.
General outbreaks accounted for 72.9% (n= 341) of 
all outbreaks notified during 2009. The remaining 
outbreaks (27.1%, n= 127) were reported as family/
household outbreaks. Similar to previous years, 
person-to-person spread was reported as the mode 
of transmission for the majority of outbreaks in 2009 
(53.0%, n=248). Most of these outbreaks were due to 
norovirus and pandemic influenza A(H1N1). 
Private houses were the most frequently reported 
outbreak location in 2009, accounting for 25.6% (n=120) 
of all outbreaks while schools were the second most 
common outbreak location, accounting for 19.7% (n=92) 
of all outbreaks. The highest numbers ill were reported 
from outbreaks in schools (n=2,526), hospitals (n=2,137) 
and residential institutions (n=1,088). Table 2 details the 
number of IID and non-IID outbreaks and numbers ill by 
outbreak location for outbreaks reported during 2009.
Infectious intestinal disease (IID) outbreaks:
IID outbreaks accounted for 56.4% (n=264) of all 
outbreaks reported during 2009. This was a 6% 
decrease compared to the number of IID outbreaks 
reported during 2008 (n=281).
7. Outbreaks
Summary
Number of outbreaks: 468
Number of IID outbreaks: 264
Number of non-IID outbreaks: 204
-89-HPSC Annual Report 2009 7. Infectious Disease Outbreaks
Table 1:  Number of outbreaks and numbers ill by HSE area for all outbreaks, IID outbreaks and non-IID outbreaks (2009)
HSE area Number of 
outbreaks
Outbreak rate per 
100,000
Number ill Number 
hospitalised
Number of IID 
outbreaks
Number of Non-
IID outbreaks
HSE-E 124 8.3 3,190 126 66 58
HSE-M 31 12.3 263 36 23 8
HSE-MW 22 6.1 182 36 14 8
HSE-NE 55 14.0 956 138 27 28
HSE-NW 68 28.7 866 87 45 23
HSE-SE 45 9.8 680 37 28 17
HSE-S 74 11.9 820 38 35 39
HSE-W 47 11.3 781 79 24 23
HPSC 2 - 31 13 2 0
Total 468 11.0 7,769 590 264 204
Norovirus/ suspect viral outbreaks, accounted for 
48.1% of all IID outbreaks reported in 2009. Norovirus 
was also responsible for the two largest outbreaks 
during 2009. Both occurred in hospitals with 717 and 
576 cases of illness respectively. Figure 1 compares 
norovirus/suspect viral outbreaks with non-norovirus 
IID outbreaks by year from 2001 to 2009. 2009 was the 
first year where less norovirus/suspect viral outbreaks 
were reported than other IID outbreaks.
After norovirus (n=115), the next most commonly 
reported IID outbreaks during 2009 were acute 
infectious gastroenteritis (n=68), Enterohaemorrhagic 
E. coli  (n=42), salmonellosis (n=15) and campylobacter 
(n=9). The number of general and family outbreaks of 
IID disease and numbers ill, are outlined in Table 3.  
The most frequently reported locations for IID 
outbreaks were private houses (n=69), residential 
institutions (n=54) and hospitals (n=49). The most 
commonly reported outbreaks in private homes were 
of EHEC (n=36), Campylobacter (n=9) and Salmonella 
(n=9). In residential institutions the most commonly 
reported outbreak were of norovirus/suspected 
norovirus (n=40) while in hospitals the most commonly 
reported outbreaks were also of norovirus/ suspected 
norovirus (n=38) and of C. difficile (n=6).
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Figure 1:  Number of norovirus/suspect viral outbreaks and number of non-norovirus IID outbreaks by 
year, 2001-2009
Table 2: Number of IID and non-IID outbreaks and numbers ill by outbreak location, 2009
Outbreak location
IID Non-IID Total outbreaks
Number of 
outbreaks Number ill
Number of 
outbreaks Number ill
Number of 
outbreaks Number ill
Private house 69 185 51 143 120 328
School 4 144 88 2,382 92 2,526
Residential institution 54 915 16 173 70 1,088
Hospital 49 2,127 3 10 52 2,137
Comm. Hosp/Long-stay unit 40 686 2 10 42 696
Other 12 87 8 58 20 145
Crèche 9 70 8 56 17 126
University/College 0 0 13 249 13 249
Hotel 8 169 1 3 9 172
Community outbreak 6 87 3 48 9 135
Travel related 4 10 3 11 7 21
Extended family 3 8 4 55 7 63
Workplace 1 5 2 33 3 38
Coach tour 2 14 0 0 2 14
Unknown 1 11 1 2 2 13
Guest house / B and B 1 9 0 0 1 9
Restaurant / Cafe 1 5 0 0 1 5
Public house 0 0 1 4 1 4
Total 264 4,532 204 3,237 468 7,769
Person-to-person (P-P) spread was the most frequently 
reported mode of transmission implicated in IID 
outbreaks during 2009 (54.9%, n=248). The second 
most frequently reported transmission mode was P-P 
and airborne (9.5, n=25).
The number of IID outbreaks peaked during the first 
three months of 2009. This peak is due to high numbers 
of norovirus outbreaks, with 30 norovirus outbreaks 
reported during January, 28 during February and 
22 during March. This seasonal variation has been 
observed in previous years. Figure 2 illustrates the 
number of IID and non-IID outbreaks by month of 
notification during 2009.
Non-IID outbreaks:
During 2009, 204 outbreaks of non-IID diseases were 
reported, which was more than double the number of 
non-IID outbreaks reported during 2008 (n=99). This 
increase was due to the high numbers of outbreaks of 
pandemic influenza A(H1N1) and influenza-like illness 
(ILI) which accounted for 54.4% (n=111) and 16.2% 
(n=33) of all non-IID outbreaks reported respectively. 
The third most common non-IID outbreak was mumps 
accounting for 15.7% (n=32) of all non-IID outbreaks 
reported. The number of general and family outbreaks 
of non-IID disease and numbers ill are outlined in  
Table 4.  
During 2009, the number of non-IID outbreaks peaked 
during September and October with 30 and 72 
outbreaks reported respectively (figure 2). This peak 
was due to high numbers of outbreaks of pandemic 
influenza (AH1N1) and ILI reported, with 29 outbreaks 
of pandemic influenza (AH1N1)/ILI reported during 
September and 71 during October. The most frequently 
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Figure 2: Number of IID and non-IID outbreaks by month of notification, 2009
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Table 3:  Number of general and family IID outbreaks by disease, 2009
Outbreak disease/pathogen
Family outbreak General outbreak Total IID outbreaks
Number of 
outbreaks
Number 
ill
Number of 
outbreaks Number ill
Number of 
outbreaks Number ill
Acute infectious gastroenteritis 6 38 62 777 68 815
Campylobacter infection 9 33 0 0 9 33
Clostridium perfringens (type A) food-
borne disease 1 11 0 0 1 11
Cryptosporidiosis 5 14 1 3 6 17
Enterohaemorrhagic E. coli (EHEC) 36 78 6 16 42 94
Giardiasis 0 0 1 3 1 3
Hepatitis A (acute) 1 2 2 17 3 19
Noroviral infection 1 10 114 3,424 115 3,434
Paratyphoid 1 2 0 0 1 2
Salmonellosis 12 27 3 66 15 93
Shigellosis 2 8 1 3 3 11
Total 74 223 190 4,309 264 4,532
reported locations for non-IID outbreaks were schools 
(n=88), private houses (n=51), residential institutions 
(n=16) and university/college (n=13). Non-IID outbreaks 
in these locations were most frequently caused by 
pandemic influenza A(1N1)/ILI and mumps (table 2) . 
Person-to-person (P-P) spread was the most frequently 
reported mode of transmission implicated in non-IID 
outbreaks during 2009 (50.5%, n=103). The second 
most frequently reported transmission mode was P-P 
and airborne (29.4%, n=60).
The information gathered from outbreaks reported 
is used to inform public health professionals on the 
causes and factors contributing to outbreaks, to target 
prevention strategies and to monitor the effectiveness 
of prevention programmes.
For further information on disease specific outbreaks, 
please refer to the individual disease chapter.
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Table 4: Number of family and general non–IID outbreaks by disease, 2009
Outbreak disease/pathogen Family outbreak General outbreak Total Non-IID outbreaks
Number 
outbreaks
Numbers ill Number 
outbreaks
Numbers ill Number 
outbreaks
Numbers ill
Pandemic influenza A(H1N1) 34 97 77 2,011 111 2,108
Influenza-like illness 0 0 33 585 33 585
Mumps 13 37 19 243 32 280
Measles 4 11 4 94 8 105
Influenza 0 0 3 44 3 44
Coronavirus 0 0 1 30 1 30
Scabies 0 0 1 20 1 20
Varicella 0 0 2 9 2 9
ESBL 0 0 2 9 2 9
Chickenpox 0 0 2 9 2 9
Scarlet fever 0 0 1 8 1 8
Tinea 0 0 1 7 1 7
Possible rubella 0 0 1 6 1 6
Mycobacterium tuberculosis 0 0 1 5 1 5
Rubella-like illness 1 3 0 0 1 3
Suspected Streptococcus pyogenes 0 0 1 3 1 3
MRSA 0 0 1 2 1 2
Hepatitis B (acute and chronic) 0 0 1 2 1 2
Legionellosis 1 2 0 0 1 2
Total 53 150 151 3,087 204 3,237
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Immunisation Uptake
Health Protection Surveillance Centre   Annual Report 2009
In 2009, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area.  
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website.  
The annual immunisation uptake rates presented 
here represent the collation of the 2009 quarterly 
data.  The proportion of children who completed the 
recommended childhood immunisation schedule by 12 
months (born between 01/01/2008 and 31/12/2008) or 
24 months (born between 01/01/2007 & 31/12/2007) of 
age in 2009 are reported.
The Irish childhood immunisation schedule 
recommended that babies born during 2007 and 
January to June 2008 should receive one dose of 
vaccine against tuberculosis (BCG vaccine) at birth 
or by one month of age and three doses of vaccines 
against diphtheria (D3), tetanus (T3), pertussis (P3), 
Haemophilus influenzae type b (Hib3), polio (Polio3) 
and meningococcal group C (MenC3) with one dose 
of each given at two, four and six months of age.  
Between 12 and 15 months of age these children were 
recommended to receive the first dose of the measles-
mumps-rubella vaccine (MMR1) and a Hib booster 
(Hibb).  Children born on or after September 2
nd 2006 
were recommended pneumococcal conjugate vaccine 
(PCV) as part of a catchup campaign introduced in 
September 2008, however, PCV catch-up data are not 
reported here.  
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after 1st July 2008 (table 1).  These 
children should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month 
of age; three doses of vaccines against diphtheria, 
tetanus, pertussis, Haemophilus influenzae type b, 
polio and Hepatitis B (HepB3) with one dose of each 
given at two, four and six months of age; three doses 
of pneumococcal conjugate vaccine (PCV) given at 
8. Immunisation Uptake
Summary
At 12 months (based on available data) uptake of:
D3,  T3,  P3, Hib3, Polio3, HepB3, MenC2 and PCV2 was 89% and 
MenC3 was 86%
Note: MenC3 data were for Quarters 1 and 2 only and HepB3, 
MenC2 and PCV2 data were for Quarters 3 and 4 only
At 24 months (based on available data) uptake of:
D3, T3, P3 and Polio3 was 94%
Hib3 and MenC3 was 93% 
MMR1 was 90% 
Hibb was 87%
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Age Children born before 01/07/2008 Children born on or after 01/07/2008
Birth BCG BCG
2 months DTaP/Hib/IPV + MenC DTaP/Hib/IPV/HepB + PCV
4 months DTaP/Hib/IPV + MenC DTaP/Hib/IPV/HepB + MenC
6 months DTaP/Hib/IPV + MenC DTaP/Hib/IPV/HepB + PCV + MenC
12 months MMR + Hib MMR + PCV
13 months - MenC + Hib
Please see www.immunisation.ie for complete information on the Irish childhood immunisation schedule.
BCG  Bacille Calmette Guerin vaccine 
DTaP Diphtheria, Tetanus and acellular Pertussis vaccine
Hib Haemophilus influenzae type b vaccine
IPV Inactivated Polio Virus vaccine
MenC  Meningococcal group C vaccine
HepB Hepatitis B vaccine
PCV Pneumococcal Conjugate Vaccine
MMR Measles, Mumps and Rubella vaccine
Table 1.  Change in primary childhood immunisation schedule (introduced on September 1st 2008)
two, six and 12 months of age and three doses of 
meningococcal group C (MenC) given at given at four, 
six and 13 months of age.  At 12 months of age the 
uptake rates of two doses of PCV (PCV2) and MenC 
(MenC2) are measured.  At 12 months of age MMR1 is 
recommended and at 13 months Hibb is recommended.
Further vaccinations are recommended for older 
children, please see www.immunisation.ie for complete 
information on the Irish childhood immunisation 
schedule. 
The immunisation uptake rates are reported here by 
HSE Area and LHO.  While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee 
and South Lee are reported as a combined figure.
Caveats to data
As a new childhood immunisation schedule was 
introduced in 2008, for those born on or after July 
1st 2008, the 2009 MenC3 data at 12 months are for 
those born between January 1st and June 30th 2008 (i.e. 
Quarters 1 and 2 data) only and the 2009 HepB3, MenC2 
and PCV2 data at 12 months are for those born between 
July 1st and December 31st 2008 (i.e. Quarters 3 and 4 
data) only.
The 2009 data for those at 12 months are incomplete 
as the following were unavailable: the Quarter 1 2009 
HSE-E D3, T3, P3 and Polio3 data for those born on the 
31/03/2008; the Quarter 3 2009 HSE-M data, HSE-S 
data, HSE-E MenC2 and PCV2 data and HSE-MW MenC2 
data and; the Quarter 4 2009 HSE-M, HSE-MW and 
HSE-S data.  The available 2009 national 12 month D3, 
T3, P3, Hib3 and Polio3 cohort data may be around 88% 
(this figure is an estimate only) of the 2009 national 
birth cohort.  The MenC3 cohort data are complete (for 
Quarters 1 and 2 2009).  The available national HepB3, 
MenC2 and PCV2 data may be around 76%, 54% and 
58% (these figures are estimates only), respectively, of 
the (combined Quarters 3 and 4) national birth cohort.
The 2009 data for those at 24 months are incomplete 
as the following were unavailable: the Quarter 1 2009 
HSE-E D3, T3, P3 and Polio3 data for those born on the 
31/03/2007; the Quarter 2 2009  HSE-E Dublin North 
Hibb uptake data and; the Quarter 4 2009 HSE-MW 
data, HSE-E Dublin North Hibb data and HSE-SE Hibb 
data for those given a Hib dose as part of the five in 
one or six in one vaccine after 12 months of age.  The 
available 2009 national 24 month D3, T3, P3, Hib3, Polio3, 
MenC3 and MMR1 birth cohort data may be around 98% 
of the national birth cohort and the available Hibb data 
may be around 95% of the national birth cohort (these 
figures are estimates only).  
Data in 2009 are compared here to data in 2008.  
The 2008 MenC3 data (at 12 and 24 months) were 
incomplete as the HSE-E and HSE-MW MenC3 data were 
not available in Quarter 3 2008 and the 2008 Hibb figure 
is incomplete, as the HSE-SE data for Quarter 2 2008 
and the HSE-MW data for Quarter 3 2008 were not 
available.  The available 2008 12 month national MenC3 
data may be around 88% of the national birth cohort.  
The available 2008 24 month national MenC3 and Hibb 
data may be around 89% and 95%, respectively, of the 
national birth cohort.
BCG uptake data were available for the HSE-M, HSE-
MW, HSE-NW, HSE-SE and HSE-S Areas (HSE-S data 
relate to Kerry only) in 2008 and in Quarters 1 and 2 
2009; for the HSE-MW, HSE-NW and HSE-SE Areas in 
Quarter 3 2009 and for the HSE-NW and HSE-SE Areas 
in Quarter 4 2009.  The available 2008 national BCG 
data represent one third of the national birth cohort 
and the available 2009 national BCG cohort data may 
be around 27% (this figure is an estimate only) of the 
national birth cohort.  
Immunisation uptake rates at 12 months
National immunisation uptake rates (based on available 
data), in children 12 months of age in 2009, were 89% 
for D3, P3, T3, Hib3 and Polio3, 95% for BCG, 86% for 
MenC3 (based on Quarters 1 and 2 2009 data only) and 
89% (based on available data in Quarters 3 and 4 2009 
only) for HepB3, MenC2 and PCV2 (table 2).  Compared 
with 2008, the uptake rates for D3, P3, T3, Hib3, Polio3 and 
BCG increased by one percent while MenC3 decreased 
by two percent.
Among the LHOs, uptake rates (based on available 
data) for D3, T3, P3 and Polio3 ranged from 82% to 96%, 
Hib3 ranged from 82% to 95% and MenC3 (based on 
Quarters 1 and 2 2009 data only) ranged from 76% 
to 94% (appendix 2.1).  Based on available data in 
Quarters 3 and 4 2009 only HepB3 ranged from 84% to 
95%, MenC2 ranged from 82% to 95% and PCV2 ranged 
from 82% to 96% (appendix 2.1).  The target uptake of 
95% was reached or exceeded in Roscommon for D3, P3, 
T3, Hib3, Polio3, HepB3, MenC2 and PCV2 (appendix 2.1).  
Immunisation uptake rates at 24 months
National immunisation uptake rates, in children 24 
months of age in 2009, were 94% for D3, T3, P3 and 
Polio3 and 93% for Hib3 and MenC3 (table 2).  Compared 
with 2008, the uptake rates for these vaccines increased 
by one percent in 2009 except for Hib3 uptake which 
was unchanged (figure 1).  
Among the HSE Areas, uptake rates for D3, P3, T3 and 
Hib3 ranged from 92% to 96%, Polio3 ranged from 92% 
to 97% and MenC3 ranged from 91% to 96% (table 2).  
The target uptake of 95% was reached or exceeded 
during 2009 for D3, T3, P3, Hib3, Polio3 and MenC3 in 
the HSE-M and HSE-NW and for MenC3 in the HSE-NE 
(table 2).
Uptake rates for D3, T3, P3, Hib3, Polio3 and MenC3 
ranged from 89% to 98% among the LHOs, with 27 
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 LHOs reporting uptake rates of *90% (appendix 2.2).  
The target uptake of 95% was reached or exceeded for 
D3 (figure 2a), T3, P3 and Polio3 in 13 LHOs, for MenC3 in 
12 LHOs and for Hib3 in 11 LHOs (appendix 2.2). 
During 2009 MMR1 uptake was 90% nationally; an 
increase of one percent when compared to 2008 
(figure 1).  Among the HSE Areas, uptake rates for 
MMR1 ranged from 89% to 93%, with seven HSE Areas 
reporting uptake of *90% (table 2).  Uptake rates for 
MMR1 ranged from 84% to 97% among the LHOs, 
with 21 LHOs reporting uptake of *90% and one LHO 
(Roscommon) reaching and exceeding the target 
uptake of 95% (figure 2b, appendix 2.2).  
Hibb figures relate to children who received a dose of 
Hib after 12 months of age.  National uptake (based on 
available data) of Hibb in 2009, in those 24 months of 
age, was 87% (table 2 and figure 1).  This is an increase 
of five percent compared to available data in 2008.   
Among the HSE Areas, uptake of Hibb in 2009 ranged 
from 83% to 93%, with four HSE Areas reporting uptake 
rates of *90% (table 2).  Among the LHOs, uptake of 
Hibb ranged from 78% to 98%, with 13 of the LHOs 
reporting uptake of *90% and one (Roscommon) 
reporting uptake of *95% (appendix 2.2).
Annual immunisation uptake rates at 24 months, for 
the majority of vaccines, have continually increased 
since 2003 (figure 1); however, further improvements 
in uptake are necessary so that the 95% target rate is 
achieved nationally for all vaccines.  In 2009, national 
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Figure 1.  National annual immunisation uptake rates (based on available data) at 24 months, 1999-2009
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
The 2005 MMR1 uptake figure is incomplete as the HSE-E was unable to provide MMR data for Quarter-4 2005, due to technical problems 
with extraction of MMR1 data from the HSE-E database.  The 2006 MMR1 figure includes the Quarter-1 2006 HSE-E figure, which is an 
estimate only due to technical problems with extraction of MMR1 data from the HSE-E database.  The 2007 national Hibb figure is incomplete, 
as the HSE-W data for Quarter 1 2007 and the HSE-NW data for Quarter 3 2007 were not available.  The 2007 national Hibb figure also 
includes the HSE-SE data which are an underestimate due to data extraction methods.  The 2008 Hibb figure is incomplete as the HSE-SE data 
for Q2 2008 and the HSE-MW data for Quarter 3 2008 were not available.  The 2008 national MenC3 figure is incomplete as the HSE-E and 
HSE-MW MenC3 data for Quarter 3 2008 were not available.  The 2009 data are incomplete, please see text for details of caveats.
Table 2.  Annual immunisation uptake rates (based on available data) by HSE Area for children 12 and 24 months of age in 2009
% Uptake at 12 months
Cohort born 01/01/2008 - 31/12/2008*
% Uptake at 24 months
Cohort born 01/01/2007 - 31/12/2007
D3 Hib3 Polio3 MenC3 HepB3 MenC2 PCV2 BCG D3 Hib3 Hibb Polio3 MenC3 MMR1
HSE-E 87 87 87 83 88 87 87 na 93 92 83 93 92 89
HSE-M 92 92 92 92 na na na 94 96 96 93 96 96 93
HSE-MW 91 91 91 89 92 na 92 97 94 93 89 94 93 91
HSE-NE 91 91 91 87 92 91 89 na 94 94 92 94 95 92
HSE-NW 92 92 92 91 90 90 90 95 96 96 93 97 95 92
HSE-SE 90 90 90 88 90 90 90 96 92 92 90 92 91 90
HSE-S 86 86 86 86 na na na 93 94 94 88 94 94 90
HSE-W 88 88 88 87 88 88 89 na 94 94 86 94 93 90
Ireland 89 89 89 86* 89* 89* 89* 95 94 93 87 94 93 90
na=not available
The 2009 data are incomplete, please see text for details of caveats
*HepB3, MenC2 and PCV2 uptake data presented here are only for those born between 01/07/2008 and 31/12/2008 and MenC3 data at 12 
months are only for those born between 01/01/2008 and 30/06/2008
Since T3 and P3 uptake identical to D3 uptake only D3 uptake figures presented
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uptake rates at 24 months for D3, T3, P3 and Polio3 were 
one percent below the target rate, Hib3 and MenC3 
were two percent below the target, MMR1 was five 
percent below the target and Hibb was eight percent 
below the target rate.  However, among the HSE Areas 
the target uptake of 95% was reached or exceeded 
for those at 24 months during 2009 for D3, T3, P3, Hib3, 
Polio3 and MenC3 in the HSE-M and HSE-NW and for 
MenC3 in the HSE-NE.  Among the LHOs, the target 
uptake of 95% was reached or exceeded for those at 
24 months during 2009 for D3, T3, P3, Hib3, Polio3 and 
MenC3 in 10 LHOs and for all vaccines in one LHO 
(Roscommon).  Roscommon reached or exceeded 
the target of 95% for D3, T3, P3, Hib3, Polio3, HepB3, 
MenC2 and PCV2 at 12 months and for all vaccines at 24 
months and had the highest uptake for all vaccines at 
24 months.  
The 2009 immunisation uptake rates for each LHO are 
presented in appendix 2.  The immunisation reports for 
Quarters 1 to 4 2009 are available on the HPSC website 
in Topics A-Z under the heading vaccination. 
 
Figure 2.  D3 (A) and MMR1 (B) immunisation uptake rates (%) in those 24 months of age in 2009 by Local Health Office (LHO)
2009 data are incomplete, please see text for details
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see appendix 2.3 to translate LHO codes
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Antimicrobial Consumption 
and  Resistance 
Health Protection Surveillance Centre   Annual Report 2009
Ireland participates in the European Surveillance of 
Antimicrobial Consumption (ESAC) project which 
aims to collect systemic antibiotic usage data from 
the outpatient (ambulatory, community or primary 
care) setting and from the hospital (inpatient) setting. 
Consumption is measured in Defined Daily Dose (DDD), 
which is the assumed average maintenance dose per 
day for a drug used for its main indication in adults. 
Rates are calculated in DDD per 1000 inhabitants per 
day (DID) for outpatients and DDD per 100 bed-days 
used (DBD) for inpatients. Please see “Antimicrobial 
consumption” and “Denominator data” parts of the 
explanatory notes section for further details.
Outpatient Antibiotic Consumption
The overall outpatient antibiotic consumption for Ireland 
in 2009 was 20.8 DID, a fall from the previous year’s rate 
of 21.5 DID. In the latest ESAC annual yearbook (2008), 
the reported range of outpatient antibiotic usage was 
10.0 DID (Russian Federation) to 45.2 DID (Greece). The 
median for all 30 European countries with reliable data 
was 19.7 DID and the interquartile range (25%-75%) was 
15.1 to 23.1 DID. Since outpatient antibiotic usage in 
Ireland has been 19 - 23 DID over the last five years, the 
overall rate in Ireland is mid-to-high in Europe. 
In Ireland in 2009, outpatient consumption of penicillins 
accounted for the largest class used (51% of total at 
10.7 DID), followed by macrolides (18%, 3.8 DID), 
tetracyclines (13%, 2.7 DID), cephalosporins (6%, 1.3 
DID), sulphonamides (5%, 1.1 DID) and quinolones (5%, 
0.9 DID). Other antibiotic classes accounted for just 
over 1% of total use.
Penicillin in combination with beta-lactamase inhibitor 
(such as co-amoxiclav) accounted for the largest 
proportion of penicillins. This group of antibiotics had 
been showing a dramatic rise in the rate of consumption 
in recent years (2000-2008), however, 2009 was the first 
year a decrease was observed (5.5 DID in 2009 from 
5.6 DID in 2008). Broad-spectrum penicillin (such as 
ampicillin and amoxicillin) usage was high (3.3 DID) but 
showed a slight decline.
There was considerable variability in the overall 
outpatient antibiotic usage at county level (16.8 to 28.1 
DID) as shown in figure 2. 
9.1 Antimicrobial Consumption 
 
Summary
Outpatient antibiotic consumption, 2009: 20.8 DID
Outpatient antibiotic consumption, 2008: 21.5 DID
Median hospital antibiotic consumption, 2009: 75.2 DBD
Median hospital antibiotic consumption, 2008: 77.4 DBD
EU Network: ESAC       www.esac.ua.ac.be 
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Figure 1. Outpatient antibiotic consumption in Ireland by month, 2000-2009. 
In a separate analysis of recent Irish data, it was shown 
that outpatient use of specific antibiotics is strongly 
associated with influenza activity. It is very likely that 
the General Practitioner education programme and 
interventions that took place around the European 
Antibiotic Awareness Day (EAAD) in November 2008 
had an effect on lowering the antibiotic consumption 
rate in 2009. Despite this effort, antibiotic consumption 
rates did increase at two time periods during 2009: in 
January, and between September and October 2009.
The 2008/2009 seasonal influenza activity was the 
highest in the preceding nine years with the influenza-
like illness (ILI) rate at over 120 consultations per 
100,000 population. It is therefore likely that the high 
antimicrobial use in January of 2009 was, at least partly, 
a result of inappropriate prescribing for respiratory 
viral infections. The rate for September and October 
2009 returned to levels in line with expected rates 
projected from the historical trend. Influenza 2009 H1N1 
Pandemic, which resulted in a peek ILI rate of over 200 
consultations per 100,000 and lasted over 20 weeks, 
may be the reason for this return to former levels. 
Hospital Antibiotic Consumption
Forty-two public acute hospitals provided valid 
antibiotic usage data for 2009. The median rate of 
antibiotic consumption usage was 75.2 DBD (range 20.1 
– 113.0 DBD). This was a drop from the previous year’s 
revised rate of 77.4 DBD. These levels are again mid-to-
high in Europe.
Hospital function was the main driver for the differences 
in the rates of antibiotic consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 77.8 and 79.0 DBD) centred just 
above the median for Ireland, while the rate for single 
specialist facilities (maternity, orthopaedic or paediatric) 
was much lower (median 42.9 DBD). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case-mix, compared to other 
hospitals. However it may also reflect the fact that 
DDDs are based on adult dosing and may therefore 
underestimate antibiotic consumption in paediatric 
settings. 
There was also a small reduction in the proportionate 
use of intravenously administered specific antibiotics 
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Figure 2. Outpatient antibiotic consumption in Ireland by county, in 
DDD per 100 inhabitants per day for 2009. 
(those with good oral bioavailability) over total use, from 
a median of 9.4% in 2008 to 8.1% in 2009. This measure 
reflects patient acuity and also the hospital function.
ESAC Hospitals Care Point Prevalence Survey 2009 
(ESAC HC PPS 2009)
ESAC co-ordinated a hospital care sector point 
prevalence study (HC PPS) between May and July of 
2009 among 172 acute facilities across 25 European 
countries. In Ireland, 21 hospitals provided valid data 
that were also analysed at the HSPC.
In all 5824 Irish patients’ records were examined, of 
which 2000 received systemic antimicrobial therapy. The 
median prevalence in Irish hospitals was 34.3% (range 
21.4 - 55.3%) compared with the European median of 
29.0%. 
The Irish Antibiotic Pharmacists Group (IAPG) facilitated 
HC PPS 2009. As most of the participating hospitals 
already had an antibiotic pharmacist in place, the 
results may be an under-estimation of the true national 
prevalence. 
The data collected included patient demographics, 
details of systemic antimicrobial therapy, diagnoses 
and indication, compliance with local guidelines and 
documentation of reason for therapy. In most respects 
practices in Ireland were broadly in line with other 
European hospitals. Feedback from Irish participants 
highlighted difficulties encountered in data entry 
and the length of time commitment involved in 
data collection. A third of the participants said they 
implemented changes as a result of the survey outcome 
and this shows the value of PPS as a method of 
antimicrobial consumption surveillance. The IAPG plan 
to conduct a national point prevalence survey annually.
ESAC Nursing Home Point Prevalence Surveys 2009 
(ESAC NH PPS 2009-1 & -2)
Two point prevalence surveys were co-ordinated by 
ESAC to measure antibiotic use in nursing homes (NH) 
across Europe: NH PPS-1 in April 2009 and NH PPS-2 in 
November 2009.
In PPS-1, 304 NH took part across 20 countries. In 
Ireland, 18 skilled NH participated, in which antibiotics 
were prescribed to a total of 175 out of the 1662 
eligible residents (overall prevalence of 10.5%, median 
12.4%, range 2.8 – 27.8%) compared to the European 
overall prevalence of 5.9%, median of 5.4% and a range 
of 0 – 30%. By country, the medians ranged from 0.6% 
to 15.1%.
For PPS-2, 11 Irish NH participated with an overall 
prevalence of 10.1% (range 2.3 – 22.0%). An ESAC 
report on PPS-2 is due later in 2010. 
More detailed analyses of antibiotic usage data can 
be found at www.hpsc.ie, through “Topics A-Z”, 
under “ESAC”. The figures presented in this report 
may vary from previously published levels owing to 
methodological changes. 
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9.2 Antimicrobial Resistance
Summary
 Key Points
UÊÊÊÊThere were 1,309 reports of S. aureus bacteraemia 
submitted to the European Antimicrobial Resistance 
Surveillance Network (EARS-Net), of which 355 
(27.1%) were meticillin-resistant S. aureus (MRSA).  
This represents a significant decrease from 33.7% 
reported in 2008.  Overall, the number of MRSA 
reports was down by 19% from 439 in 2008
  For acute hospitals, the rate of MRSA bacteraemia 
was 0.089 cases per 1,000 patient bed days used, a 
decrease from 0.111 in 2008. Over the same period, 
the rate of meticillin-susceptible S. aureus (MSSA) 
increased from 0.216 to 0.237
UÊÊÊThere were 356 reports of invasive S. pneumoniae 
infection compared to 447 in 2008, a decrease of 
20%.  The national rate of invasive infection was 8.6 
compared to 10.8 per 100,000 population in 2008. 
The biggest reductions in numbers of reports and 
rates of infection were seen in children <2 years, the 
target population for the 7-valent conjugate (PCV-7) 
introduced in September 2008
  The proportion of penicillin-non-susceptible 
S. pneumoniae (PNSP) decreased from 23.1% in 
2008 to 20.2% in 2009; the proportion of isolates 
with high-level resistance to penicillin decreased 
marginally from 6.1% in 2008 to 5.6% in 2009 while 
intermediate level resistance decreased significantly 
from 16.9% to 13.3% 
  Serotype data were available on 302 of 356 isolates 
(85%) and results indicate good coverage for both 
the 23-valent polysaccharide (PPV23) and PCV7 
vaccines in their target populations: 87% (adults *65 
years) and 56% (children <2 years), respectively
UÊÊÊThere were 397 reports of E. faecium bacterae-
mia compared with 406 in 2008.  The proportion 
that was vancomycin-resistant E. faecium (VREfm) 
increased from 35.7% in 2008 to 38.3% in 2009. 
Multi-drug resistant (MDR) E. faecium increased from 
16.2% to 26.7%  
UÊÊÊThere were 2,064 reports of invasive E. coli infection, 
an increase of 7% from 1,924 reports in 2008.  
Resistance to third-generation cephalosporins 
(3GCs) remained stable at 7.5% but extended-
spectrum beta-lactamase (ESBL)-production 
increased from 5.0% to 5.8% in 2009.  Ciprofloxacin 
resistance decreased slightly from 23.3% to 22.3%, 
the first decrease since surveillance began in 2002. 
MDR E. coli also decreased from 12.1% in 2008 to 
10.4% in 2009
UÊÊÊThere were 323 reports of invasive K. pneumoniae 
infections compared to 311 in 2008
UÊÊÊThere were 248 reports of invasive P. aeruginosa 
infections compared to 199 in 2008, an increase of 
25% 
UÊÊÊFor the 14 laboratories participating in enhanced 
bacteraemia surveillance, the rate of clinically-signif-
icant MRSA bloodstream infection decreased from 
0.065 cases per 1,000 patient bed days used in 2008 
to 0.058 in 2009, while the rate for MSSA increased 
from 0.080 in 2008 to 0.122 in 2009
UÊÊÊSee http://www.hpsc.ie for further details of 
EARS-Net, antimicrobial resistance and enhanced 
bacteraemia surveillance in Ireland
UÊÊÊÕÀ«i>Ê`>Ì>Ê>ÀiÊ>Û>>LiÊ>ÌÊhttp://ecdc.europa.
eu/en/activities/surveillance/EARS-Net/Pages/
Database.aspx
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Introduction
The European Antimicrobial Resistance Surveillance 
Network (EARS-Net), previously the European 
Antimicrobial Resistance Surveillance System (EARSS), 
in Ireland collects routinely-generated antimicrobial 
susceptibility testing data on seven important bacterial 
pathogens using the EARS-Net case definition. 
Participating laboratories submit data on the “primary” 
or first isolate from blood or cerebrospinal fluid (CSF) 
per patient per quarter.  EARS-Net does not distinguish 
clinically significant isolates from contaminants and 
primarily serves as a surveillance system to measure 
national levels of antimicrobial resistance (AMR).  In 
2009, all 44 microbiology laboratories (43 by year-
end) participated in EARS-Net resulting in complete 
coverage of the Irish population.
Staphylococcus aureus
There were 1,309 reports of S. aureus bacteraemia from 
1,262 patients, of which 355 (27.1%) were meticillin-
resistant S. aureus (MRSA) (table 1).  This represents the 
lowest annual proportion since surveillance began in 
1999.  In 2008, the proportion was 33.7%.  The decrease 
observed in 2008 was highly significant (Chi2=13.3, 
P=0.0003).  This is the third successive year in which 
a decrease has been observed and this downward 
trend is also highly significant (Chi2trend=71.4, P<0.0001) 
(figure 1).  Overall, there was a 19.1% reduction in 
the number of MRSA bacteraemia reports compared 
with 2008 (355 vs. 439). The total number of meticillin-
susceptible S. aureus (MSSA) bacteraemia reports 
increased by 10.4% from 864 in 2008 to 954 in 2009. 
The reason for this increase is unclear, but may be 
related to differences in the epidemiology of MSSA 
versus MRSA, or to infection control interventions 
that selectively target MRSA. Greater participation 
of laboratories in enhanced bacteraemia surveillance 
would go some way to elucidate the key risk factors 
for acquisition and infection by MSSA strains, thereby 
allowing appropriate measures to be implemented 
to help reduce the burden of infection associated 
with these organisms. One key factor to consider is 
that MRSA tends to be clonal (i.e. one or two strains 
may be responsible for the majority of infections in a 
healthcare setting) while MSSA is generally much more 
heterogeneous in nature (i.e. many different strains are 
present) and often acquisition is from the patient’s own 
normal bacterial flora, although clonal spread of MSSA 
in healthcare settings is increasingly recognised. 
Despite the decrease in numbers and proportion of 
MRSA, Ireland still had one of the higher proportions of 
MRSA in Europe in 2009 (see http://ecdc.europa.eu/en/
activities/surveillance/EARS-Net/Pages/Database.aspx 
for European data, including EARS-Net tables, charts 
and maps).  
No MRSA isolates with reduced susceptibility to 
vancomycin were detected at the National MRSA 
Reference Laboratory by the Etest® macromethod.  
The MRSA rate for all acute hospitals in 2009 was 0.089 
cases per 1,000 patient bed days used, representing 
a decrease from 0.111 in 2008, while the MSSA rate 
increased from 0.216 to 0.237 [Note: the rates are now 
calculated taking into account the denominator data 
(bed days used) obtained from the Business Intelligence 
Unit at the Health Services Executive for all acute public 
hospitals; and directly from the hospitals for private 
hospitals where available, where both numerator (MRSA 
numbers) and denominator data have been provided. 
This contrasts with previous reports when only data from 
acute public hospitals were considered]. 
In patients with laboratory-confirmed S. aureus 
bacteraemia, the probability that the infecting organism 
was MRSA as compared to MSSA was over 1.7-times 
greater in patients aged *65years than in those aged 
<65 years (RR=1.66, Chi2=29.5, P<0.0001).
Males were approximately 1.8-times more likely to get 
an invasive S. aureus infection (2.1-times for MRSA, 
z=7.0, P<0.0001; 1.7-times for MSSA, z=8.7, P<0.0001) 
than females (z=11.0, P<0.0001).  The frequency of 
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Total S.aureus MRSA %MRSA
Figure 1. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage MRSA with 
95% confidence intervals The numbers of participating laboratories by year-end are indicated 
above the bars
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Table 1. Summary of EARSS data by pathogen and year, 1999-2009
Pathogen Year
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Number laboratories by year-end 12 19 20 23 28 41 42 42 44 43 43
S. aureus
Number of isolates 510 639 815 1042 1140 1323 1424 1412 1393 1303 1309
Number Meticillin-R (or MRSA) 198 249 337 445 480 553 592 592 536 439 355
Meticillin-R (or MRSA) 38.8% 39.0% 41.3% 42.7% 42.1% 41.8% 41.6% 41.9% 38.5% 33.7% 27.1%
Number VISA 0 0 0 0 0 0 0 2 1 0 0
VISA* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0% 0.0%
Number laboratories by year-end 12 19 20 23 28 41 42 42 44 42 43
S. pneumoniae
Number of isolates 157 201 245 278 364 400 401 407 438 447 356
Penicillin-NS* 19.1% 13.4% 12.2% 11.5% 11.8% 10.3% 11.7% 15.7% 17.4% 23.1% 20.2%
of which:   HLR 0.0% 3.5% 1.6% 1.4% 2.2% 1.8% 3.0% 2.9% 5.7% 6.1% 5.6%
                  Int 16.6% 8.5% 10.6% 9.7% 8.8% 7.0% 8.7% 12.5% 11.0% 16.9% 13.8%
Erythromycin-R* 14.0% 12.0% 12.5% 12.7% 11.6% 14.4% 12.1% 16.1% 16.4% 16.7% 17.3%
E. faecalis
Number of isolates
No 
data
No 
data
No 
data
168 218 242 290 294 281 301 289
Ampicillin-R* 8.1% 5.1% 0.8% 3.5% 4.5% 2.2% 0.7% 2.1%
Vancomycin-R 2.4% 1.4% 1.3% 2.5% 3.7% 2.8% 3.7% 0.7%
HLG-R* 38.5% 33.9% 41.3% 43.1% 42.4% 37.2% 30.5% 36.7%
E. faecium
Number of isolates
No 
data
No 
data
No 
data
85 135 187 224 265 332 406 397
Ampicillin-R* 88.9% 91.0% 95.7% 92.3% 93.9% 93.1% 95.1% 92.9%
Vancomycin-R 11.1% 19.4% 23.2% 31.7% 37.1% 33.5% 35.7% 38.3%
HLG-R* 16.7% 53.8% 58.0% 51.4% 44.3% 34.9% 28.1% 39.1%
MDR* 3.7% 11.4% 18.5% 25.6% 25.6% 22.3% 16.2% 26.7%
E. coli
Number of isolates
No 
data
No 
data
No 
data
741 991 1256 1445 1656 1784 1924 2064
Ampicillin-R* 62.2% 61.9% 65.0% 67.6% 70.7% 68.3% 70.3% 68.7%
3GC-R* 3.0% 2.4% 2.4% 4.1% 4.1% 6.7% 7.5% 7.5%
Ciprofloxacin-R* 5.4% 9.5% 12.6% 17.3% 21.5% 22.1% 23.3% 22.3%
Gentamicin-R* 2.7% 3.9% 5.7% 8.5% 7.7% 9.9% 10.2% 7.7%
Gentamicin/Tobramycin/Amikacin-R* 2.9% 4.3% 6.1% 8.6% 8.6% 10.6% 11.0% 9.3%
ESBL-producers* 1.2% 1.3% 1.1% 2.4% 2.5% 4.1% 5.0% 5.8%
MDR* 2.4% 3.8% 5.6% 7.7% 9.0% 11.4% 12.1% 10.4%
Number laboratories by year-end 36 39 41 42
K. pneumoniae
Number of isolates
No 
data
No 
data
No 
data
No 
data
No 
data
No 
data
No 
data
217 244 311 323
Ampicillin-R* 97.7% 99.2% 99.7% 99.7%
3GC-R* 10.2% 9.9% 11.3% 11.2%
Ciprofloxacin-R* 15.3% 18.1% 12.7% 13.0%
Gentamicin-R* 7.8% 9.9% 10.6% 11.1%
Imipenem/meropenem-R* 0.0% 0.6% 0.0% 0.0%
ESBL-producers* 8.6% 3.7% 7.7% 8.2%
MDR* 11.2% 11.9% 9.9% 11.9%
P. aeruginosa
Number of isolates
No 
data
No 
data
No 
data
No 
data
No 
data
No 
data
No 
data
128 177 199 248
Pipericillin/tazobactam-R* 9.4% 12.6% 9.7% 8.9%
Ceftazidime-R* 10.6% 11.8% 8.7% 11.8%
Imipenem/meropenem-R* 11.8% 12.2% 9.3% 9.7%
Ciprofloxacin-R* 18.0% 22.9% 21.8% 12.1%
Gentamicin-R* 10.2% 13.3% 9.0% 7.7%
MDR* 9.5% 12.5% 11.1% 6.4%
          R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VISA, Vancomycin-Intermediate S. aureus
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime and cefpodoxime);
ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
Changes to the data presented in previous reports are highlighted in red
invasive S. aureus infection increased with age, with 
the majority of infections (n=775; 59%) occurring in 
adults over 60 years.  The median age for patients with 
an MRSA infection was 72 years (95%CI, 70-73) while 
the median age for patients with MSSA was 62 years 
(95%CI, 60-64).  This was considered to be a significant 
difference as the confidence intervals did not overlap.
Streptococcus pneumoniae
There were 356 reports of invasive S. pneumoniae 
infection (350 from blood and six from CSF) from 356 
patients, a decrease of 20.4% from 447 reports in 2008.  
See table 1 for the annual proportions of S. pneumoniae 
isolates non-susceptible/resistant to penicillin and 
erythromycin by year since 1999 when surveillance 
began.  Penicillin-non-susceptible S. pneumoniae 
(PNSP) accounted for 20.2% (n=72) of all isolates tested 
against penicillin (n=356) in 2009 (table 1). Of the 72 
PNSP isolates, 49 were intermediately-resistant (Int; 
MIC=0.1-1.0mg/L) and 20 were HLR (MIC >1.0mg/L) to 
penicillin.  No penicillin MICs were available for three 
non-susceptible (NS) isolates. The proportion of PNSP 
in Ireland increased significantly over the four years 
from 10.3% in 2004 to 23.1% in 2008 (Chi2trend=31.5, 
P<0.0001) but shows signs of a decrease in 2009 (figure 
2).  The proportion of isolates with high-level resistance 
(HLR) to penicillin decreased slightly from 6.1% in 2008 
to 5.6% in 2009.  Fifty-eight (17.3%) of 336 isolates were 
resistant to erythromycin, a slight increase from 16.7% in 
2008.  
In 2009, Ireland had one of the highest proportions of 
PNSP, and HLR to penicillin among S. pneumoniae, in 
countries reporting to EARS-Net, although comparisons 
with other EARS-Net countries is problematic due to 
the possibility of different interpretive criteria being 
applied to the data. [Note: The Clinical Laboratory 
Standards Institute (CLSI) now provides three sets of 
breakpoints for interpreting penicillin susceptibility of 
S. pneumoniae isolates: meningitis, non-meningitis and 
oral. In Ireland, EARS-Net data are reported using the 
“oral” breakpoints (which correspond to the original 
CLSI breakpoints) for epidemiological purposes, and 
thus consistency].  
Moderately high levels of erythromycin resistance 
were seen, similar to the situation observed in much 
of Southern and Central Europe. Of isolates tested 
against both penicillin and erythromycin (n=336), 40 
(11.9%) were simultaneously PNSP (29 Int, 10 HLR) and 
erythromycin-resistant in 2008 compared with 10.2% in 
2008.
Prior to the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008, a national 
pilot project was established early in 2007 as a result 
of a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple St and 
HPSC with the aim of providing baseline serotyping 
data on invasive S. pneumoniae isolates.  Serotype 
data were available on 302 pneumococcal isolates from 
30 laboratories (of 34 that reported pneumococcal 
isolates to EARS-Net in 2009) representing 85% of all 
pneumococcal isolates reported in 2009.  Overall, 272 
(90%) and 124 (41%) isolates belonged to serotypes 
covered by the pneumococcal polysaccharide (PPV23; 
target population: adults *65 years and at risk groups) 
and conjugate (PCV7; target population: children <2 
years) vaccines, respectively.  From adults *65 years, 
119 of 137 (87%) isolates were covered by PPV23, while 
from children <2 years, 15 of 27 (56%) isolates were 
covered by PCV7.  Of the 57 PNSP isolates for which 
serotyping data were available, 28 of 30 (93%) from 
adults *65 years were covered by PPV23 while 7 of 8 
(87.5%) from children <2 years were covered by PCV7. 
On-going surveillance of the predominant serotypes 
is required as strains with serotypes other than those 
in the vaccine have been reported to increase in 
prevalence following introduction of PCV7 in other 
countries, hence the need for a fully resourced reference 
facility.  
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Total S.pneumoniae PNSP %PNSP %Pen-HLR %Pen-I
Figure 2a. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and percentage 
PNSP with 95% confidence intervals
HLR, High-level resistant; I, Intermediately resistant
The numbers of participating laboratories by year-end are indicated above the bars
The rate of invasive pneumococcal disease (IPD) in 
Ireland in 2009 was estimated to be 8.6 per 100,000 
population compared with 10.8 in 2008 (note: both 
calculated using the 2006 census data and adjusted 
for the estimated population coverage by EARS-Net 
for that year).  The highest rates of IPD were observed 
in children <1 year (27.8 per 100,000) and adults aged 
75-79 years (24.4), 80-84 years (44.3) and *85 years 
(53.1) (figure 2b).  The rates in all age groups decreased 
compared with the data for 2008 with the exception of 
the 5-9 year group, which increased marginally from 1.0 
to 2.8.  The biggest drop was seen in the <1 and 1 year 
age groups, which decreased from 57.3 to 27.8 and 28.1 
to 18.2, respectively. 
Males were approximately 1.2-times more likely to 
have an invasive S. pneumoniae infection [1.25-times 
for PNSP, z=0.95, P=0.35; 1.2-times for penicillin-
susceptible S. pneumoniae (PSP), z=1.55, P=0.12] than 
females (z=1.8, P=0.07). None of these findings were 
significant.  The median age was 63 years (95%CI, 59-
65).
Enterococcus faecalis
There were 289 reports of E. faecalis bacteraemia from 
285 patients, a decrease of 4.0% from 301 reports 
in 2008.  See table 1 for the annual proportions of 
E. faecalis isolates resistant to the three “indicator” 
antibiotics (ampicillin, vancomycin and high-level 
gentamicin) by year since 2002 when surveillance began. 
Vancomycin-resistant E. faecalis (VREfa) accounted for 
0.7% of isolates, a significant decrease from 3.7% in 
2008 (Chi2=5.9; P=0.015). Although this proportion was 
low, Ireland still had one of the higher proportions of 
VREfa in Europe in 2008.  
Six isolates were ampicillin-resistant, which suggests that 
these isolates were either misidentified as E. faecalis 
or misclassified as ampicillin-resistant, as resistance to 
ampicillin is rare in E. faecalis.
Males were approximately 1.6-times more likely to 
have an invasive E. faecalis infection than females 
(z=3.9, P<0.0001).  The frequency of invasive E. faecalis 
infection increased with age with the majority of 
infections (n=218; 75%) occurring in adults over 50 
years.  The median age was 66 years (95%CI, 64-71).
Enterococcus faecium
There were 397 reports of E. faecium bacteraemia from 
386 patients, a decrease of 2.2% from 406 reports in 
2008 (but still up on 332 in 2007). See table 1 for the 
annual proportions of E. faecium isolates resistant to the 
three “indicator” antibiotics (as for E. faecalis above) 
by year since 2002.  Vancomycin-resistant E. faecium 
(VREfm) accounted for 38.3% of isolates.  This 
represents an increase from 35.7% in 2008.  While the 
rate of increase in the proportion of VREfm appeared 
to slow down after 2006, the number of VREfm isolates 
increased by almost 50% between 2006 (n=98) and 
2009 (n=145). Between 2002 and 2009, the proportion 
of isolates that was VREfm increased significantly 
(Chi2trend=36.9; P<0.0001) (figure 3).  In 2009, Ireland had 
the highest proportion of VREfm in Europe, followed by 
Luxembourg (35.7%) and Greece (29.2%). 
Resistance to high-level gentamicin increased 
significantly from 28.1% in 2008 to 29.1% in 2009 
(Chi2=10.2; P=0.0014). This marks a reversal of the 
highly significant downward trend seen between 2004 
and 2008 (Chi2trend=62.1; P<0.0001) (figure 3).
Of 375 isolates tested against all three “indicator” 
antibiotics, 100 (26.7%) were resistant to all three and 
therefore classed as multi-drug resistant (MDR).  This 
represents a significant increase from 16.2% in 2008 
(Chi2=12.3; P=0.0005). 
Males were approximately 1.3-times more likely to have 
an invasive E. faecium infection than females (z=2.8, 
P=0.005).  The frequency of invasive E. faecium infection 
increased with age with the majority of infections 
(n=324; 81%) occurring in adults over 45 years.  The 
median age was 66 years (95%CI, 63-67).
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Figure 2b. Numbers and age-specific incidence rates of patients with invasive S. pneumoniae 
infection in 2009 compared with 2008
Escherichia coli
There were 2,064 reports of invasive E. coli infection 
(2,061 from blood and three from CSF) from 2,012 
patients, an increase of 7.3% from 1,924 reports in 2008. 
See table 1 for the proportion of E. coli isolates resistant 
to the four “indicator” antibiotics/antibiotic classes 
[ampicillin, third-generation cephalosporins (3GCs; 
cefotaxime, ceftriaxone, ceftazidime or cefpodoxime), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
aminoglycosides (gentamicin, amikacin or tobramycin)] 
by year since 2002.  Ciprofloxacin resistance decreased 
from 23.3% in 2008 to 22.3% in 2009 (non-significant; 
Chi2=0.54, P=0.46).  Looking at the overall trend, the 
proportion of ciprofloxacin resistant isolates increased 
significantly between 2002 and 2008 (Chi2trend=209.5, 
P<0.0001) (figure 4), although the rate of increase 
slowed down since 2006 and showed the first signs 
of a downward trend in 2009, but this finding is not 
statistically significant. The proportion of isolates with 
resistance to 3GCs remained the same in 2009 as in 
2008 (7.5%) while resistance to gentamicin decreased 
from 10.2% in 2008 to 7.6% in 2009 (borderline not 
significant; Chi2=7.4, P=0.064). Resistance to 3GCs, 
ciprofloxacin and gentamicin in E. coli isolates increased 
in many European countries in 2009, which is not the 
case in Ireland. 3GC and gentamicin resistance are at 
moderately low levels in this country, similar to those in 
other northern European countries, while ciprofloxacin 
resistance is at moderately high levels along with the 
majority of other European countries. 
Extended spectrum beta-lactamases (ESBLs) were 
detected in 114 (5.8%) of 1,978 isolates tested.  
Although the increase in ESBLs from 5.0% in 2008 was 
not found to be significant (Chi2=1.2, P=0.28), the 
increasing trend since 2004 (1.1%) is highly significant 
(Chi2trend=60.1, P<0.0001).  ESBLs are enzymes that 
confer resistance to most penicillins and cephalosporins 
(including 3GCs).  ESBL-producing bacteria (including 
E. coli and K. pneumoniae) are often resistant to other 
classes of antibiotics and have emerged as important 
causes of infections in hospitals.
Of 2,032 isolates tested against all four “indicator” 
antibiotics, 211 (10.4%) were identified as MDR (defined 
as resistance to three or more of these), including 56 
with resistance to all four.  The proportion of isolates 
that are MDR increased significantly (Chi2trend=125.3, 
P<0.0001) from 2.4% in 2002 when surveillance began. 
However, the decrease from 12.1% in 2008 was not 
significant (Chi2=2.9, P=0.09).  
Females were approximately 1.25-times more likely 
to have an invasive E. coli infection than males (z=4.9, 
P<0.0001), however males were 1.2-times more likely 
to get an infection with ciprofloxacin-resistant E. coli 
(z=2.3, P=0.024) and 1.2-times more likely to get an 
infection with MDR E. coli (z=1.45, P=0.15), however, 
the latter was not significant.  The frequency of invasive 
E. coli infection increased with age with the majority of 
infections (n=1,597; 77%) occurring in adults over 55 
years.  The median age was 72 years (95%CI, 71-73).
Klebsiella pneumoniae
There were 323 reports of invasive K. pneumoniae 
infection (all from blood) from 316 patients (with 42 of 
43 laboratories participating in the surveillance of this 
pathogen), an increase of 3.8% from 311 reports in 
2008.  See table 1 for the proportion of K. pneumoniae 
isolates resistant to the four “indicator” antibiotics (as 
for E. coli above), plus imipenem/meropenems, since 
2006.  
Ciprofloxacin resistance increased marginally from 
12.7% in 2008 to 13.0% in 2009, while gentamicin 
resistance increased slightly from 10.6% to 11.1%. 
Neither of these increases was found to be significant. 
Resistance to 3GCs remained approximately stable 
(11.2% in 2008 vs. 11.3% in 2009). No isolates with 
resistance to imipenem/meropenem were reported. 
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Total E. faecium
Figure 3. Trends for E. faecium – total numbers of E. faecium and percentage resistance to 
high-level gentamicin (HLG) and vancomycin (VAN) with 95% confidence intervals
The numbers of participating laboratories by year-end are indicated above the bars
One isolate was ampicillin-susceptible, which either 
represents an isolate that was misidentified as 
K. pneumoniae or misclassified as ampicillin-susceptible, 
as all klebsiellae are inherently resistant to this 
antibiotic.
ESBLs were detected in 25 (8.2%) of 305 isolates tested, 
representing a slight increase from 7.7% in 2008. 
Thirty-eight, or 11.9%, of 319 isolates tested against 
all four “indicator” antibiotics were identified as MDR, 
including 16 with resistance to all four, an increase from 
9.9% in 2008.
Males were approximately 1.3-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=2.3, P=0.021).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=250; 77%) occurring in adults 
over 50 years.  The median age was 65 years (95%CI, 
62-68).
Pseudomonas aeruginosa
There were 248 reports of invasive P. aeruginosa 
infection (247 from blood and one from CSF) from 236 
patients (with 42 of 43 laboratories participating in the 
surveillance of this pathogen), an increase of 24.6% from 
199 reports in 2008.  See table 1 for the proportion of 
P. aeruginosa isolates resistant to the five “indicator” 
antibiotics/antibiotic classes [piperacillin-tazobactam, 
ceftazidime, carbapenems (meropenem or imipenem), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
gentamicin] since 2006.  The most significant change in 
the resistance proportions in 2009 compared to 2008 
was for ciprofloxacin, which decreased from 21.8% to 
12.1% (Chi2=7.6, P=0.006).  This may be related to a 
reduction in fluoroquinolone prescribing in hospitals 
with antibiotic stewardship interventions that targeted 
this class of antibiotics. Ceftazidime resistance increased 
from 8.7% to 11.8% but this was not significant 
(Chi2=1.1, P=0.29).  
Fifteen (6.4%) of 235 isolates tested against all five 
“indicator” antibiotics were MDR, including one with 
resistance to all five.  This represents a decrease from 
11.1% in 2008, which was not significant (Chi2=2.95, 
P=0.09).
Males were approximately 1.3-times more likely to have 
an invasive P. aeruginosa infection than females (z=2.05, 
P=0.04).  The frequency of invasive P. aeruginosa 
infection increased with age with the majority of 
infections (n=180; 73%) occurring in adults over 55 
years.  The median age was 67 years (95%CI, 65-70).
Enhanced Surveillance
EARS-Net in Ireland has been enhanced to collect 
demographic, risk factor and clinical data since 
2004. The enhanced programme involves voluntary 
participation by hospitals that provide data on invasive 
pathogens causing bloodstream infections (BSI).
There were 2,003 individual records (cases or isolates 
under the EARS-Net definition) submitted from 14 
laboratories. This figure is up from the 2008 finalised 
figure of 1,917. The total number of records thus far 
for 2009 represents 40% of the total core EARS-Net 
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Figure 4. Trends for E. coli – total numbers of E. coli and percentage resistance to 3GCs, 
ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin/amikacin/tobramycin (GEN/AMK/TOB), 
and percentage ESBL-positive with 95% confidence intervals.
The numbers of participating laboratories by year-end are indicated above the bars
dataset. Demographic and other basic data for the 
major resistance profiles of EARS-Net pathogens are 
shown in table 2.
 
Analysis of consistent data from hospitals showed that 
the rate of clinically significant BSI that was acquired 
in the reporting hospital has changed for S. aureus 
infection. For MRSA, the rate decreased from 0.065 
cases per 1,000 patient bed days used in 2008 to 0.058 
in 2009, while the rate for MSSA increased from 0.080 
in 2008 to 0.122 in 2009.
For further details, go to the HPSC website (http://
www.hpsc.ie) and click on “Topics A-Z”, then 
“Enhanced Bacteraemia Surveillance”.   
Conclusion
Recent improvements in infection prevention and 
control resources and interventions, along with 
hospital antibiotic stewardship programmes, may 
have contributed to reducing the burden of MRSA 
bacteraemia in Ireland since 2006. The introduction 
of the 7-valent pneumococcal conjugate vaccine, 
PCV7, into the childhood immunisation program in 
September 2008 has already resulted in a reduction 
in the burden of invasive pneumococcal disease in 
children.  Despite these successes, AMR remains a 
major problem in other EARS-Net pathogens in this 
country, in particular the high numbers and proportions 
of VREfm and E. coli isolates that are fluoroquinolone-
resistant, plus increases in ESBL-production in E. coli 
and K. pneumoniae and high levels of MDR in all three 
pathogens. AMR is also an issue in other bacterial 
species as well as in sites other than blood and/or 
CSF for which no surveillance is currently undertaken 
in Ireland. The observed increase in reports of MSSA 
bloodstream infection remains unexplained. 
In addition, there are continued threats posed 
by emerging resistance mechanisms in these 
and other bacterial pathogens in other countries 
(e.g. carbapenemases in klebsiellae and other 
enterobacteriaceae, and vancomycin resistance in 
S. aureus). These current problems and future threats 
highlight the on-going commitment and resources 
that are necessary to reduce the burden of AMR and 
healthcare-associated infection (HCAI) in this country, as 
outlined in the Strategy for the control of Antimicrobial 
Resistance in Ireland (SARI) in 2001, and in particular 
measures to promote more prudent antibiotic use in 
both hospital and community settings. 
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-
Net project.
The data presented in this report were taken from the 
EARS-Net database on 1st August 2010.
For further details of EARS-Net and antimicrobial 
resistance in Ireland see http://www.hpsc.ie 
European data are available at http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/Pages/Database.
aspx
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 Total for  
2009
Percent 
female
Mean age 
in years
Percent <5 
years
Percent 65 
years or 
older
Detected 
<48 hours 
after 
admission
Detected 
>5 days 
after 
admission
MRSA 168 38% 69.7 1% 68% 42% 48%
MSSA 431 35% 60.9 4% 53% 56% 28%
PNSP 24 46% 60.7 13% 63% 67% 8%
PSSP 112 42% 56.8 5% 46% 64% 12%
FQREC 194 46% 70.0 0% 70% 54% 19%
FQSEC 591 59% 66.9 3% 63% 53% 20%
VRE 66 32% 61.9 0% 41% 11% 76%
VSE 199 45% 65.4 3% 60% 30% 44%
KPN 134 44% 64.2 1% 52% 49% 32%
PAE 84 45% 65.7 0% 60% 33% 37%
Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data 
from 14 laboratories participating in enhanced surveillance). Proportion of isolates detected <48 
hours and >5 days post-admission is also shown. 
Abbreviations used (not in text): PSSP, Penicillin-susceptible S. pneumoniae; FQREC, Fluoroquinolone-
resistant E. coli; FQSEC, Fluoroquinolone-susceptible E. coli; VRE, Vancomycin-resistant enterococci; VRE, 
Vancomycin-susceptible enterococci; KPN, Klebsiella pneumoniae; PAE, Pseudomonas aeruginosa
Healthcare-associated infection surveillance
Healthcare-associated infection (HCAI) is increasingly 
recognised as an important cause of patient morbidity 
and mortality and contributes significantly to healthcare 
costs. The establishment of HCAI surveillance programs 
reduces HCAI, however, for surveillance to be effective, 
it needs to be standardised, timely and relevant to the 
institution providing the data.
Surgical site infection surveillance
The 2006 UK and Ireland HCAI prevalence survey 
revealed that in the Republic of Ireland, surgical site 
infection and urinary tract infection were the most 
common HCAI at the time of the survey. The HPSC 
established a multidisciplinary expert group in 2007 
under the auspices of the Strategy for the Control 
of Antimicrobial Resistance in Ireland (SARI) to 
evaluate and recommend standardised internationally 
comparable methods for surgical site infection 
surveillance. Following the publications of national 
recommendations for surveillance infrastructure and 
a national surveillance protocol for general surgery 
in 2007, the group produced a national protocol 
for surveillance of SSI in Caesarean section in 2008. 
These protocols are available at: http://www.hpsc.
ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
SurgicalSiteInfectionSurveillance/SurgicalSiteInfectionSu
rveillance-Protocols/.
MRSA in ICU prevalence
The meticillin-resistant Staphylococcus aureus (MRSA) in 
intensive care unit (ICU) prevalence study commenced 
in April 2008. The primary objective of the study is to 
provide a weekly snapshot of MRSA in the critical care 
setting that requires minimal if any additional resources. 
Participants complete the survey once weekly and 
capture ICU data on MRSA prevalence, transmission, 
bed occupancy and isolation capabilities. Data is 
fedback to participants on a quarterly basis to enable 
ICUs to monitor trends over time. Information on MRSA 
screening practices are also collected annually.
In 2009, 34 ICUs participated in the MRSA in ICU 
prevalence study, an additional two ICUs compared to 
2008. ICUs were stratified by ICU type;  
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true ICU patients and coronary care unit (CCU) or 
high dependency unit (HDU) patients or a variable 
combination of these groups. 
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ICU patients only.
There were 20 level 2/3 ICUs and 14 level 3 ICUs in 
2009. 
During 2009, ICU bed occupancy and isolation room 
occupancy were high in both level 2/3 (88% and 
9.3  Healthcare-associated infection 
surveillance 
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72%, respectively) and level 3 ICUs (89% and 79%, 
respectively). However, this is an underestimate of the 
true occupancy of ICUs as this project only accounts for 
patients within the ICU and not those receiving intensive 
care ‘off-site’, e.g., in a theatre recovery or hospital 
ward area, the level of which is substantial.
Large differences in isolation room resources were 
reported among the 34 participating ICUs. Five ICUs 
were reported as having no single rooms to isolate 
patients (table 1). Of the remaining 29 ICUs, there were 
a total of 65 single rooms ranging from 1 to 6 per ICU. 
The ratio of single rooms to critical care beds ranged 
from 1:9 to 1:1.5 with 32% of ICUs falling below the 
recommendation of one single room to every four to six 
critical care beds as set out in the 2005 national MRSA 
guidelines. The majority (63%, n=41) of single rooms are 
found within level 3 ICUs (table 1). Seventy-five percent 
of ICUs with single rooms have one to two single rooms. 
All ICUs with five or more single rooms are level 3 ICUs. 
All single rooms were found to be equipped with hand 
sinks but only 40% were found to have anterooms. 
On average 78% of all MRSA patients reported were 
capable of being isolated in 2009, similar to what was 
reported in 2008. Only 14.7% (n=5) of participating 
ICUs could successfully isolate all of their MRSA patients 
all of the time when surveyed, an increase from 6.3% (n 
= 2) in 2008. There are several reasons for this, including 
lack of isolation room availability, isolation room 
occupancy for other reasons, e.g., a risk assessment 
prioritises other patients with infectious disease for a 
room, (e.g., tuberculosis), or insufficient staff available to 
care for a patient in an isolation room. The data showed 
that on average 19.5% of all ICU patients were isolated 
in 2009; another 3.3% required isolation but could not 
be isolated due to a lack of facilities. This data does not 
include isolation of patients in designated cohort areas.
As recommended in national MRSA guidelines, all ICUs 
screen for MRSA colonisation on admission to ICU 
and weekly thereafter. However, different hospitals are 
using screening methodologies with different levels 
of sensitivity. Effective control of MRSA in a hospital 
setting hinges on early detection and early isolation 
of patients who are found to be colonised or infected 
with MRSA. It is difficult to control MRSA transmission 
within a unit when the population of patients admitted 
have a high prevalence of MRSA on admission. While 
all patients are being screened upon admission, there is 
still a large delay in the diagnosis of MRSA using culture 
alone, which can take up to 48 hours or longer. Once 
the results are available there are often no isolation 
rooms available to accommodate MRSA patients, 
therefore making MRSA containment a difficult issue. 
An improvement in the time to diagnose patients along 
with an improvement in isolation room resources would 
enhance efforts to minimise ICU transmission of MRSA.
The mean prevalence of MRSA within participating ICUs 
ranged nationally from 1.4% to 21.2%, with a median of 
9.3%. This reflects mostly patients colonised with MRSA 
upon admission to the ICU. No direct information on 
MRSA infection was collected. MRSA prevalence varies 
widely depending on the type of ICU (figure 1). The 
level 2/3 ICU group had a median MRSA prevalence of 
7.9% in 2009, up from 5.9% in 2008. The level 3 group 
had a significantly higher median prevalence of 9.6%, (p 
<0.001) in 2009, down from 13% in 2008. 
Transmission of MRSA in the ICU was monitored by 
capturing the weekly proportion of MRSA that were 
ICU-acquired. The mean weekly proportion of ICU-
acquired MRSA varied nationally from 0 to 2.9% in 
2009 with a national median of 0.6%. No difference 
was observed in the proportion of ICU-acquired MRSA 
between level 2/3 (median = 0.6%) and level 3 ICUs 
(median = 0.5%). Since April 2008, the majority of 
ICUs (82%) reported that <1.5% of MRSA cases were 
acquired in the ICU indicating that figures on MRSA 
transmission in the majority of ICUs is low (figure 2). 
While there are several limitations to using a simple 
point prevalence surveillance tool, this project has 
allowed the collation of national data within current 
resources which have provided valuable insights into 
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Table 2: National data on alcohol hand rub consumption in 
acute public hospitals in Ireland, 2006 – 2009.
 Year
 2006 2007 2008 2009
Number of participating hospitals 52 50 50 49
Minimum value 0.5 5.2 5.9 7.8
National consumption rate* 10.5 15.0 18.7¥ 21.2
Maximum value 29 47.1 52.5 48
* The consumption rate is the total volume of alcohol hand rub 
consumed in the defined time period (in litres) per 1,000 bed days 
used. The national rate represents the median of the national sample 
for each time period.
¥ An error was made in the 2008 annual report where a national 
consumption rate of 19.5 was reported. This has now been corrected 
to 18.7.
Table 1: Number of single rooms by ICU type and hospital bed 
capacity.
ICU Type
Number 
of 
Isolation 
Rooms
Hospital Bed Capacity
<150 151-300 301-450 >450
Level 2/3 
(n=24)
0 4 1   
1 1 4 5  
2 1 1 1  
4  1 1  
Level 3 
(n=41)
1  4 1  
2    3
3    1
4    1
5    1
6    3
the burden of MRSA in Irish ICUs. The prevalence of 
MRSA is significantly higher in level 3 ICUs compared to 
level 2/3 ICUs. This is most likely due to the difference 
in patient case-mix between groups. Level 3 ICUs are 
mainly based in tertiary referral hospitals and thus cater 
for a complex patient population with a higher risk 
of acquiring MRSA prior to ICU admission and post 
admission through increased intensity of care.  
Since the prevalence of MRSA increases in high-risk 
patient groups, ICU data should ideally be stratified 
by ICU acuity (i.e., APACHE score) to allow robust 
comparison and avoid misinterpretation of the 
parameters measured. The association between 
intensity of care and risk for MRSA acquisition is well 
described. ICUs with more ‘at-risk’ patient populations 
are more prone to higher rates of MRSA acquisition 
for a number of reasons including more staff to patient 
contact, higher use of medical devices compared 
to units with less acute patients and more selective 
pressures induced by antibiotic therapy. This type of risk 
stratification is not possible with the current protocol 
as it was designed so that the burden of data collection 
was kept to a minimum. Moreover, many ICUs do not 
capture APACHE scores on all patients. It is therefore 
important to emphasise the limitations of using a simple 
surveillance tool such as this point prevalence survey. 
A point prevalence survey only captures ICU data at a 
particular point in time on a single day each week. This 
is in contrast to a period prevalence which captures data 
every day in the ICU over a particular period of time, 
(e.g., a year) or incidence data, the collection of which 
would be even more time consuming. Therefore, the 
purpose of this tool is for ICUs to compare their own 
data on MRSA over time at a local level and feedback 
to their local infection prevention and control team 
and management team. It is unsuitable to compare 
individual ICUs due to the large variability in patient 
case-mix. 
HPSC plan to continue to improve this project in 2010 
to allow hospitals capture other aspects of infection 
prevention and control such as the staff to patient ratio 
as a predictor of cross-infection. Such improvements 
will enhance the ability of this tool to more accurately 
identify the underlying issues surrounding differences in 
MRSA prevalence and acquisition within the ICU setting.
Alcohol-based hand rub surveillance
Alcohol-based hand rubs have been shown to be 
an effective and rapid method of hand hygiene in 
healthcare settings, and are recommended as the 
primary means of hand hygiene in Irish national 
guidelines. Measurement of hospital-level consumption 
of alcohol-based hand rub, expressed as volume used 
per 1,000 bed-days, has been shown to correlate 
with overall hand hygiene activity in hospitals. It is a 
recommended process measure of hand hygiene activity 
by both the World Health Organisation (WHO) and the 
US Centers for Disease Control (CDC). 
HPSC have collated data on alcohol hand rub 
consumption in acute public hospitals in Ireland since 
2006. The data collected represents the total volume 
of alcohol-based hand rub delivered or dispensed to 
wards, clinics and other hospital areas per quarter, 
excluding that used for pre-operative surgical ‘scrub’. 
The rate of usage per hospital was calculated as the 
total volume of hand rub consumed (in litres) per 1,000 
bed-days used (table 2).
In 2009 the median rate of alcohol hand rub 
consumption increased to 21.2 litres per 1,000 bed-days 
used, from 18.7 in 2008.  This represents a 13% increase 
in national consumption since 2008 and a 100% overall 
increase in consumption since surveillance began in 
2006 (table 2). This increase between 2006 and 2009 
could be explained in part by the increased importance 
placed on hand hygiene since the publication of the 
national hand hygiene guidelines by the SARI Infection 
Control Subcommittee in 2005 and local hospital 
initiatives. The overall level of alcohol-based hand rub 
consumption is comparable to other successful hand 
hygiene campaigns internationally. The wide variation 
in levels of alcohol-based hand rub consumption 
between hospitals (table 2) may be largely explained 
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Figure 1. National trends on the median MRSA prevalence in Irish ICUs stratified by ICU 
type, 2008 – 2009.
by differences in methodologies for collecting and 
reporting the data, and difference in types and range of 
hand hygiene agents used.
The main limitations to be noted when examining the 
data in table 2 is that the data only refers to the use of 
alcohol-based hand rub, and does not take account of 
other hand hygiene agents (e.g. medicated liquid soap) 
that may also be in use in hospitals. In addition, the data 
does not give an indication of the frequency with which 
hand decontamination is carried out at a given hospital 
nor distinguish between who has used the hand rub 
(visitor, patient and healthcare worker). There is clearly 
a need for better standardisation of data collection and 
reporting. However, even with better standardisation, 
the volume of alcohol-based hand rub consumed 
remains a crude measure of hand hygiene activity and 
additional outcome measures are required. In 2009 
a hand hygiene observation audit tool and standard 
operating procedure for use in acute hospitals was 
developed in conjunction with the Infection Prevention 
Society.( http://www.hpsc.ie/hpsc/A-Z/Gastroenteric/
Handwashing/) 
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Figure 2. National trends in the average weekly proportion of ICU-acquired MRSA by ICU 
type, 2008 - 2009
Clostridium difficile as a notifiable disease
New cases of Clostridium difficile-associated disease 
(CDAD) in persons two years or older have been 
notifiable in Ireland under the disease category acute 
infectious gastroenteritis (AIG) since 4th May 2008. 
Recurrent CDAD cases are not currently notifiable.  
There were 4,359 notifications of acute infectious 
gastroenteritis (AIG) in 2009, of which 1,897 (44%) were 
new CDAD cases, giving a national crude incidence rate 
(CIR) of 44.7 new CDAD cases per 100,000 population. 
All cases were laboratory confirmed. This represents 
a decrease from 56.9 cases per 100,000 population 
reported in 2008 (table 1). Regional variation was 
observed in the incidence of CDAD (table 1); however, 
this most likely reflects differences in diagnosis and 
reporting rather than true variation in disease incidence. 
As in 2008, new cases of CDAD in 2009 were more 
prominent in female patients (57.6%) and older age 
groups.  The mean age of cases was 71 years (range 
2-102 years) (figure 1) and 1418 cases (74.7%) were 
reported in the over 65 year age category.  Of note, the 
75-84 year age group had the highest number of cases 
(615, representing 43% of the over 65 year age group). 
The majority of CDAD cases (67%) were notified by 
healthcare institutions. Patients classified as ‘hospital 
inpatient’ had the highest occurrence of cases 
accounting for 64% of all cases notified. 
Of the remaining, 9% were classified as GP patients, 
3% hospital outpatient, 2% as ‘other’ and 22% as either 
‘not specified’ or ‘unknown’. However, this data does 
not provide information on the origin or onset of CDAD; 
rather it represents the location of the patient at CDAD 
diagnosis.  Information on the origin and onset of CDAD 
cases is collected as part of the enhanced surveillance 
system. 
The seasonal trend is indistinguishable at present 
as only one complete annual data set is available. In 
addition, identification of seasonal patterns is hindered 
by late and batch notifications from institutions.
In 2009, nine Clostridium difficile outbreaks, all 
healthcare-associated, involving 50 patients were 
notified on CIDR (table 2). Six of these were linked to 
hospitals, two to nursing homes and one to a long-term 
care facility.
C. difficile Enhanced Surveillance
Although the information notified through CIDR has 
given important preliminary information on the burden 
of new cases of CDAD in Ireland, it represents an 
underestimate of the true burden of infection (capturing 
new cases only) and does not capture information on 
9.4  Clostridium difficile-associated 
disease in Ireland
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Table 2. C. difficile outbreaks reported in Ireland in 2009 by HSE 
area
HSE Region Outbreak location Total number ill
East Nursing Home 6
Mid-West Hospital 3
Mid-West Hospital 19
North East Hospital 7
North East Nursing Home 2
North East Hospital 4
South Comm. Hosp /Long-stay 
unit
2
South Hospital 3
West Hospital 4
Table 1.  Number of notified cases, crude incidence rate of 
CDAD in Ireland by HSE area, 2009, and total number with 
estimated crude incidence rate for 2008. 
HSE Area No. of cases *CIR incl. 95% C.I.
East 705 47 [43.5 - 50.5]
Midlands 44 17.5 [12.3 - 22.7]
Mid West 184 51 [43.6 - 58.4]
North East 84 21.3 [16.7 - 25.9]
North West 133 56.1 [46.6 - 65.6]
South East 251 54.5 [47.8 - 61.2]
South  237 38.2 [33.3 - 43.1]
West 259 62.5 [54.9 - 70.1]
Total 2009 1897 44.7 [42.7 - 46.7]
Total 2008** 1624 56.9 [54.6 - 59.2]**
* Rates calculated using 2006 census data
** Using the number of notifications over the 35 week period in 2008, 
the estimated CIR for a 52 week period was calculated
the origin or onset of cases. Since 1st August 2009, 
national collation of C. difficile enhanced surveillance 
commenced on a voluntary basis in Ireland. Information 
on case type, origin, onset and severity of CDAD is 
collected. CDAD case definitions proposed by the 
European Centre for Disease Control are employed. 
By the end of 2009, 33 hospitals were participating, 
corresponding to 30 acute public hospitals (seven 
regional, 21 general, two specialist hospitals) and three 
private hospitals. 
From August to December 2009, there were 527 cases 
of CDAD reported to the enhanced surveillance project, 
444 (84.3%) new cases and 79 (15%) recurrent CDAD. 
Of these, 337 (64%) originated within the participating 
hospital. This corresponds to an overall national CDAD 
incidence rate of 3.2 cases per 10,000 bed days used. 
This rate is based only on the number of cases that 
originated in the participating healthcare facility and is 
calculated using acute public hospital activity data from 
the National Hospitals Office at the Health Services 
Executive. There was a wide range in the incidence of 
CDAD infection among participating hospitals (range, 
0 – 8.6 cases per 10,000 bed days used, median, 2.7 
cases) with general hospitals showing a higher median 
incidence rate (CDAD rate = 3.8, n = 21) compared to 
tertiary hospitals (CDAD rate = 3.0, n = 7) over the five 
month period. This is likely due to the differences in 
patient case mix, C. difficile ribotypes, testing facilities 
and practices, antibiotic policies and surveillance 
resources between hospitals. 
Most cases were in females (59%) and in the over 
65 age group (74%). While the majority of cases 
were associated with healthcare facilities, specifically 
acute hospitals (78%), 15% of all CDAD cases were 
community-associated (figure 2). Ten percent of all 
healthcare-associated cases originated in nursing 
homes. Of note, while the majority of patients with 
CDAD had onset of symptoms in a healthcare facility 
(75%), predominantly in acute hospitals (acute hospitals 
90%, nursing homes, 9%), a significant proportion of 
patients with CDAD had onset of symptoms in the 
community (24%) (figure 2). 
There was a low incidence of severe CDAD (defined 
as admission to ICU or surgery due to complications 
arising from CDAD) reported in 2009 (1%, n = 5).
National Typing Project
In March 2009, HPSC in conjunction with St. Vincent’s 
University Hospital and University College Dublin 
conducted a one month national C. difficile typing 
study.  Participating healthcare facilities collected 
clinical details of all CDAD cases in March 2009, 
which included; case type, onset and origin of CDAD, 
antimicrobial exposure prior to diagnosis and case 
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*Rates calculated using 2006 census data  
Figure 1: Age and Sex distribution of CDAD in Ireland, 2009
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severity.  In addition, faecal specimens from patients 
with CDAD were submitted for PCR ribotyping.
Information on 211 CDAD cases was submitted from 
33 inpatient healthcare facilities.  The national median 
CDAD rate in acute hospitals was 2/10,000 bed days 
used (range 0 - 13).
Seventy-nine percent of cases (166) were new and 
18% (38) were recurrent.  The median age of cases 
was 78 years and 76% of patients (160) had received 
antimicrobial therapy within eight weeks prior to CDAD 
diagnosis.  Eighty-three percent of cases (176) were 
healthcare-associated, of which 13% (23) originated 
in nursing homes.  Ten percent (21) of cases were 
community-associated.  
Thirty-four percent of toxin-positive faecal specimens 
submitted (72) failed to grow C. difficile on culture. 
Of the 139 samples successfully cultured, the most 
common ribotypes encountered were; 027 (19%), 001 
(16%), 106 (13%), 078 (10%) and 014 (8%).  Ribotypes 
001 (21%), 027 (20.7%) and 106 (19.5%) predominated 
among new cases with 027 (37.5%), 001 (21%) and 078 
(16.6%) among recurrent cases.
Conclusion
The collation of national data on C. difficile through 
both surveillance systems has provided a valuable 
insight into the burden of CDAD in Ireland.
Data to date suggests a decline in the number of new 
CDAD cases reported in 2009 compared to 2008, 
however, due to the large weekly variability in the data 
it is too soon to determine if this decline is significant.
Fifteen percent of all CDAD cases reported in 2009 
were recurrent infections. Recurrence of CDAD is 
difficult to manage clinically, can result in severe 
infection, places a burden on already limited isolation 
resources and results in significant patient morbidity. 
Therefore, knowledge of the burden of recurrent CDAD 
in Ireland is important to help guide preventative 
strategies.
During 2009, 15% of all CDAD cases from hospital 
inpatients (including patients admitted through 
emergency departments and outpatient clinics) were 
associated with the community and 10% of cases were 
associated with nursing homes. This indicates that C. 
difficile is no longer an infection limited to the hospital 
setting. Moreover a quarter of all cases had onset of 
symptoms in the community. This information collected 
on the burden of CDAD outside acute hospitals will 
help to direct appropriate preventative and control 
programmes at a national level.
In March 2009, national C .difficile ribotype data was 
collected for the first time.  In addition to highlighting 
the burden of CDAD outside acute care facilities, this 
study demonstrated the overall predominance of PCR 
ribotype 027 at this time. 
National guidelines for the surveillance, diagnosis, 
management, and prevention and control of 
CDAD in Ireland are available for download 
(http://www.hpsc.ie/hpsc/A-Z/Gastroenteric/
Clostridiumdifficile/) and hospital antibiotic 
stewardship guidelines available at http://www.hpsc.
ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
StrategyforthecontrolofAntimicrobialResistanceinIreland 
SARI/AntibioticStewardship/Publications/.  All 
healthcare professionals must promote practices 
known to reduce the incidence of CDAD including; 
antimicrobial stewardship and compliance with infection 
prevention and control measures. These measures are 
outlined in the national guidelines. 
Figure 2. Origin and Onset of CDAD Cases by Case Type, Aug – Dec 2009 
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Increased Number of Infectious Disease Notifications 
on CIDR Through 2009
CIDR continued to support infectious disease 
surveillance and reporting through 2009 as activity 
increased over previous years (see Figure 1). Although a 
proportion of this increased activity was associated with 
the H1N1 influenza pandemic there was also increased 
activity in relation to mumps notifications.
2009 Influenza A (H1N1) Pandemic 
The major event in 2009 in relation to CIDR, as for 
the rest of HPSC, was the 2009 Influenza A (H1N1) 
Pandemic from April 25th to the end of 2009. For the 
CIDR team the immediate initial task was to define 
2009 pandemic influenza A (H1N1) as a new notifiable 
condition in CIDR and 2009 pandemic influenza A 
(H1N1) virus as a new organism. CIDR user data access 
rights needed to be updated to allow pandemic 
influenza to be managed as a national outbreak in 
CIDR. The CIDR team worked closely with the National 
Pandemic Influenza Epidemiological Team within HPSC 
to identify the additional ‘enhanced’ information that 
needed to be collected and to configure CIDR to collect 
this information. The large number of these ‘enhanced’ 
data items (163 during the initial ‘containment’ phase 
of the pandemic), over and above core variables and 
laboratory results, was a major challenge. Additional 
work was then required to enable these data to be 
readily retrieved for reporting purposes. Additional 
‘enhanced’ data items were also required to be 
recorded in conjunction with outbreaks of pandemic 
influenza, again over and above those associated with 
individual cases or events. 
10. Computerised Infectious Disease 
 Reporting (CIDR)
Summary
UÊÊCIDR continued to support an increasing number 
of infectious disease notifications through 2009
UÊÊCIDR coped well with 2009 influenza A (H1N1) 
Pandemic 2009 although significant challenges 
were posed and lessons learned
UÊÊCIDR went live in HSE West, including Public 
Health in Merlin Park, and the laboratories in 
University College Hospital Galway, Portiuncula 
Hospital and Mayo General Hospital
UÊÊCIDR Disaster Recovery Site relocated to HSE 
National Data Hosting Centre
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Figure 1. The increase in infectious disease notifications recorded in CIDR since the system 
went ‘live’ at the beginning of 2005
Yearly Noti!cations on CIDR
Rapidly evolving and expanding reporting requirements 
for local, regional, national and international reporting 
of 2009 pandemic influenza A(H1N1) posed a particular 
challenge on several fronts. The version of reporting 
software had been significantly updated at the end of 
2008 but users (and the CIDR team supporting them) 
were still familiarising themselves with this when the 
pandemic occurred. The number, size and complexity 
of the reports required during the 2009 influenza A 
(H1N1) pandemic were much greater than the CIDR 
team might have envisaged beforehand and it was 
a major challenge to ensure that ongoing reporting 
needs were met whilst at the same time keeping the 
CIDR system stable and running. It was also a challenge 
to ensure that CIDR users were aware of what CIDR 
could and could not do. Nonetheless the reporting 
functionality of CIDR was highly praised. It was used 
to produce the daily EPI report and retrieve real-time 
data. The standard reports for the National Public 
Health Emergency Team (NPHET) and the Pandemic 
Influenza Expert Group (PIEG) etc were very impressive. 
The system was found to be very flexible for facilitating 
ad-hoc analysis and queries with a great capacity for 
diverse reports. CIDR enhanced the profile of HPSC in 
relation to data management / data quality / response 
– underscored by the fact that Ireland was one of first 
countries in EU reporting on surveillance of initial cases, 
and also hospitalised cases. The system facilitated the 
national collection of standardised data that would not 
have been as easy to achieve using stand-alone local 
health area data systems that were in use pre-CIDR.
Although the new version of CIDR had been extensively 
load and stress tested before it was deployed in 
December 2008, it was not possible to anticipate all 
of the stresses and strains associated with its real life 
use during a pandemic. The large number of enhanced 
questions (163) on events of pandemic influenza 
began to cause significant problems / system errors 
from the beginning of July as the numbers of events 
began to increase rapidly (see Figure 2) and multiple 
users were seeking to enter data at the same time to 
meet reporting deadlines. Fortunately a decision in the 
middle of July to move from the containment phase to 
the mitigation phase  was accompanied by a significant 
reduction in the number of enhanced questions (to 
49) which resulted in these errors no longer being 
encountered.
A number of changes to the CIDR software (some 
of which were specified before the pandemic but 
unfortunately had not been developed at that time) are 
being made to address many of these issues before the 
occurrence of the next pandemic.
Figure 2. The increase in events of Pandemic influenza on CIDR from 26/04/2009 ( Week 17) 
to 19/07/2009 ( Week 29)
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Despite the focus on pandemic influenza through 2009 
it was also essential to ensure CIDR continued to be 
able to record and retrieve data for the rest of the 
notifiable diseases.
CIDR Implementation in HSE West
Another significant milestone achieved in April 2009 was 
the implementation of CIDR in the Department of Public 
Health in Merlin Park in Galway and in the laboratories 
in University College Hospital Galway (UCHG), in 
Portiuncula Hospital in Ballinasloe, and in Mayo General 
Hospital in Castlebar. This required significant effort 
to map existing business processes to identify how 
to meet these needs within CIDR and to align local 
personally identifiable data with the anonymised historic 
HSE West data already loaded into CIDR for national 
reporting purposes. There was similarly significant work 
with the laboratories to configure them on CIDR before 
everyone could go live. HPSC delivered a number of 
training courses to HSE West Public and laboratory 
staff to support the go-live that occurred on April 20th. 
Unfortunately this proved to be a go-live date that 
immediately became problematic with the declaration 
of the influenza pandemic by the World Health 
Organisation the following weekend. A CIDR go-live is 
a challenge for everyone at the best of times and it is to 
the credit of our colleagues in HSE West as well as the 
CIDR team that this particular additional challenge was 
overcome.
CIDR Disaster Recovery Site relocated to HSE 
National Data Hosting Centre
An essential element of the CIDR system is the 
‘Disaster Recovery’ (DR) system that enables CIDR to 
continue to be accessible to users if the main system 
becomes unavailable because of hardware, software or 
connectivity problems. This DR site has been located 
in the Data Centre at Fujitsu’s premises in Swords in 
County Dublin since the system was first built in 2004. 
Fujitsu were unfortunately unable to continue to provide 
this service beyond 2009 and it became necessary to 
find an alternative site. With the help of HSE ICT staff, 
and supported by Fujitsu, the CIDR team relocated 
the CIDR DR equipment to the new HSE National Data 
Hosting Centre in Clonshaugh, Co. Dublin, in August to 
ensure this backup CIDR system would continue to be 
available.
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Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures for the year 2009 presented in this appendix were extracted from the Computerised Infectious Disease Reporting 
(CIDR) system on the 9th September 2010. These figures may differ from those published previously due to ongoing updating 
of notification data on CIDR.
Figures on EARSS pathogens, tuberculosis and sexually transmitted infections are not presented here.  Separate databases are 
used to collate data on these diseases. Details on the epidemiology of these diseases can be found in separate chapters in this 
document.
Please note that the pandemic period in the influenza chapter extends from week 17, 2009 to week 32, 2010 and does not 
include the period weeks 1-16, 2009. 
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Table  A1.1. List of notifiable infectious diseases and their respective causative pathogens under Infectious Diseases (Amendment) (No. 3) 
Regulations 2003 (S.I. No. 707 of 2003)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Acute infectious gastroenteritis
Ano-genital warts
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)
Botulism Clostridium botulinum
Brucellosis Brucella species
Campylobacter infection Campylobacter species
Chancroid Haemophilus ducreyi
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease
Creutzfeldt Jakob disease (new variant)
Cryptosporidiosis Cryptosporidium parvum
Diphtheria Corynebacterium diphtheriae
Echinococcosis Echinococcus species
Enterococcal bacteraemia Enterococcus species (blood)
Enterohaemorrhagic Escherichia coli Escherichia coli of serogroup known to be toxin-producing
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) Hepatitis A virus
Hepatitis B (acute and chronic) Hepatitis B virus
Hepatitis C Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Influenza Influenza A and B virus
Legionellosis Legionella species
Leptospirosis Leptospira species
Listeriosis Listeria monocytogenes
Lymphogranuloma venereum
Malaria Plasmodium falciparum, P. vivax, P. ovale, P. malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis
Noroviral infection Norovirus
Paratyphoid Salmonella paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Q fever Coxiella burnetii
Rabies Rabies virus
Rubella Rubella virus
Salmonellosis Salmonella enterica
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella species
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Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus  pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella species
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella typhi
Typhus Rickettsia prowazekii
Viral encephalitis
Viral haemorrhagic fevers Lassa virus, Marburg virus, Ebola virus, Crimean-Congo haemorrhagic fever virus
Viral meningitis
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
Infectious Disease Causative Pathogen(s)
Table A1.2 Number of notifiable infectious diseases, 2007-2009 and crude incidence rates of diseases, 2009
Infectious Disease 2007 2008 2009 CIR* 2009
Acute infectious gastroenteritis 2522 4178 4359 102.81
Bacillus cereus food-borne infection or intoxication 0 0 1 0.02
Bacterial meningitis (not otherwise specified) 33 40 40 0.94
Botulism 0 7 0 0.00
Brucellosis 28 3 0 0.00
Campylobacter infection 1890 1747 1808 42.64
Clostridium perfringens (type A) food-borne disease 0 1 1 0.02
Creutzfeldt Jakob disease 3 2 5 0.12
Cryptosporidiosis 609 415 445 10.50
Echinococcosis 0 2 1 0.02
Enterohaemorrhagic Escherichia coli 192 238 255 6.01
Giardiasis 62 71 61 1.44
Haemophilus influenzae disease (invasive) 31 22 43 1.01
Hepatitis A (acute) 32 42 50 1.18
Hepatitis B (acute and chronic) 860 931 824 19.43
Hepatitis C 1552 1527 1259 29.69
Influenza 280 473 484** 11.42
Legionellosis 16 12 9 0.21
Leptospirosis 22 29 24 0.57
Listeriosis 21 13 10 0.24
Malaria 71 82 90 2.12
Measles 53 55 162 3.82
Meningococcal disease 179 168 147 3.47
Mumps 142 1380 3629 85.59
Noroviral infection 1313 1770 1638 38.63
Pandemic H1N1 (2009) 0 0 4572 107.83
Paratyphoid 4 8 8 0.19
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Pertussis 77 104 78 1.84
Q fever 17 13 17 0.40
Rubella 19 40 19 0.45
Salmonellosis 456 449 333 7.85
Shigellosis 43 76 71 1.67
Staphylococcal food poisoning 0 1 1 0.02
Streptococcus group A infection (invasive) 57 70 60 1.42
Streptococcus pneumoniae infection (invasive) 361 465 433 10.21
Tetanus 1 2 0 0.00
Toxoplasmosis 49 49 37 0.87
Trichinosis 2 0 0 0.00
Typhoid 9 5 9 0.21
Viral encephalitis 8 5 5 0.12
Viral meningitis 45 97 142 3.35
Yersiniosis 7 3 3 0.07
Total 11066 14595 21133 498.44
 See explanatory note on first page of Appendix 1.
 *Crude incidence rate per 100,000 total population.
 **  134 of these cases were possibly due to 2009 pandemic influenza as they occurred between weeks 17 and 52, 2009,  but were reported as influenza.
Infectious Disease 2007 2008 2009 CIR* 2009
Table A1.3 Number of notifiable infectious diseases by HSE area, 2009 
Infectious Disease HSE-E
HSE-
M
HSE-
MW
HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W Total
Acute infectious gastroenteritis 1204 206 294 211 305 721 693 725 4359
Bacillus cereus food-borne infection or 
intoxication * * * * * * * * 1
Bacterial meningitis (not otherwise 
specified) 13 4 2 0 0 6 8 7 40
Campylobacter infection 612 111 159 135 82 193 280 236 1808
Clostridium perfringens (type A) food-borne 
disease * * * * * * * * 1
Creutzfeldt Jakob disease 3 0 0 1 0 1 0 0 5
Cryptosporidiosis 11 60 56 30 29 72 79 108 445
Echinococcosis * * * * * * * * 1
Enterohaemorrhagic Escherichia coli 31 20 45 8 31 34 56 30 255
Giardiasis 29 1 1 7 1 2 10 10 61
Haemophilus influenzae disease (invasive) 12 3 8 1 1 5 8 5 43
Hepatitis A (acute) 34 1 1 1 5 3 3 2 50
Hepatitis B (acute and chronic) 473 31 59 46 17 60 73 65 824
Hepatitis C 929 47 48 49 24 42 72 48 1259
Influenza 107 20 134 15 15 26 144 23 484**
Legionellosis 4 2 1 0 2 0 0 0 9
Leptospirosis 6 0 5 3 0 5 4 1 24
Listeriosis 2 1 3 0 0 2 1 1 10
Malaria 33 10 10 10 2 2 11 12 90
Measles 30 3 3 3 0 37 52 34 162
Meningococcal disease 49 8 16 17 8 15 23 11 147
Mumps 974 142 341 333 156 300 559 824 3629
Noroviral infection 593 83 186 241 96 62 223 154 1638
Pandemic H1N1 (2009) 1471 165 335 329 223 399 913 737 4572
Paratyphoid 4 0 0 1 0 3 0 0 8
Pertussis 23 6 17 7 7 3 10 5 78
Q fever 0 1 0 1 0 0 14 1 17
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Rubella 11 0 2 0 1 4 1 0 19
Salmonellosis 127 22 24 38 24 37 35 26 333
Shigellosis 40 7 6 3 1 2 6 6 71
Staphylococcal food poisoning * * * * * * * * 1
Streptococcus group A infection (invasive) 32 2 5 3 1 8 5 4 60
Streptococcus pneumoniae infection 
(invasive) 152 15 27 19 23 99 59 39 433
Toxoplasmosis 13 1 3 0 3 0 12 5 37
Typhoid 5 0 2 0 0 1 1 0 9
Viral encephalitis 0 0 0 0 0 3 0 2 5
Viral meningitis 56 5 6 17 5 15 20 18 142
Yersiniosis * * * * * * * * 3
Total 7087 977 1800 1531 1062 2162 3375 3139 21133
See explanatory note on first page of Appendix 1.
*Data not reported to HSE area level when total number in Ireland <5 cases.
**  134 of these cases were possibly due to 2009 pandemic influenza as they occurred between weeks 17 and 52, 2009, but were reported as influenza.
Infectious Disease HSE-E
HSE-
M
HSE-
MW
HSE-
NE
HSE-
NW
HSE-
SE
HSE-
S
HSE-
W Total
Table A1.4 Number of notifiable infectious diseases by age group (years), 2009
Infectious Disease 0-4
5-
9
10-
14
15-
19
20-
24
30-
34
35-
44
45-
54
55-
64 65+ Unknown Total
Acute infectious gastroenteritis 2354 60 13 12 28 65 74 102 202 1417 32 4359
Bacillus cereus food-borne infection or 
intoxication 0 0 0 0 0 0 1 0 0 0 0 1
Bacterial meningitis (not otherwise 
specified) 18 1 2 3 0 4 4 4 2 2 0 40
Campylobacter infection 499 134 72 92 134 245 163 166 122 180 1 1808
Clostridium perfringens (type A) food-
borne disease 0 0 0 0 0 0 0 1 0 0 0 1
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 0 1 4 0 5
Cryptosporidiosis 277 90 38 9 5 10 4 3 3 6 0 445
Echinococcosis 0 0 0 0 1 0 0 0 0 0 0 1
Enterohaemorrhagic Escherichia coli 123 27 13 6 8 18 22 12 13 13 0 255
Giardiasis 6 2 0 1 3 24 10 8 3 4 0 61
Haemophilus influenzae disease 
(invasive) 8 5 2 0 0 3 3 0 6 16 0 43
Hepatitis A (acute) 4 9 3 0 8 9 6 3 3 5 0 50
Hepatitis B (acute and chronic) 5 0 7 35 136 360 165 73 28 13 2 824
Hepatitis C 4 2 0 13 91 561 338 177 57 14 2 1259
Influenza 92 31 22 30 26 86 72 46 32 41 6 484*
Legionellosis 0 0 0 0 0 0 1 2 4 2 0 9
Leptospirosis 0 0 0 1 2 7 5 3 4 2 0 24
Listeriosis 0 0 0 0 0 1 0 2 2 5 0 10
Malaria 6 11 4 6 7 25 22 6 1 2 0 90
Measles 88 28 18 11 6 9 0 0 0 0 2 162
Meningococcal disease 81 11 6 21 9 3 4 3 1 8 0 147
Mumps 74 108 204 990 1305 643 142 66 37 26 34 3629
Noroviral infection 96 12 9 17 40 55 51 76 133 1087 62 1638
Pandemic H1N1 (2009) 561 665 660 645 457 679 438 267 131 56 13 4572
Paratyphoid 0 3 0 2 1 1 0 1 0 0 0 8
Pertussis 64 3 5 2 0 1 1 1 1 0 0 78
Q fever 1 0 1 1 0 3 4 2 3 2 0 17
Rubella 15 1 1 0 1 1 0 0 0 0 0 19
Salmonellosis 72 28 17 19 29 53 37 29 17 32 0 333
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Shigellosis 12 3 1 1 9 20 10 10 5 0 0 71
Staphylococcal food poisoning 1 0 0 0 0 0 0 0 0 0 0 1
Streptococcus group A infection 
(invasive) 9 1 3 0 1 6 7 6 6 21 0 60
Streptococcus pneumoniae infection 
(invasive) 52 10 6 5 11 28 32 40 53 196 0 433
Toxoplasmosis 0 0 1 2 5 19 5 2 1 2 0 37
Typhoid 1 1 0 0 1 4 2 0 0 0 0 9
Viral encephalitis 0 0 0 0 0 0 2 1 0 2 0 5
Viral meningitis 46 10 4 12 13 24 23 5 3 2 0 142
Yersiniosis 0 0 1 0 1 1 0 0 0 0 0 3
Total 4569 1256 1113 1936 2338 2968 1648 1117 874 3160 154 21133
See explanatory note on first page of Appendix 1
* 134 of these cases were possibly due to 2009 pandemic influenza as they occurred between weeks 17 and 52, 2009, but were reported as influenza.
Infectious Disease 0-4
5-
9
10-
14
15-
19
20-
24
30-
34
35
-44
45-
54
55-
64 65+ Unknown Total
Table A1.5 Number of notifiable infectious diseases by gender, 2009
Infectious Disease Male Female Unknown Total
Acute infectious gastroenteritis 2098 2248 13 4359
Bacillus cereus food-borne infection or intoxication 1 0 0 1
Bacterial meningitis (not otherwise specified) 21 19 0 40
Campylobacter infection 953 846 9 1808
Clostridium perfringens (type A) food-borne disease 0 1 0 1
Creutzfeldt Jakob disease 4 1 0 5
Cryptosporidiosis 243 200 2 445
Echinococcosis 0 1 0 1
Enterohaemorrhagic Escherichia coli 131 124 0 255
Giardiasis 29 32 0 61
Haemophilus influenzae disease (invasive) 23 20 0 43
Hepatitis A (acute) 26 24 0 50
Hepatitis B (acute and chronic) 470 330 24 824
Hepatitis C 826 411 22 1259
Influenza 223 258 3 484*
Legionellosis 5 4 0 9
Leptospirosis 23 1 0 24
Listeriosis 5 5 0 10
Malaria 57 33 0 90
Measles 87 74 1 162
Meningococcal disease 82 64 1 147
Mumps 1964 1649 16 3629
Noroviral infection 703 934 1 1638
Pandemic H1N1 (2009) 2112 2440 20 4572
Paratyphoid 6 2 0 8
Pertussis 37 39 2 78
Q fever 7 10 0 17
Rubella 11 8 0 19
Salmonellosis 172 160 1 333
Shigellosis 40 31 0 71
Staphylococcal food poisoning 1 0 0 1
Streptococcus group A infection (invasive) 34 26 0 60
Streptococcus pneumoniae infection (invasive) 240 193 0 433
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Toxoplasmosis 9 28 0 37
Typhoid 7 2 0 9
Viral encephalitis 3 2 0 5
Viral meningitis 80 61 1 142
Yersiniosis 1 1 1 3
Total 10734 10282 117 21133
See explanatory note on first page of Appendix 1
* 134 of these cases were possibly due to 2009 pandemic influenza as they occurred between weeks 17 and 52, 2009, but were reported as influenza.
Infectious Disease Male Female Unknown Total
Table A1.6 Number of notifiable infectious diseases by case classification, 2009
Infectious Disease Confirmed Probable Possible Not Specified Total
Acute infectious gastroenteritis 4251 108 0 0 4359
Bacillus cereus food-borne infection or intoxication 1 0 0 0 1
Bacterial meningitis (not otherwise specified) 17 10 13 0 40
Campylobacter infection 1802 3 0 3 1808
Clostridium perfringens (type A) food-borne disease 1 0 0 0 1
Creutzfeldt Jakob disease 5 0 0 0 5
Cryptosporidiosis 445 0 0 0 445
Echinococcosis 1 0 0 0 1
Enterohaemorrhagic Escherichia coli 250 5 0 0 255
Giardiasis 61 0 0 0 61
Haemophilus influenzae disease (invasive) 43 0 0 0 43
Hepatitis A (acute) 49 0 1 0 50
Hepatitis B (acute and chronic) 822 2 0 0 824
Hepatitis C 1258 0 0 1 1259
Influenza 443 0 37 4 484**
Legionellosis 8 1 0 0 9
Leptospirosis 24 0 0 0 24
Listeriosis 10 0 0 0 10
Malaria 90 0 0 0 90
Measles 103 0 58 1 162
Meningococcal disease** 130 4 13 0 147
Mumps 1375 417 1803 34 3629
Noroviral infection 1541 97 0 0 1638
Pandemic H1N1 (2009) 4521 2 49 0 4572
Paratyphoid 8 0 0 0 8
Pertussis 61 0 15 2 78
Q fever 17 0 0 0 17
Rubella 1 0 18 0 19
Salmonellosis 332 1 0 0 333
Shigellosis 71 0 0 0 71
Staphylococcal food poisoning 1 0 0 0 1
Streptococcus group A infection (invasive) 60 0 0 0 60
Streptococcus pneumoniae infection (invasive) 356 69 8 0 433
Toxoplasmosis 37 0 0 0 37
Typhoid 9 0 0 0 9
Viral encephalitis 4 0 1 0 5
Viral meningitis 106 0 0 36 142
Yersiniosis 3 0 0 0 3
Total 18317 719 2016 81 21133
See explanatory note on first page of Appendix 1.
Case classifications are assigned to notifications as per the Case Definitions for Notifiable Diseases booklet, available at http://www.hpsc.ie
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience 
   they are reported in this table as confirmed, probable and possible, respectively.
**  134 of these cases were possibly due to 2009 pandemic influenza as they occurred between weeks 17 and 52, 2009,  but were reported as influenza.
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Table A2.1 Immunisation uptake (%) at 12 months of age in 2009 (i.e. cohort born 01/01/2008-31/12/2008*), based on available data
HSE Area Local Health Office/HSE Area
Number in 
cohort for 
BCG †
Number in 
cohort for 
D3, T3, P3 
& Polio3 †
Immunisation Uptake (%)†
BCG† D3 Hib3 Polio3 HepB3 MenC3 MenC2 PCV2
HSE-E
Dublin South na 1565 na 91 91 91 88 90 90 89
Dublin South East na 1476 na 93 93 93 92 89 91 90
Dublin South City na 1766 na 85 85 85 90 76 89 89
Dublin South West na 2619 na 93 92 93 92 90 91 92
Dublin West na 2847 na 85 85 85 86 82 86 85
Dublin North West na 3889 na 84 84 84 84 81 82 82
Dublin North Central na 1722 na 90 89 90 90 85 88 88
Dublin North na 4375 na 89 89 89 89 87 88 89
Kildare/West Wicklow na 4392 na 82 82 82 86 77 86 86
Wicklow na 2114 na 87 87 87 87 85 87 87
HSE-E Total na 26765 na 87 87 87 88 83 87 87
HSE-M
Laois/Offaly 1466 1466 95 92 92 92 na 92 na na
Longford/Westmeath 1109 1109 94 94 94 94 na 94 na na
HSE-M Total 2575 2575 94 92 92 92 na 92 na na
HSE-MW
Clare 1379 1378 98 91 91 91 93 89 na 93
Limerick 1635 1606 97 90 90 90 92 87 na 91
Tipperary NR/East Limerick 1546 1602 96 91 91 91 91 91 na 92
HSE-MW Total 4560 4586 97 91 91 91 92 89 na 92
HSE-NE
Cavan/Monaghan na 2287 na 93 93 93 94 88 93 91
Louth na 2272 na 91 91 91 91 87 89 88
Meath na 3745 na 91 91 91 92 87 91 89
HSE-NE Total na 8304 na 91 91 91 92 87 91 89
HSE-NW
Donegal 2464 2464 94 92 92 92 91 91 91 92
Sligo/Leitrim 1481 1481 96 91 91 91 88 91 87 88
HSE-NW Total 3945 3945 95 92 92 92 90 91 90 90
HSE-SE
Carlow/Kilkenny 2170 2170 95 88 88 88 88 87 87 87
South Tipperary 1458 1458 95 91 91 91 92 91 91 91
Waterford 2247 2247 95 89 89 89 89 87 89 89
Wexford 2489 2489 96 91 91 91 92 89 92 92
HSE-SE Total 8364 8364 96 90 90 90 90 88 90 90
HSE-S
North Cork na 763 na 87 87 87 na 87 na na
North South Lee na 2952 na 87 87 87 na 87 na na
West Cork na 406 na 82 82 82 na 82 na na
Kerry 1039 1029 93 83 83 83 na 82 na na
HSE-S Total 1039 5150 93 86 86 86 na 86 na na
HSE-W
Galway na 4250 na 87 87 87 86 85 87 87
Mayo na 1906 na 88 88 88 88 87 86 88
Roscommon na 1000 na 96 95 96 95 94 95 96
HSE-W Total na 7156 na 88 88 88 88 87 88 89
Ireland 20483 66845 95 89 89 89 89 86 89 89
na=not available
Since T3 and P3 uptake identical to D3 uptake only D3 uptake figures are presented
* Since September 1st 2008 the new primary childhood immunisation schedule has been implemented.   The changes to the primary schedule for children born 
on or after 1st July 2008 include introduction of a hepatitis B vaccine (as part of a 6 in 1 vaccine) given at 2, 4, 6 months of age, introduction of pneumococcal 
conjugate vaccine given at 2, 6 and 12 months of age and a change in timing of meningococcal serogroup C conjugate vaccination, now given at 4, 6 and 13 
months of age.  Therefore, HepB3, MenC2 and PCV2 uptake data presented here are only for those born between 01/07/2008 and 31/12/2008 and MenC3 data are 
only for those born between 01/01/2008 and 30/06/2008.
† The 2009 data for those at 12 months are incomplete as the following were unavailable: the Quarter 1 2009 HSE-E D3, T3, P3 and Polio3 data for those born on the 
31/03/2008; the Quarter 3 2009 HSE-M data, HSE-S data, HSE-E MenC2 and PCV2 data and HSE-MW MenC2 data and; the Quarter 4 2009 HSE-M, HSE-MW and 
HSE-S data.  The available 2009 national 12 month D3, T3, P3, Hib3 (n=66,913) and Polio3 cohort data may be around 88% (this figure is an estimate only) of the 2009 
national birth cohort.  The national MenC3 cohort data (n=37,434) are complete (for Quarters 1 and 2 2009).  The available national HepB3 (n=29,486), MenC2 (n= 
20,838) and PCV2 (n=22,401) data may be around 76%, 54% and 58% (these figures are estimates only), respectively, of the (combined Quarters 3 and 4) national 
birth cohort.
BCG uptake data were available for the HSE-M, HSE-MW, HSE-NW, HSE-SE and HSE-S Areas (HSE-S data relate to Kerry only) in Quarters 1 and 2 2009; for the 
HSE-MW, HSE-NW and HSE-SE Areas in Quarter 3 2009 and for the HSE-NW and HSE-SE Areas in Quarter 4 2009.  The available 2009 national BCG cohort data 
may be around 27% (this figure is an estimate only) of the national birth cohort.  
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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Table A2.2 Immunisation uptake (%) at 24 months of age in 2009 (i.e. cohort born 01/01/2007-31/12/2007), based on available data
HSE Area Local Health Office/HSE Area
Number 
in cohort 
for Hibb
Number 
in cohort 
for other 
vaccines*
Immunisation Uptake (%)†
D3 P3 T3 Hib3 Hibb Polio3 MenC3 MMR1
HSE-E
Dublin South 1605 1601 97 97 97 96 87 97 96 93
Dublin South East 1391 1388 97 97 97 97 86 97 97 93
Dublin South City 1647 1642 90 90 90 89 78 90 89 84
Dublin South West 2478 2475 95 95 95 94 86 95 93 94
Dublin West 2798 2791 92 92 92 92 82 92 91 88
Dublin North West 3636 3631 92 92 92 91 85 92 92 87
Dublin North Central 1601 1601 95 95 95 94 83 95 93 90
Dublin North 2160 4259 94 94 94 93 86 94 93 91
Kildare/West Wicklow 4377 4372 89 89 89 89 80 89 89 85
Wicklow 2045 2039 92 92 92 91 81 92 91 85
HSE-E Total 23738 25799 93 93 93 92 83 93 92 89
HSE-M
Laois/Offaly 2728 2769 95 95 95 95 92 95 95 92
Longford/Westmeath 1900 1941 97 97 97 97 94 97 97 94
HSE-M Total 4628 4710 96 96 96 96 93 96 96 93
HSE-MW
Clare 1427 1427 93 93 93 93 89 93 93 92
Limerick 1537 1537 92 92 92 92 86 92 92 89
Tipperary NR/East Limerick 1529 1529 96 96 96 95 91 96 95 94
HSE-MW Total 4493 4493 94 94 94 93 89 94 93 91
HSE-NE
Cavan/Monaghan 2116 2116 95 95 95 95 92 95 96 92
Louth 2083 2083 93 93 93 93 92 93 95 91
Meath 3559 3559 94 94 94 94 92 94 95 92
HSE-NE Total 7758 7758 94 94 94 94 92 94 95 92
HSE-NW
Donegal 2329 2329 96 96 96 96 93 96 95 92
Sligo/Leitrim 1467 1467 96 96 96 96 93 97 94 93
HSE-NW Total 3796 3796 96 96 96 96 93 97 95 92
HSE-SE
Carlow/Kilkenny 2050 2050 92 92 92 91 91 92 91 91
South Tipperary 1457 1457 93 93 93 93 90 93 92 90
Waterford 2113 2113 90 90 90 90 87 90 89 86
Wexford 2339 2339 94 94 94 94 92 94 93 91
HSE-SE Total 7959 7959 92 92 92 92 90 92 91 90
HSE-S
North Cork 1486 1475 96 96 96 96 89 96 95 92
North South Lee 5738 5810 95 95 95 95 90 95 95 92
West Cork 771 765 90 90 90 90 82 90 89 84
Kerry 2147 2111 92 92 92 92 84 92 91 87
HSE-S Total 10142 10161 94 94 94 94 88 94 94 90
HSE-W
Galway 3950 3950 94 94 94 94 86 94 93 90
Mayo 1879 1879 93 93 93 93 82 93 93 87
Roscommon 877 877 98 98 98 98 98 98 98 97
HSE-W Total 6706 6706 94 94 94 94 86 94 93 90
Ireland 69220 71382 94 94 94 93 87 94 93 90
*As the denominator/number in cohort may vary slightly according to vaccine, most commonly used number is presented here.  
†The 2009 data for those at 24 months are incomplete as the following were unavailable: the Quarter 1 2009 HSE-E D3, T3, P3 and Polio3 data for those born on the 
31/03/2007; the Quarter 2 2009  HSE-E Dublin North Hibb uptake data and; the Quarter 4 2009 HSE-MW data, HSE-E Dublin North Hibb data and HSE-SE Hibb data 
for those given a Hib dose as part of the five in one or six in one vaccine after 12 months of age.  The available 2009 national 24 month D3, T3, P3, Hib3, Polio3, MenC3 
and MMR1 birth cohort data may be around 98% of the national birth cohort and the available Hibb data may be around 95% of the national birth cohort.   
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here
Table A2.3 Local Health Office (LHO) abbreviations used in the immunisation uptake chapter of this 
document
Local Health Office Abbreviations Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs their combined immunisation uptake data are 
reported
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Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system.  Notification data were inputted directly by 
areas using the system.  For areas not yet on CIDR, 
data were forwarded weekly to HPSC for input to 
CIDR.  Enhanced surveillance was undertaken for certain 
diseases and these data collated on CIDR.   Outbreak 
data were also collated on CIDR using the same process 
outlined above.  Since 4th May 2008, new cases of 
Clostridium difficile-associated disease (CDAD) were 
notified on CIDR under the category ‘acute infectious 
gastroenteritis’ (AIG). Weekly Reports on infectious 
disease notifications (including a separate report for 
AIG with the emphasis on C. difficile) and outbreaks 
were produced by HPSC.  Throughout the year data 
were cleaned and validated on an ongoing basis 
and final data checks and cleaning were undertaken 
following year end by HPSC and the Departments of 
Public Health.  Data analysis was performed using CIDR 
Business Objects Reporting and MS Excel.  Figures for 
the relevant chapters within this report were extracted 
from CIDR between July and September 2010. These 
figures may differ from those previously published due 
to ongoing updating of data on CIDR. 
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
National Tuberculosis Surveillance System (NTBSS)
TB notification data (including enhanced information) 
for 2008 were collated in the regional Departments of 
Public Health, where data were entered on the Epi2000 
NTBSS database.  Each HSE Area provided finalised 
2008 data with outcome information to HPSC during 
2010.  Data were validated and cleaned with each area 
and the national data were collated.  Provisional 2009 
data were obtained from each area in August 2010.
European Antimicrobial Resistance Surveillance 
Network (EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories in 2009 on the first invasive 
isolate per patient per quarter on Staphylococcus 
aureus and Enterococcus faecalis from blood only 
and on Streptococcus pneumoniae, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa 
from blood and cerebrospinal fluid (CSF).  Data 
were reported quarterly to HPSC and collated in the 
WHONET database.  Quarterly and annual reports were 
produced.  
Note:  In general, invasive infections due to   
K. pneumoniae and P. aeruginosa are not notifiable 
but these pathogens are now included for surveillance 
under the EARS-Net project.
Sexually Transmitted Infections (STIs)
Clinicians and laboratories notified their respective 
Departments of Public Health of probable and 
confirmed cases of STIs in 2008.  Notifications were 
anonymised prior to notification.  Data were collated 
and analysed by Departments of Public Health and 
aggregated data were reported to HPSC.  National 
data were collated on an MS Access database, analysis 
preformed and reports produced by HPSC.
An enhanced surveillance system is in place for syphilis 
since 2000.  Enhanced forms were completed by 
clinicians and forwarded to the appropriate Department 
of Public Health from where they were sent to HPSC.  
An MS Access database was used at HPSC for collation 
and analysis of the national syphilis case-based data.
Other Surveillance Systems
Influenza Surveillance
Since 2000, HPSC has worked in collaboration with 
the National Virus Reference Laboratory (NVRL), the 
Irish College of General Practitioners (ICGP) and 
the Departments of Public Health on the influenza 
sentinel surveillance project. During 2009, 60 practices 
(located in all HSE-Areas and representing 5.6% of the 
population) were recruited to report electronically, on 
a weekly basis, the number of patients who consulted 
with influenza-like illness (ILI). Sentinel GPs were 
requested to send a combined nasal and throat swab to 
the NVRL on at least five ILI patients per week. Other 
indicators of influenza activity reported by Departments 
of Public Health to HPSC on a weekly basis included 
a network of sentinel hospitals reporting admission 
levels and sentinel schools reporting absenteeism. The 
Departments of Public Health also notified HPSC weekly 
of all cases of influenza, all influenza/ILI outbreaks and 
enhanced surveillance data on all hospitalised cases of 
seasonal influenza in 0-14 year olds.  HPSC was notified 
of all registered deaths on a weekly basis from the 
General Register Office.
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On 25th April 2009, a public health emergency of 
international concern was declared by the WHO due 
to an outbreak of 2009 pandemic influenza A (H1N1) 
infection in Mexico and the USA. Once the public health 
emergency was declared, routine seasonal influenza 
surveillance was augmented as detailed in chapter 2.1. 
The 2009 pandemic covered the period of time from 
week 17 (April) 2009 to week 32 (August) 2010. 
At HPSC data were collated from the various sources, 
analysed and weekly influenza reports were produced. 
Clinical and virological data were reported weekly to 
EISN and WHO. During the pandemic period additional 
epidemiological reports were produced.
HIV
HIV and AIDS surveillance in Ireland is voluntary 
and anonymised and operates in co-operation with 
laboratories, clinicians and Departments of Public 
Health.  In 2009, clinicians completed surveillance forms 
on newly diagnosed HIV cases, AIDS cases and AIDS 
related deaths and forwarded these to the appropriate 
Department of Public Health who in turn forwarded 
them to HPSC where national data were collated on an 
MS Access database.  Bi annual analysis of these data 
were performed at HPSC and reports produced.  
Immunisation Uptake
Each HSE Area maintains a childhood immunisation 
database.  In 2009, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis.  National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website.  
For further details on methods used, please see the 
immunisation uptake chapter within this report.
Antimicrobial consumption
Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the support 
of the Irish Antimicrobial Pharmacists Association. 
Quarterly and annual consumption trends by named 
public acute hospitals are published on the HPSC 
website. All data were stored at the HSPC in an MS 
Access database, and interpreted using the WHO 
Anatomical Therapeutic Chemicals index (www.whocc.
no/atcddd/) in line with European Surveillance of 
Antimicrobial Consumption (ESAC) methodology. See 
relevant section for notes on the denominator data.
Healthcare associated infections
In 2009 data were collected by participating general 
ICUs on MRSA colonisation/infection in the critical 
care setting. Data were reported monthly to HPSC and 
stored in an MS Access database. Quarterly and annual 
reports were produced.  Data were also collected 
on the total volume of alcohol-based hand rub used 
per hospital per year/quarter, excluding that used for 
pre-operative surgical “scrub”. Hospital activity data, 
bed days used, obtained from the HSE Performance 
Monitoring Unit (PMU), was used to calculate the rate of 
alcohol-based hand rub usage per hospital. See relevant 
section for notes on the denominator data. The rate of 
usage per hospital was calculated as the total volume of 
hand rub consumed (in litres) per 1000 bed days used. 
Data were reported quarterly to HPSC and stored in an 
MS Access database. Quarterly and annual reports were 
produced.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, http://www.
cso.ie).  Population figures were applied as follows: 
Census 2006 for analysis of 2004-2009 data, Census 
2002 for 2000-2003 data and Census 1996 for 1999 
data. 
Monthly population changes were estimated between 
1993 and 2009 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rates. These are based on April 2010 update of the 
mid-year population estimates published by the CSO.  
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA 
and hospital antibiotic consumption.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
board regions/areas).  This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
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CIDR Computerised Infectious Diseases Reporting
DoHC Department of Health and Children
EARS-Net European Antimicrobial Resistance Surveillance Network 
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
FSAI Food Safety Authority of Ireland
FSPB Food Safety Promotion Board
ICGP Irish College of General Practitioners
IDU Injecting Drug User
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE-E HSE Eastern Region
HSE-M HSE Midland Area
HSE-MW HSE Mid-Western Area
HSE-NE HSE North Eastern Area
HSE-NW HSE North Western Area
HSE-SE HSE South Eastern Area
HSE-S HSE Southern Area
HSE-W HSE Western Area
MRSA Meticillin Resistant Staphylococcus aureus
MSM Men who have Sex with Men
NSRL National Salmonella Reference Laboratory
NVRL National Virus Reference Laboratory
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organisation
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